360_CampETEC _Campy_Protocol_V 1.1_12September 2023  1 Clinical Study Protocol                                             [STUDY_ID_REMOVED]
Protocol Title : Double -blind, Placebo -Controlled Trial Assessing the Efficacy and 
Safety of CampETEC Hyperimmune Bovine Colostrum (HBC) for the 
Prevention of Campylobacter -Mediated Diarrheal Diseases  
Protocol Version/Date : Version 1.1/ 12 September 2023  
FDA IND Number:  28504  
JHU IRB Number : IRB00026228  
CIR Number :  360 
Sponsor Investigator  David Sack, MD  
Department of International Health  
Johns Hopkins Bloomberg School of Public Health  
615 N Wolfe St / E5537  
Baltimore, MD 21205 -5748  
Telephone: 443 -287-8795  
Email: dsack1@jhu.edu  
Principal Investigator:  Kawsar Talaat, MD  
Center for Immunization Research (CIR)  
Department of International Health  
Johns Hopkins University (JHU)  
Bloomberg School of Public Health (SPH)  
624 N. Broadway, HH, Room 205  
Baltimore, MD 21205  
Associate Investigators”  Subhra Chakraborty, PHD  
DIH, JHU, SPH  
Rediet Tekalign MD, MPH  
CIR, JHU, SPH  
Barbara DeNearing, BSN, RN, CCRC  
CIR, JHU, SPH  
Courtney Swisher BSN, RN, CPEN  
CIR, JHU, SPH  
Brittany Feijoo, MSN, FNP -BC 
CIR, JHU, SPH  
Kamal Dhanjani, MPAS, PA -C, FCCM  
CIR, JHU, SPH  
A Louis Bourgeois, PhD  
CIR, JHU, SPH  
Daniel Selig, MD  
Walter Reed Army Institute of Research (WRAIR)  
Frederic Poly, PhD  
Head, Operationally Relevant Infections Department (ORI)  
Directorate for DoD Infectious Diseases (DDID)  
Naval Medical Research Command (NMRC)  
Chad Porter, PhD, MPH  
Head, Translational and Clinical Rese arch Department  (TraCR)  
DDID, NMRC  
Samuel Walther, DO  
TraCR, NMRC  
Sandra Isidean, PhD, MPH  
TraCR, NMRC  
360_CampETEC _Campy_Protocol_V 1.1_12September 2023  2  
Kayla Testa, MPH  
TraCR, NMRC  
 
 
Research Monitor:  Nekhonti Adams, MD  
Director, Clinical Trials Center  
Translational and Clinical Rese arch Department  (TraCR)  
DDID, NMRC  
 
 
Data Management:  The Emmes Company, LLC  
401 N. Washington Street, Suite 700  
Rockville, MD 20850  
Telephone: 301 -251-1161 (Administrative Coordinator)  
 
Study Sites:  Center for Immunization Research (CIR) Isolation Unit  
301 Building  
301 Mason Lord Drive Suite 4300  
Baltimore, MD 21224  
 
CIR Outpatient Clinic  
624 N Broadway, Hampton House Rm.117  
Baltimore, MD 21205  
 
Center for Immunization Research Annex  
1101 North Point Blvd Suite 101 103 112  
Baltimore, MD 21224  
 
Laboratories:  Quest Diagnostics Incorporated, Baltimore, MD 21227  
1901 Sulphur Spring Rd.  
Baltimore, MD 21227  
 
Johns Hopkins Hospital  
600 N Wolfe Street / Meyer B -130 
Baltimore, MD 21287 –– 7070  
 
Johns Hopkins Bayview Medical Center  
4940 Eastern Ave  
Baltimore, MD 21224  
 
Immunology Laboratories:  Dilara Islam , PhD  
ORI, DDID, NMRC  
Phone: 301 -319-9094  
Email: dilara.islam.ctr@health. mil 
 
Research Laboratories:  Johns Hopkins University School of Public Heath  
GDEC Lab  
615 N. Wolfe Street  
Baltimore, MD 21205  
Johns Hopkins Biological Repository  
Johns Hopkins Bloomberg School of Public Health Room W6620 / 
615 N. Wolfe Street  
Baltimore, MD 21205  
Telephone: 410 -955-7203  
Email: JHSPH.jhbrlab@jhu.edu  
 
Institutional Review Board:  JHSPH IRB Office  
615 N. Wolfe Street  
Suite E1100  
Baltimore, MD 21205 Phone: 410 -955-3193 Toll -Free: 1 -888-262-
3242  
 Fax: 410 -502-0584  
Email: JHSPH.irboffice@jhu.edu  
 
360_CampETEC _Campy_Protocol_V 1.1_12September 2023  3 Investigator’s Agreement  
 
 
Double Blind, Placebo -Controlled Trial Assessing the Efficacy and Safety of CampETEC Hyperimmune Bovine Colostrum 
(HBC) for the Prevention of Campylobacteriosis  
 
“I have read this protocol and agree to conduct the study as outlined herein in accordance with International Conference on 
Harmonization Good Clinical Practice Guideline, and FDA and DoD Regulations.”  
 
    
Kawsar R. Talaat, M.D.  Date  
Principal Investigator  
 
 
 
360_CampETEC _Campy_Protocol_V 1.1_12September 2023  4  
TABLE OF CONTENTS  
LIST OF TABLES  ................................ ................................ ................................ ........................... 7 
LIST OF FIGURES  ................................ ................................ ................................ ......................... 7 
Glossary Of Abbreviations  ................................ ................................ ................................ .............. 8 
1.0 BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE  ........................... 18 
1.1 Diarrheal Disease  ................................ ................................ ................................ ................................ ................................ .. 18 
1.1.1  Campylobacter  ................................ ................................ ................................ ................................ ..............................  18 
1.2 Rationale for a Campylobacter -ETEC Hyperimmune Bovine Colostrum (CampETEC HBC)  ................................ ..................  18 
1.2.1  C. jejuni  HS23/36 Capsule  ................................ ................................ ................................ ................................ .............  18 
1.2.2  ETEC CfaEB  ................................ ................................ ................................ ................................ ................................ .... 19 
1.2.3  Campylobacter -ETEC CPS -CfaEB  ................................ ................................ ................................ ................................ ... 19 
1.3 Previous Clinical Studies Using Bovine -Derived Immunoprophylactics  ................................ ................................ ................  19 
1.4 C. jejuni  CG8421 Controlled Human Infection Model  ................................ ................................ ................................ ...........  19 
2.0 Objectives  ................................ ................................ ................................ ........................... 19 
2.1 Primary Objectives  ................................ ................................ ................................ ................................ ................................  19 
2.2 Secondary Objectives  ................................ ................................ ................................ ................................ ............................  20 
2.3 Exploratory Objectives  ................................ ................................ ................................ ................................ ..........................  20 
3.0 STUDY DESIGN ................................ ................................ ................................ ................ 20 
4.0 Study Population  ................................ ................................ ................................ ................. 21 
4.1 Participant Inclusion Criteria  ................................ ................................ ................................ ................................ .................  21 
4.2 Participant Exclusion Criteria  ................................ ................................ ................................ ................................ ................  21 
5.0 STUDY PROCEDURES  ................................ ................................ ................................ ....22 
5.1 Study -Specific Screening and Consenting  ................................ ................................ ................................ .............................  22 
5.2 Randomization  ................................ ................................ ................................ ................................ ................................ ...... 23 
5.3 Study Identification Number  ................................ ................................ ................................ ................................ .................  23 
5.4 Blinding  ................................ ................................ ................................ ................................ ................................ .................  23 
5.5 Clinical Evaluations ................................ ................................ ................................ ................................ ................................  23 
5.5.1  Monitoring During Inpatient Phase  ................................ ................................ ................................ ..............................  23 
5.5.2  Monitoring During Outpatient Phase  ................................ ................................ ................................ ...........................  24 
5.6 Concomitant Medications/Treatments  ................................ ................................ ................................ ................................  24 
5.6.1  Antibiotic Treatment  ................................ ................................ ................................ ................................ .....................  25 
5.6.2  Criteria for Early Antibiotic Treatment  ................................ ................................ ................................ .........................  25 
5.6.3  Unscheduled Visit  ................................ ................................ ................................ ................................ .........................  25 
5.7 Laboratory Evaluations  ................................ ................................ ................................ ................................ .........................  25 
5.7.1  Specimen Preparation, Handling, and Shipping  ................................ ................................ ................................ ............  25 
5.7.2  Laboratory Evaluations  ................................ ................................ ................................ ................................ .................  25 
5.8 Outcome Measures  ................................ ................................ ................................ ................................ ...............................  25 
5.8.1  Clinical  ................................ ................................ ................................ ................................ ................................ ...........  25 
5.8.2  Exploratory Immunological Analysis  ................................ ................................ ................................ .............................  26 
5.8.3  Microbiological  ................................ ................................ ................................ ................................ ..............................  26 
5.8.4  5.8.4 Exploratory  ................................ ................................ ................................ ................................ ...........................  26 
5.9 Outcome Adjudication Committee  ................................ ................................ ................................ ................................ .......  27 
6.0 STUDY SCHEDULE – PROCEDURES BY STUDY DAY  ................................ ............. 27 
6.1 Screening (Day –120 to Day –5) ................................ ................................ ................................ ................................ ............  27 
6.2 Inpatient Phase (Day –3 to Day 9)  ................................ ................................ ................................ ................................ ........  28 
6.2.1  Admission to the Inpatient Unit (Study Day –3) ................................ ................................ ................................ ...........  28 
360_CampETEC _Campy_Protocol_V 1.1_12September 2023  5 6.2.2  Study Days –2 to 6 CampETEC/Placebo Dosing  ................................ ................................ ................................ ............  28 
6.2.3  Campylobacter Challenge (Day 1)  ................................ ................................ ................................ ................................ . 29 
6.3 Day 7 - Antibiotic Treatment ................................ ................................ ................................ ................................ ..................  29 
6.4 Study Days 8 – 10 Planned Discharge  ................................ ................................ ................................ ................................ ... 29 
6.5 Outpatient Monitoring  ................................ ................................ ................................ ................................ ..........................  30 
6.5.1  Study Day 15 Safety Follow -Up (±2 Days)  ................................ ................................ ................................ .....................  30 
6.5.2  Study Day 29 (± 2 Days) ................................ ................................ ................................ ................................ .................  30 
6.5.3  Study Day 42 (± 2 Days) ................................ ................................ ................................ ................................ .................  30 
6.5.4  Study Day 57 (± 2 Days) ................................ ................................ ................................ ................................ .................  30 
6.5.5  Study Day 85 (± 2 Days) ................................ ................................ ................................ ................................ .................  30 
6.5.6  Study Day 113 (± 2 Days) - ................................ ................................ ................................ ................................ .............  31 
6.5.7  Study Day 181 Telephone Follow -up (± 1 Month)  ................................ ................................ ................................ ........  31 
A phone check will be done to track:  ................................ ................................ ................................ ................................ ............  31 
6.6 Management plan in the event of C. jejuni  recrudescence  ................................ ................................ ................................ .. 31 
6.7 Early Termination  ................................ ................................ ................................ ................................ ................................ .. 32 
7.0 STUDY INTERVENTION/INVESTIGATIONAL PRODUCTS  ................................ .....32 
7.1 Study Products  ................................ ................................ ................................ ................................ ................................ ...... 32 
7.1.1  CampETEC  ................................ ................................ ................................ ................................ ................................ ..... 32 
7.1.2  Placebo  ................................ ................................ ................................ ................................ ................................ ..........  33 
7.2 C. jejuni  CG8421 Challenge Strain  ................................ ................................ ................................ ................................ .........  34 
7.2.1  Challenge Inoculum  ................................ ................................ ................................ ................................ .......................  34 
7.2.2  Packaging and Labeling  ................................ ................................ ................................ ................................ .................  34 
7.2.3  Storage and transportation  ................................ ................................ ................................ ................................ ...........  35 
7.2.4  Preparation, administration and dosage  ................................ ................................ ................................ ......................  35 
7.3 Accountability Procedures for the Investigational Products  ................................ ................................ ................................  35 
7.4 Assessment of Participant Compliance with Investigational Products  ................................ ................................ .................  35 
8.0 ASSESSMENT OF SAFETY  ................................ ................................ ............................. 35 
8.1 Vital Signs  ................................ ................................ ................................ ................................ ................................ ..............  36 
8.2 Physical Examination ................................ ................................ ................................ ................................ .............................  36 
8.3 Laboratory Assessments  ................................ ................................ ................................ ................................ .......................  36 
8.4 IND Safety Reporting  ................................ ................................ ................................ ................................ .............................  38 
8.4.1  Adverse Event or Suspected Adverse Reaction  ................................ ................................ ................................ ............  38 
8.5 Serious Adverse Events  ................................ ................................ ................................ ................................ .........................  40 
8.5.1  Unexpected Adverse Event or Unexpected Suspected Adverse Reaction  ................................ ................................ ... 40 
8.5.2  Other Adverse Events  ................................ ................................ ................................ ................................ ...................  40 
8.6 Relationship to Investigational Product (Assessment of Causality)  ................................ ................................ ......................  40 
8.6.1  Causality  ................................ ................................ ................................ ................................ ................................ ........  40 
8.7 Recording of Adverse Events  ................................ ................................ ................................ ................................ ................  41 
8.7.1  Methods for Assessing, Recording, and Analyzing Safety Endpoints  ................................ ................................ ...........  41 
8.7.2  Recording Period for Adverse Events ................................ ................................ ................................ ............................  41 
8.7.3  Duration of Follow -Up of Participants after Adverse Events  ................................ ................................ ........................  41 
8.7.4  Safety Assessment  ................................ ................................ ................................ ................................ ........................  41 
8.8 Reporting Adverse Events  ................................ ................................ ................................ ................................ .....................  42 
8.8.1  Reporting Serious and Unexpected Adverse Events  ................................ ................................ ................................ ..... 42 
8.8.2  Immediately Reportable Events  ................................ ................................ ................................ ................................ .... 44 
8.8.3  IND Reporting  ................................ ................................ ................................ ................................ ................................  44 
360_CampETEC _Campy_Protocol_V 1.1_12September 2023  6 8.9 Safety Criteria for Stopping Doses  ................................ ................................ ................................ ................................ ........  44 
8.10 Treatment of Adverse Events  ................................ ................................ ................................ ................................ ...............  45 
8.11 Study Termination Criteria  ................................ ................................ ................................ ................................ ....................  45 
8.12 Six Month Follow -Up Safety Surveillance  ................................ ................................ ................................ .............................  45 
9.0 CLINICAL TRIAL MONITORING  ................................ ................................ .................. 45 
10.0  STATISTICAL CONSIDERATIONS  ................................ ................................ ............ 45 
10.1 Introduction  ................................ ................................ ................................ ................................ ................................ ..........  45 
10.2 Sample Size Considerations  ................................ ................................ ................................ ................................ ..................  46 
10.3 Analysis  ................................ ................................ ................................ ................................ ................................ .................  46 
10.3.1  Safety  ................................ ................................ ................................ ................................ ................................ ............  46 
10.3.2  Protective Efficacy Determination  ................................ ................................ ................................ ................................  46 
10.3.3  Immunogenicity  ................................ ................................ ................................ ................................ ............................  46 
11.0  DATA MANAGEMENT  ................................ ................................ ................................ 46 
11.1 Ethics and Legal Compliance  ................................ ................................ ................................ ................................ .................  47 
11.2 Storage of Data and Samples  ................................ ................................ ................................ ................................ ................  47 
12.0  OBLIGATIONS AND ROLES OF THE SPONSOR, INVESTIGATOR, AND STUDY PERSONNEL  47 
13.0  QUALITY CONTROL AND ASSURANCE  ................................ ................................ .47 
13.1 QA/QC Monitoring  ................................ ................................ ................................ ................................ ................................  47 
13.2 Protocol Deviation Management  ................................ ................................ ................................ ................................ ..........  48 
14.0  HUMAN PARTICIPANTS PROTECTIONS CONSIDERATIONS  ............................. 48 
14.1 Risks/Benefits  ................................ ................................ ................................ ................................ ................................ ........  48 
14.1.1  Risks ................................ ................................ ................................ ................................ ................................ ...............  48 
14.1.2  Risk Mitigation Strategies  ................................ ................................ ................................ ................................ .............  50 
14.1.3  Benefits  ................................ ................................ ................................ ................................ ................................ .........  51 
14.2 Participant Compensation  ................................ ................................ ................................ ................................ ....................  51 
14.3 Research -Related Injury  ................................ ................................ ................................ ................................ ........................  51 
14.4 Compensation for Investigators  ................................ ................................ ................................ ................................ ............  52 
14.5 Fair and Equitable Selection of Participants  ................................ ................................ ................................ .........................  52 
14.6 Informed Consent  ................................ ................................ ................................ ................................ ................................ . 52 
14.7 Recruitment  ................................ ................................ ................................ ................................ ................................ ..........  52 
15.0  PRIVACY AND CONFIDENTIALITY  ................................ ................................ ......... 52 
15.1 Provisions Protecting Privacy and Confidentiality  ................................ ................................ ................................ ................  52 
15.2 Safeguards for Vulnerable Participants  ................................ ................................ ................................ ................................  53 
16.0  PROTOCOL REVIEW PROCESS  ................................ ................................ ................. 53 
17.0  PUBLICATION POLICY  ................................ ................................ ............................... 53 
18.0  Reference  ................................ ................................ ................................ ......................... 54 
 
 
360_CampETEC _Campy_Protocol_V 1.1_12September 2023  7  
LIST OF TABLES  
 
Table 1: Time and Events Schedule  ................................ ................................ ................................ ................................ ......................  15 
Table 2 : Description of Study Groups  ................................ ................................ ................................ ................................ .................  20 
Table 3: Order of Events on Day of Challenge  ................................ ................................ ................................ ................................ ..... 29 
Table 4. Time and Events Schedule for Recrudescence  ................................ ................................ ................................ ..................  31 
Table 5 : Release Criteria for C. jejuni  cGMP MCB . ................................ ................................ ................................ ...........................  34 
Table 6: Reference Ranges and Adverse Event Coding for Vital Signs Parameters  ................................ ................................ ............  36 
Table 7: Reference Ranges and Adverse Event Coding for Clinical Hematology Parameters  ................................ .............................  37 
Table 8: Reference Ranges and Adverse Event Coding for Blood Chemistry Parameters  ................................ ................................ ... 37 
Table 9: Challenge Phase Campylobacter Infection Anticipated Adverse Event / Endpoint Assessments  ................................ ..........  42 
Table 10 : Study Contacts for Reporting Serious Adverse Events  ................................ ................................ ................................ .......  43 
Table 11: SAE Information to Be Reported to the Sponsor  ................................ ................................ ................................ ..................  43 
 
LIST OF FIGURES  
 
Figure 1: Label for CampETEC Product  ................................ ................................ ................................ ................................ ..............  33 
Figure 2: Placebo Label  ................................ ................................ ................................ ................................ ................................ ........  34 
Figure 3: Label for C. jejuni stain challenge product ................................ ................................ ................................ ............................  35 
 
 
360_CampETEC _Campy_Protocol_V 1.1_12September 2023  8  
GLOSSARY OF ABBREVIATIONS  
 
Abbreviation  Definition  
AE Adverse event  
ALS  Antibodies from lymphocyte supernatant  
ASC  Antibody secreting cell  
BSIgG  Bovine serum -derived immunoglobulin G  
CBC  Complete Blood Count  
CF ETEC colonization factor  
CFA  ETEC colonization factor antigen  
CFA+BS  Colonization factor antigen agar plates with bile salts  
CfaB  Repeating subunit of CFA/I  
CfaE  The tip -localized adhesin subunit of CFA/I  
CfaEB  Fusion of CfaE and CfaB  
CFU  Colony forming unit  
cGMP  Current good manufacturing practice  
CHIM  Controlled Human Infection Model  
CLIA  Clinical Laboratory Improvement Act  
CIR Center for Immunization Research  
CMI  Cell mediated immunity  
CPS Capsule polysaccharide  
CPS-CfaEB  Conjugate vaccine composed of C. jejuni  CPS conjugated to CfaEB  
CWC  Campylobacter whole cell  
CRP  C-Reactive Protein  
CRM197  Non-toxic mutant of diphtheria toxin  
DoD  Department of Defense  
eCRF  Electronic Case Report Form  
EDD  Enteric Disease Department  
ESR Erythrocyte Sedimentation Rate  
ETEC  Enterotoxigenic Escherichia  coli 
ELISA  Enzyme -linked immunosorbent assay  
FBD  Functional Bowel Disorder  
FQ Fluoroquinolones  
GBS  Guillain -Barré Syndrome  
GCP  Good Clinical Practice  
GE Glycine extract  
G CSF/Gm -
CSF Granulocyte colony stimulating factor/ Granulocyte -macrophage colony stimulating 
factor  
360_CampETEC _Campy_Protocol_V 1.1_12September 2023  9 GMP  Good Manufacturing Practice  
HBC  Hyperimmune bovine colostrum  
HBsAg  Hepatitis B surface antigen  
HCV  Hepatitis C virus  
HIPAA  Health Insurance Portability and Accountability Act  
HIV Human immunodeficiency virus  
HSRRB  Human Subject s Research Review Board (Army Surgeon General)  
IBS Irritable Bowel Syndrome  
IBD Inflammatory Bowel Disease  
IFN Interferon  
IgA Immunoglobulin A  
IgG Immunoglobulin G  
IL Interleukin  
IP Investigational Product (CampETEC HBC)  
IRB Institutional Review Board  
IVF Intravenous fluids  
JHBSPH  Johns Hopkins Bloomberg School of Public Health  
JHU Johns Hopkins University  
LMIC  Low- and middle -income  country  
LPS Lipopolysaccharides  
LT Heat-labile enterotoxin  
MCB  Master Cell bank  
MCP  Monocyte chemoattractant protein  
NMRC  Naval Medical Research C ommand  
MH Mueller -Hinton agar  
ORS  Oral Rehydration solution  
PBMC  Peripheral blood mononuclear cells  
PE Protective Efficacy  
PI Principal Investigator  
PSG Protocol specific guideline  
PVT  Psychomotor Vigilance Testing  
QA Quality assurance  
ReA Reactive Arthritis  
SAE  Serious adverse event  
SD Study day  
SOP Standard Operating Procedure  
SSP Study Specific Procedure  
ST Heat stable  enterotoxin  
360_CampETEC _Campy_Protocol_V 1.1_12September 2023  10 TD Travelers’ diarrhea  
TLUS  Time to Last Unformed Stool  
TNF  Tumor necrosis factor  
USP United States Pharmacopeia  
WBC  White blood cell  
WIRB  Western Institutional Review Board  
WRAIR  Walter Reed Army Institute of Research  
 
 
360_CampETEC _Campy_Protocol_V 1.1_12September 2023  11  
CLINICAL PROTOCOL SYNOPSIS  
Protocol Title  Double -blind, Placebo -Controlled Trial Assessing the Efficacy and Safety of CampETEC 
Hyperimmune Bovine Colostrum (HBC) for the Prevention of Campylobacter -Mediated 
Diarrheal Diseases  
IND Number  28504  
Investigational Products  1. CampETEC Hyperimmune Bovine Colostrum (HBC)  
2. C. jejuni  CG8421 challenge strain  
Sponsor  David Sack, MD  
Manufacturers  CampETEC HBC  
Immuron Limited  
Address: Unit 10, 25 - 37 Chapman Street,  
Blackburn North, VIC 3130, Australia  
 
C. jejuni  strain CG8421  
Charles River Malvern  
358 Technology Drive  
Malvern, PA 19355  
Principal Investigator  Kawsar Talaat, MD  
Research Monitor  Nekhonti Adams, MD  
Study Site  Center for Immunization Research (CIR) Isolation Unit  
301 Building  
301 Mason Lord Drive Suite 4300  
Baltimore, MD 21224  
 
CIR Outpatient Clinic  
624 N. Broadway, Hampton House Rm. 117  
Baltimore, MD 21205  
 
Center for Immunization Research Annex  
1101 North Point Blvd Suite 101 103 112  
Baltimore, MD 21224  
Laboratories  Quest Diagnostics Incorporated, Baltimore, MD 21227  
Johns Hopkins Hospital, Baltimore, MD 21287  
Johns Hopkins University School of Public Health, Baltimore, MD 21205  
Johns Hopkins Biological Repository, Baltimore, MD 21205  
Naval Medical Research C ommand , Silver Spring, MD 20910  
Study Objectives  The primary objectives  of the study are as follows:  
1. To estimate protective efficacy (PE) of CampETEC HBC against campylobacteriosis 
following challenge with C. jejuni  strain CG8421  
2. To assess the safety and tolerability of CampETEC HBC  
 
The secondary objectives  of this research are to assess the ability of CampETEC HBC to 
prevent or reduce a variety of secondary clinical endpoints.  
The exploratory objectives  are to measure mucosal and systemic immune responses to the 
challenge organism, and to obtain and archive samples for future immunologic, proteomic, 
microbiome, and/or systems biology efforts. Additionally, we  will assess the utility of a novel 
Campylobacter disease scoring metric, and  may also assess the role of sleep on disease risk 
as well as the effect of disease on cognitive assessments.  
Study Design  This study is  designed to evaluate the ability of a hyperimmune bovine colostrum -derived 
IgG product to confer passive protection against C. jejuni  in the controlled human infection 
model  (CHIM) .  
This study is a randomized (1:1), double -blind, placebo -controlled clinical trial in which up 
to 30 participant s will receive the investigational product (IP) or placebo three times daily 
following meals beginning 2 days prior to experimental challenge with C. jejuni strain 
CG8421. The placebo is a commercially sourced high protein milk powder called ProMilk 
85. Participant s will be assigned to groups as per the table below.  
Product N Dose (approximate)  
CampETEC HBC  15 1.0 g three times daily (tid)  
Placebo  15 1.0 g tid  
 
The test article/placebo will be administered for a total of 8 days, or until antibiotic treatment 
has been initiated. Participant s will be assessed daily for adverse events and all stools will be 
collected to assess for the primary endpoint of campylobacteriosis post -inoculation. Any 
participant  passing a grade 3 -5 stool will be encouraged to start drinking oral rehydration 
360_CampETEC _Campy_Protocol_V 1.1_12September 2023  12 solution (ORS) (an oral glucose/electrolyte solution to prevent dehydration) or Gatorade (or 
a similar rehydration drink) at a rate equal to their stool output. Intravenous (IV) rehydration 
will be provided if pre -specified criteria are met. All participant s will be treated with 
ciprofloxacin (500 mg by mouth twice daily for 5 days) and azithromycin (500 mg by mouth 
daily for 5 days)  six days after ingesting the challenge strain unless  early treatment criteria 
are met. Alternate antibiotic treatment to whic h the strain is susceptible may also be 
considered as clinically appropriate. Participant s will be discharged from the inpatient facility 
when clinical symptoms are resolved or resolving,  two doses of antibiotics are taken, AND 
two consecutive stool cultures are negative for C. jejuni . 
 
All participants will receive C. jejuni  strain CG8421 administered one time at a target dose 
of 5x105 colony -forming units (CFU) diluted in 30 mL sodium bicarbonate buffer  following 
a 90 minute  fast. 
Primary and Secondary 
Endpoints  The primary efficacy outcome is campylobacteriosis, defined as a clinical illness meeting at 
least one of the following patterns starting within 144 hours of challenge:  
• Moderate diarrhea (4 to 5 loose/liquid stools or 401 -800 grams  in any 24 hour 
period ) OR  
• Severe diarrhea ( ≥ 6 loose/liquid stools or > 800 grams  in any 24 hour period ) OR  
• Fever (present on at least 2 occasions, at least 20 minutes apart) without diarrhea, 
plus an associated symptom (nausea, vomiting, abdominal cramps, tenesmus, or 
dysentery ( gross blood in ≥ 2 grade 3 – 5 stools  with in any 24 hour period ); with 
consideration of potential alternative diagnosis per clinical investigator based on 
illness time course and associated symptoms.  
The primary safety and tolerability outcome is the presence of CampETEC HBC -associated 
adverse events during the study period.  
 
Secondary efficacy endpoints are chosen to support the primary endpoint in determining the 
protective efficacy of the CampETEC product. They further quantify and qualify the degree 
to which a participant experiences Campylobacter -attributable disease .  
• Evaluate the efficacy of CampETEC in reducing various clinical and 
microbiological outcomes (e.g. disease severity, fever, dysentery, stool 
frequency, shedding).   
 
Exploratory Endpoints  Exploratory endpoints include microbiology , immunogenicity , clinical and cognitive . 
• Microbiology: Intestinal colonization by the challenge strain will be assessed by 
monitoring fecal shedding patterns by qualitative culture. Quantitative cultures for 
the challenge strain will be performed on selected inpatient days.  
• Immunogenicity : Evaluate the natural immune response to C. jejuni  infections in 
humans.  
• Blood and stool samples to detect an immune response to the infection may include 
assays using the Campylobacter  glycine extracts (GE)  antigen .). 
o Systemic immune response: Assays to determine Campylobacter  antigen -
specific (GE) serum IgA and IgG responses will be performed.  
• Stool collected from the participants will be used to assess for Campylobacter  
antigen -specific (GE) fecal IgA and total fecal IgA responses.  
• Clinical Response: We will utilize a new Campylobacter  disease scoring metric to 
assess its performance in this trial.  
• Functional Bowel Symptom Development: A functional bowel survey based on 
Rome criteria will be used to assess the prevalence of baseline bowel symptoms as 
well as the development of such symptoms at 6 months after challenge. Incidence of 
functional bowel symptoms will be compared among those who develop 
campylobacteriosis after challenge relative to those who may be protected from 
illness and against the expected incidence in the normal population.  
• Cognitive evaluations: Exploratory evaluations of the cognitive impacts of acute 
diarrhea may be performed with the use psychomotor vigilance testing (PVT).  
 
Participant  samples may also be collected for potential future use, to include the following 
studies: antibody in lymphocyte supernatant (ALS), memory B cells, flow cytometry, fecal 
microbiota, and serum and fecal proteomics.  
Study Duration  Volunteers will complete 1 -3 screening visits that may occur up to 120 days prior to 
enrollment under a separate IRB approved screening protocol. Consenting and eligible 
volunteers will spend approximately 1 3 days on the inpatient isolation unit. They will be 
asked to return for 5-6 outpatient follow -up visits at 1 5, 29, 42, 57, and 8 5 days post challenge 
and complete a telephone assessment 6 months post -challenge.  A visit at day 113  will be 
added if there is a ny recrudescence at day 85.  
Additional outpatient follow -up visits may be required if any participant has a  recrudescent 
infection after completing antibiotic treatment.  The total planned participation for an 
individual volunteer is about 9 months . 
360_CampETEC _Campy_Protocol_V 1.1_12September 2023  13  
Screening, study intervention, CHIM, follow -up, immunology studies, analysis, and reporting 
after all volunteer contact is complete is anticipated to take  1.5 to 2 years.  
Eligibility Criteria  Inclusion Criteria:  
1. Adult  between 18 and 50 years of age, inclusive.  
2. General good health, without significant medical illness, abnormal physical 
examination findings, or clinical laboratory abnormalities, as determined by principal 
investigator (PI) or PI in consultation with the research monitor and sponsor.  
3. Demonstrate comprehension of the protocol procedures, requirements, and CHIM by 
passing a written examination (passing grade ≥ 70%).  
4. Willing to participate, as evidenced by signing the informed consent document.  
5. Available for all planned follow -up visits.  
6. Negative serum pregnancy test at screening and negative serum and/or urine 
pregnancy test on the day of admittance to the inpatient phase for participants of 
childbearing potential. Participants of childbearing potential must agree to use an 
efficacious ho rmonal or barrier method of birth control during the study. Abstinence 
from intercourse with a male partner is acceptable. Participants who no longer have 
childbearing potential must have this documented (e.g., tubal ligation or 
hysterectomy).  
Exclusion criteria:  
1. Presence of a significant medical condition (e.g., psychiatric conditions , such as 
significant anxiety, depression, or somatization disorder ; gastrointestinal disease, 
such as peptic ulcer, symptoms or evidence of active gastritis/dyspepsia, 
gastroesophageal reflux disease, inflammatory bowel disease, irritable bowel 
syndrome (as suggested by the functional bowel disorder survey  or medical 
diagnosis); alcohol or illicit drug abuse/dependency; or laboratory abnormalities that 
in the opinion of the investigat or preclude participation in the study. Significant 
medical conditions include evidence of cardiac, pulmonary, endocrine, neurologic or 
renal disease that is uncontrolled or poorly controlled, any diabetes mellitus, and 
other such illnesses that can put a volunteer at increased risk. Exclusionary laboratory 
abnormalities include any abnormality that is grade 2 or above.  
2. Immunosuppressive illness or evidence of IgA deficiency (serum IgA < 7 mg/dL or 
below the limit of detection of assay ), or any autoimmune disease.  
3. Positive serology results for HIV, HBsAg, or HCV antibodies, and confirmatory tests 
if appropriate.  
4. Positive urine toxicology screen  for amphetamines , barbiturates , benzodiazepines , 
cocaine metabolite, methadone metabolite, opiates , oxycodone , or phencyclidine .  
5. Significant abnormalities in screening laboratory hematology or serum chemistry, as 
determined by PI or PI in consultation with the research monitor and sponsor.  
6. Evidence of abnormal ECG findings per PI ( e.g., QT prolongation)  
7. Use of any medication known to affect immune function (e.g., regular systemic 
corticosteroids, monoclonal antibodies that target key aspects of the immune system  
(such as rituximab or TNF blockers) ; others [topical, intranasal and inhaled steroids 
will be permitted])  within 30 days preceding receipt of the investigational product or 
planned to be used during the active study period.  
8. Nursing or lactating on the day of admittance to the inpatient unit.  
9. Inability to tolerate 150 mL sodium bicarbonate buffer (based on requirement for 
frequent dosing).  
10. Recent vaccination  (including licensed vaccines) or receipt of an investigational 
product (within 30 days before challenge through 30 days following the last challenge 
dose).  
11. Prior history of C. difficile  infection  
12. History of diarrhea in the 2 weeks prior to planned inpatient phase.  
13. Fewer than 3 stools per week or more than 3 stools per day as the usual frequency, or 
loose or liquid stools other than on an occasional basis.  
14. Regular use of laxatives or any agent that increases gastric pH (regular defined as at 
least weekly).  
15. Use of proton pump inhibitors, H2 blockers, or antacids within 48 hours of dosing.  
16. A fever (≥ 38.0°C)  in the 2 weeks prior to time of challenge.  
17. Use of antibiotics during the 7 days before bacterial dosing  or receipt of more than 2 
courses of antibiotics over the two months prior to dosing . 
18. Blood donation within 30 days prior to the planned receipt of this IP.  
19. Lactose intolerance or allergy to milk or milk products.  
20. Personal or documented family history of Guillain -Barré syndrome or 
neuromuscular disease; or an inflammatory arthritis such as reactive arthritis, 
ankylosing spondylitis, or rheumatoid arthritis.  
21. Evidence of inflammatory arthritis on exam.  
22. HLA -B27 positive.  
360_CampETEC _Campy_Protocol_V 1.1_12September 2023  14 23. Allergy or prior intolerance to two or more of the following: fluoroquinolones, 
azithromycin, augmentin or cephalosporins   
24. Have household contacts who are < 2 years old or > 80 years old or infirm or 
immunocompromised.  
25. Employment as a healthcare worker with direct patient care, in a daycare center (for 
children or the elderly), or direct food handler; includes individuals who work 
directly with food in commercial establishments.  
26. History of microbiologically confirmed Campylobacter  infection in last 3 years. 
27. Serological immunological evidence of prior Campylobacter  exposure defined as 
Campylobacter  antigen -specific (GE) specific anti -glycine extract serum IgA 
endpoint titer > 1:4,000.  
28. Occupation involving handling of Campylobacter  currently, or in the past 3 years.  
29. Symptoms consistent with travelers’ diarrhea concurrent with travel to countries 
where Campylobacter , Cholera, Salmonella, Shigella , Typhoid  or ETEC  infection 
are endemic (most of the developing world) within 3 years prior to dosing, OR 
planned travel to endemic countries during the length of the study.  
30. Vaccination for or ingestion of Campylobacter , Cholera, Salmonella, Shigella, 
Typhoid, or ETEC  within 5 years prior to dosing.  
31. Other dietary or environmental exposures that may place the participant at high risk 
for prior Campylobacter  exposure (to be determined on a case -by-case basis by the 
PI). 
 
CampETEC Dose 
Preparation  Sachets of CampETEC HBC (and placebo) will be stored at 2-8°C. Individual doses will be 
prepared by reconstitut ing in 150 mL water containing 2 g sodium bicarbonate for ingestion 
by a single individual. Each volunteer will receive either the CampETEC or placebo 3 times 
a day on specified study days . Preparation procedures will be detailed in the MOP.  
C. jejuni  Challenge Strain 
Preparation  Vials from the master cell bank will be thawed at room temperature. One hundred microliters 
of the master cell bank lot will be spread onto an appropriate number of Mueller -Hinton agar 
plates for confluent growth and incubated overnight (21±1 hours) at 42°C under microaerobic 
conditions. After overnight growth,  C. jejuni identity will be confirmed by Gram stain, 
oxidase testing, and confirmation of darting motility. After confirmation, bacterial biomass 
will be harvested by suspension in sterile PBS and adjusted to the appropriate optical density 
to achieve the target inoc ulum. Challenge inoculum will be verified by enumeration of viable 
counts and purity will be deter mined by plating and incubating according to study -specific 
procedures.  
Clinical Evaluation and 
Management of 
Recrudescence  In the event of a recrudescence, participant s will be assessed as soon as possible with a 
medical interview and physical assessments. Antibiotic treatment will be initiated (same 
dosage as initial regimen). The C. jejuni  isolate will be tested to ensure continued antibiotic 
susceptibility. The isolate will also be tested to verify that it is strain CG8421. Repeat stool 
collection will occur with testing for stool microbiology, and expanded to include routine C. 
difficile , stool bacteriology, and parasitolog y, if appropriate. The participant may be tested 
for evidence of immunocompromise;  including possible hypogammaglobulinemia testing and 
a repeat HIV test.  
 
The participant  will be followed for a total of 6 months from the date of documented 
infection recurrence. The date of the stool from which the recrudescence was identified will 
be recrudescence day 1  for follow -up purposes. Follow -up will include medical interview 
and physical assessment on recrudescence day 1 5 along with repeat stool collection for 
microbiology. On recrudescence days 2 9, 42, 57, and 8 5, the participant will undergo a 
medical interview and physical assessment, along with stool collection for microbiology; on 
recrudescence days 5 7 and 8 5, stool may also be collected for exploratory endpoints. 
Follow -up will be completed with a telephone interview on day 18 1 (± 30 days) to inquire 
about new -onset serio us health events. In the event of any recrudescence on day 85 any 
volunteer who has not previously recrudesced will be asked to return on day 113 for an 
additional visit.  
 
Sample Size  
Estimate/Analysis  The null hypothesis is that the proportion of participant s with campylobacteriosis will be the 
same in participant s receiving CampETEC HBC compared to those receiving placebo.  
A Fisher ’s Exact Test with a 5% two -sided significance level will have 79% power to detect 
the difference between a group 1 proportion, π ₁, of 0.68 and a group 2 proportion, π ₂, of 0.136 
(this is precisely 80% efficacy) when the sample size in each group is 15.  
 
360_CampETEC _Campy_Protocol_V 1.1_12September 2023  15  
Table 1: Time and Events Schedule  
 Screeninga 
(1-3 visits)  Test Article Dosing and Challenge Phase (Inpatient)  F/U (Outpatient)  
Study Event  -120 - -4  -3 -2 -1 1 2 3 4 5 6 7 8 9 10b 15 29 42 57 85 113c 181d 
Compliance  Range 
(study day)  -120 to 
-4 -30 to -
4 -- -- -- -- -- -- -- -- -- -- -- --  
±2 ±2 ±2 ±2 ±2 ±2 ±30 
Outpatient  X X              X X X X Xn (X)  
Inpatient stay    X X X X X X X X X X X X X        
Comprehension 
assessment/consentin
g (X) X                     
Medical interview  (X) X                     
Complete physical 
exame (X) X X                    
Interim history     X X X X X X X X X X X X X X X X X X  
Focused physical 
exam    X X X X X X X X X X X X X (X) (X) (X) (X) (X) (X)  
Assess A Es    X X X X X X X X X X X (X) X X X X X   
Assess AESIsf & 
SAEs       X X X X X X X X X (X) X X X X X X X 
Assess medications  X X X X X X X X X X X X X X X X X X X    
Campylobacter  prior 
exposure test  X (X)                     
Vital signsg (X) X X X X X X X X X X X X X X X X X X X X  
Serology (HIV, 
HbsAg, HCV), IgA 
level, HLA -B27, and 
ABO blood typing  (X) X                     
COVID -19 testingh   X                    
CBC with differential  (X) X X             X       
Serum chemistryi (X) X X             X       
Serum pregnancy test 
(people of child -
bearing potential)  (X) X X                    
Drug screen (urine)j  X                     
ECG   X                     
Urine hCG    (X)  X           X      
Functional bowel 
disorder survey  (X) X                    X 
CampETEC HBC     X X X X X X X X            
360_CampETEC _Campy_Protocol_V 1.1_12September 2023  16  Screeninga 
(1-3 visits)  Test Article Dosing and Challenge Phase (Inpatient)  F/U (Outpatient)  
Study Event  -120 - -4  -3 -2 -1 1 2 3 4 5 6 7 8 9 10b 15 29 42 57 85 113c 181d 
Compliance  Range 
(study day)  -120 to 
-4 -30 to -
4 -- -- -- -- -- -- -- -- -- -- -- --  
±2 ±2 ±2 ±2 ±2 ±2 ±30 
Challenge       X                 
Start antibiotic 
therapyk            X           
Cognitive assessmentl   X X X X X X X X X X X X (X)        
Stool 
weighing/grading    X X X X X X X X X X X X        
Stool bacteriology ( C. 
jejuni  detection)m      (X
) X X X X X X X X (X) X X X X X X  
Stool collection for 
exploratory objectives    X X X X X X X X X X X X X X X  
X X X  
Serum for exploratory 
objectives    X    X  X    X   X X  X X   
PBMCs for 
exploratory objectives    (X)          X    X   X   
Fingerstick for whole 
bloodn   X    X  X    X    X      
Discharge from 
inpatient phase                X        
Telephone follow -up                      X 
CPT (#, mL) -research    8, 
64          8, 64     8, 64    8, 64    
SST (#, mL) - research    1, 
10    1, 
10  1, 
10    1, 10    1, 10  1, 10   1, 10  1, 10   
Other screening blood 
volumeo (approximate)  (X) (X) (10)        0     10       
Approximate total 
Blood volume (mL)p 10 60 84 0 0 0 10 0 10 0 0 0 74 0 0 20 74 0 10 74 0 0 
Notes: (X) denotes optional event or procedure. Study completion is defined as a participant  completing all clinic visits.  
a Screening may consist of 1 to 3 visits. If within day -30 window, all screening activities may take place at one visit. After screening, participant  continuing eligibility must be confirmed by reassessing relevant inclusion and exclusion criteria prior t o first dose of IP, on either 
day of admission or day -2. 
b Participant s may be discharged from the inpatient phase of the study when they feel well enough, clinical symptoms have resolved or are resolv ing, have completed at least two doses of antibiotics, and have 2 consecutive negative stool cultures. Participa nts will be required to 
complete their antibiotics as outpatients.  Participants who meet criteria for discharge will no longer have daily procedures completed. If eligible for early discharge  prior to day 8, participants will be required to return to cente r on Days 8 for collecti on of samples , vital signs, 
interim history, A Es and SAEs. If GI symptoms they will have a focused PE. If a participant discharges prior to day 8 they will return on day 8 and have procedures as above.  
c A visit on day 11 3 will occur with the collection of stool specimens for C. jejuni  and exploratory assays for previously non -recrudesced participant s only if there are one or more recrudescent participant s on day 8 5. 
d D 181  (+/- 30 days ) phone call to inquire about new -onset serious health events or hospitalizations.  
e Physical examination will include: HEENT (Head; Ears; Eyes; Nose; Throat), skin, respiratory (lung), cardiovascular (heart), abdomen, neurological and musculoskeletal systems, and will be done at screening and on admission. During the inpatient perio d, a symptom -
focused physical examination will be completed.  
f AESI include new diagnosis of GBS, ankylosing spondylitis, reactive arthritis, any autoimmune disease after challenge, IBD, I BS  
g If a VS needs to be repeated, standard practice will be to repeat the VS within approximately 20 minutes of the original read ing. Only the VS that needs to be repeated will be repeated. Both the original and repeat measurements will be recorded in th e stud y source documents; 
however, only the repeat measurement will be recorded in the CRF field for that measurement  if needed . 
The following VS are obtained and documented in the source documents:  
• During the screening visit  
• At least 3 times daily during inpatient period  
360_CampETEC _Campy_Protocol_V 1.1_12September 2023  17 • Before and after challenge  
• At each in -person outpatient visit 
A grade 1 bradycardia, or other grade 1 abnormalities will not be considered to be exclusionary at screening, unless judged t o be clinically significant by the PI. Clinically relevant and concurrent medical conditions or surgical procedures will be r ecorde d as medical history 
if the onset is prior to administration of IP. This includes pre -existing lab abnormalities, VS abnormalities, and symptoms associated with menses (e.g., cramps, headaches, etc.). Grade 2 ab normalities recorded after screening but prio r to challenge admini stration will be 
determined on a case -by-case basis at PI discretion. Clinically significant abnormalities not on the toxicology table can be recorded on the MH if de emed necessary by the PI.  
The following VS will be captured in the electronic CRF:  
• Screening  
• Admission  
• Before and after challenge  
• At discharge  
• At outpatient visit day s 15, 29, 42, 57 and 85  
• In addition, any abnormal VS deemed to be clinically significant or clinically relevant may also be entered into the eCRF.  
h COVID -19 testing will be completed on presentation for admission 
I Serum chemistry  CMP  will include  at a minimum : serum transaminases (ALT ), Na, K+, BUN creatinine, random glucose. Follow -up samples may be taken if clinically significant abnormalities are seen. Clinically relevant laboratory abnormalities will b e recorded as medical 
history if obtained before receipt of first IP.  
j Urine drug screen will test for the presence of amphetamine, barbiturates, opiates, phencyclidine, cocaine, benzodiazepine, and methadone  at screening and at the discretion of the study clinician. In addition, the study clinician may ask for a sample to test for the presence of 
antibiotics.  
k Participant s may begin antibiotic treatment early if one or more criteria are met.  
l Exploratory cognitive assessments may be performed on individuals during the inpatient phase (thrice daily) using PVT evaluation.  
m Stool sample for bacteriology will begin the day after challenge, or prior to institution of early antibiotic therapy (whiche ver is sooner). If a stool sample is not obtained before 1300 hours, a rectal swab will be obtained. Swabs will be used only for b acteriology. Stool samples 
will be collected for assays as specified in the laboratory study event schedule and as per written SSPs.  
n Whole blood from finger pricks will be collected on filter paper, dried, and stored at -80°C for exploratory objectives.  
o Additional blood samples may be collected on a case -by-case basis at the investigator’s discretion in the event of clinically significant abnormalities.  
p Blood for immunology endpoints will be collected as specified in the laboratory study event schedule and as per written SSPs.   Blood volumes do not include finger stick  amount. Approximate total blood volume to be collected is <500 mL in 6 months.  
 
360_CampETEC _Campy_Protocol_V 1.1_12September 2023  18  
1.0 BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE  
1.1 Diarrheal Disease  
Gastrointestinal infections cause significant morbidity in the form of acute diarrheal illness in the United States (US) [1] and among 
travelers to low - and middle -income countries (LMICs) [2]. Among infants, young children, and vulnerable populations in r esource -
limited countries, the acute morbidity and mortality stemming from infectious diarrhea are particularly meaningful [3]. Nearl y 500,000 
deaths occurred among children aged ≤5 years in 2016 alone [3]. Although the number of pediatric deaths due to di arrhea has decreased 
over the last several decades, morbidity remains unchanged. In addition to the acute illness, diarrhea can lead to the develo pment of 
wasting and stunting in the most vulnerable children, causing long -term chronic disease and cognitive  limitation [3].  
Diarrhea continues to be the most frequent health problem among travelers with destinations in lower  and middle -income regions [4]. 
Deployed US military personnel, essentially representing a long -term traveler population, are particularly affected given their 
population dynamics and the context in which they seek care and treatment [5]. Diarrhea is the le ading infectious disease threat to the 
overall health and preparedness of deployed US armed forces, with diarrheagenic E. coli , Campylobacter spp., and Shi gella spp. 
among the most commonly reported etiologies [2, 6]. Diarrheal illness threatens operational capability through lost duty days  and 
mission degradation and has had historically devastating effects on military units in almost all identifiable milit ary campaigns [5, 7]. 
Research outlining the impacts of TD on military deployments continues to accumulate alongside a burgeoning evidence base of the 
chronic health consequences of the illness [8 -10]. Corollaries to this deployment health threat collectiv ely include the direct costs of 
acute diarrheal illness, secondary costs and risks associated with diminished service capabilities, and potential for long -term costs of 
post-infectious care and treatment [11].  
Diarrheal disease is primarily managed by oral rehydration and antibiotic treatment; however, antibiotics are not recommended  for 
prophylaxis due to risks of side -effects from prolonged use and increasing levels of antibiotic resistance globally [12, 13]. Until 
vaccines become available, there is an urgent need for the development of effective primary prevention modalities that are su itable 
for use in different contingencies.  
1.1.1 Campylobacter  
Campylobacter is a leading cause of foodborne disease in the US, is associated with 7.5 million disability adjusted life year s globally 
[23] and  is a pathogen of concern in pediatric populations in LMICs and adult travelers to those same regions [1, 2, 24]. 
Campylobacteriosis disproportionately affects poor and marginalized populations of the developing world and is particularly 
hazardous to the h ealth and viability of infants in this region. The global diarrhea burden caused by Campylobacter spp. is estima ted 
to include 88 million episodes in children aged ≤5 years, resulting in roughly 41,000 deaths [3]. Among all age groups, the e stimates 
of episodes and deaths are roughly 172 million and 75,000, respectively [3]. In the US, Campylobacter causes more than  1.5 million 
illnesses each year mostly due to the handling and consumption of raw or undercooked poultry [1, 25]. For travelers, Campylob acter 
causes a severe form of TD, often associated with longer illness duration, increased number of unformed stools, and a high frequency 
of other symptoms (abdominal pain, nausea, vomiting, and fever) in comparison with other TD etiologies [2]. In addition, 
Campylobacter infection is associated with several  important sequelae, including  Guillain -Barré syndrome (GBS), reactive arthritis, 
irritable bowel syndrome, and, to a lesser extent, inflammatory bowel disease [8]. Until recently, campylobacteriosis has bee n viewed 
as a self -limiting illness that is ameliorated by antibiotic treatment ; however, resistance of Campylobacter to antibiotics, particularly 
fluoroquinolones, has become a concern [26]. Thus, alternative measures to control infection are needed.  
C. jejuni  lacks virulence factors analogous to those of better -characterized pathogens [27]. However, the C. jejuni  CPS was recently 
identified and is now recognized as a major virulence factor and the focus of vaccine development efforts [28, 29]. A total o f 47 
C. jejuni  capsule types have been described and through structure homology can be collapsed into 35 groups [30]. Based on scant 
epidemiological data from developing countries, it appears that a limited number of C. jejuni  capsule types are responsib le for the 
majority of the disease [31].  
 
1.2 Rationale for a Campylobacter -ETEC Hyperimmune Bovine Colostrum (CampETEC HBC)  
Vaccines have been repeatedly demonstrated to be a cost -effective means of primary disease prevention; however, vaccine 
development is a long and costly process and there are currently no licensed vaccines available for ETEC or C. jejuni . As such, 
alternative options with a less prolonged and costly footprint for development are needed. One modality that has shown consid erable 
promise in diarrhea prevention is passive, oral administration of HBC, hyperimmune bovine colostrum. Briefly, cow s immunized with 
antigens derived from viral, bacterial, or parasitic enteropathogens, produce high levels of antigen -specific IgG in their colostrum. 
Manufacturing processes to make  concentrates of these products that are highly enriched for IgG are well -developed, reliable, and 
effective. In a number of clinical trials, HBC as well as bovine serum IgG (BSIgG), with specific activity against enteropath ogens like 
ETEC, Shigella, and r otavirus, have shown to prevent diarrheal disease in CHIMs [32 -37]. While there is no bovine immunoglobulin 
antidiarrheal product licensed in the US for human use, there are comparable veterinary products [38] as well as commercially  
available as a dietary supplement. Using this platform, we are advancing an ETEC -C. jejuni -based hyperimmune bovine colostrum 
(HBC) using immunizing antigens for cows developed from ongoing human vaccine development efforts.  
1.2.1 C. jejuni  HS23/36 Capsule  
As noted above, the C. jejuni  capsule is a major virulence determinant for Campylobacter -mediated disease. Mutants deficient in 
capsule production exhibit decreased adherence and binding in vitro [43], complement resistance [44], and exhibit reduced 
colonization in the ferret model of  disease [43]. NMRC is currently developing a C. jejuni  CPS conjugate vaccine for the prevention 
of campylobacteriosis in US military troops [45]. The prototype vaccine is composed of HS23/36 CPS type conjugated to CRM 197. 
360_CampETEC _Campy_Protocol_V 1.1_12September 2023  19 When parenterally administered to Aotus nancymaae , the vaccine demonstrated 100% protection against disease following challenge 
with a C. jejuni  strain expressing the HS23/36 CPS type [45].  
1.2.2 ETEC CfaEB  
As part of an active ETEC vaccine development program, investigators at NMRC developed a recombinant fusion protein containin g 
the adhesin (CfaE) and pilin (CfaB) subunit proteins of CFA/I as part of one component of a multivalent vaccine approach. In a Phase 
1 CHIM study, an HBC concentrate derived from cows immunized with killed ETEC of many different serotypes and a cocktail of 
enterotoxins yielded 100% protection following challenge with the prototype ETEC strain H10407 (CFA/I; LT/ST; O78:H11) [32]. 
The central role of exogenous antibodies to CFA/I in such protection was confirmed in a subsequent trial where orally administere d 
HBC made from cows immunized with purified CFA/I conferred 90% protection against H10407 challenge in a placebo  controlled 
volunteer trial [37]. Investigators at NMRC followed that work by demonstrating that HBC made from cows immunized with purifi ed 
CFA/I as well as CfaE significantly protected volunteers from diarrhea after challenge with ETEC strain H10407 [35].  
While antibodies against CfaE are expected to neutralize ETEC adhesion to host cells and protect against infection, CfaE is o nly a 
minor component of CFA/I and the majority of antibodies raised against CFA/I are to CfaB. Although CfaB is not thought to 
participate in the adhesion of ETEC to epithelial cells, oral administration of anti -CFA/I HBC to human volunteers was also protective 
against ETEC challenge. Thus, anti -CfaB antibodies may also play a role in protection against ETEC infection. In contrast to  
neutralizing the functionality of the fimbriae, the anti -CfaB antibodies damage the biomechanical properties of the fimbriae by 
increasing their stiffness and, due to their bivalent binding moiety, tangling two or more fimbriae together [39]. Given the lack of 
sufficient antibody response to CfaE in immunizations with CFA/I, we designed a stable, recombinant fusion that consists of d onor 
strand complemented CfaB fused to the C -terminus of CfaE, resulting in a CfaE -CfaB fusion (CfaEB) using donor strand 
complementation as previously described [40]. In mice, intradermal immunization with an attenuated mutant of the heat -labile 
enterotoxin led to robust immune responses against both CFA/I and to CfaE [41, 42].  
1.2.3 Campylobacter -ETEC CPS -CfaEB  
Based on these data, a research grade formulation of the CPS -CfaEB conjugate was recently evaluated for immunogenicity in mice 
and demonstrated an ability to induce robust immune responses against both the C. jejuni  and ETEC components [46]. A similar 
construct has been utilized to immunize cows, and colostrum from the immunized cows has been collected and will be processed to 
assess whether antibodies directed to this conjugate bi -pathogen vaccine are able to preven t ETEC - and Campylobacter -attributable 
illness in two separate controlled human infection model (CHIM) studies.  
1.3 Previous Clinical Studies Using Bovine -Derived Immunoprophylactics  
While the CampETEC product has not been administered to humans previously, concentrates of immunoglobulin from bovine milk, 
colostrum, or serum have been evaluated in several human clinical trials in hundreds of volunteers, and these products have b een ver y 
well-tolerated. The products have been investigated as both a prophylactic and treatment for infectious diseases caused by organis ms 
like diarrheagenic E. coli  [35-37, 47 -52], rotavirus [34, 53 -55], Shigella [33], V. cholerae  [56], Cryptosporidium parvum  [57-60], 
Clostridium difficile  [61, 62], and Helicobacter pylori  [63]. Depending on the target disease and population, the products have been 
tested for safety and efficacy in healthy adults, immunocompromised adults and children, and healthy children or children hos pitalized 
with diarrhea.  
1.4 C. jejuni  CG8421 Controlled Human Infection Model  
The C. jejuni  CG8421 strain was isolated from a 29 -year-old male US soldier deployed in Thailand and is sensitive to nalidixic acid, 
ciprofloxacin, and azithromycin, with resistance to tetracycline. The strain has been characterized in detail and was determi ned to lack  
ganglioside mimicry [ 64, 65]. Clinical evaluation of C. jejuni  strain CG8421 has been undertaken in healthy adult participant s at doses 
ranging from 1 x 104 CFU to 1 x 106 CFU, with an acceptable safety profile [ 66-68]. After an initial dose -ranging study  [66], the strain 
was subsequently utilized to assess the efficacy of a prototype vaccine, ACE393; however, doses administered fell below the t arget 
dose of 5 x 105 CFU, which yielded lower placebo attack rates than anticipated (71%) (B. Kirkpatrick, personal communication; 
[STUDY_ID_REMOVED]). The strain was used in a subsequent study of homologous protection; however, there were no significant differen ces 
were observed in  the number or volume of diarrheal stools, incubation time, or duration of the diarrheal episode among those who 
met the primary outcome [ 68]. Most recently, 1.7 x 105 CFU was given in a randomized, double -blind study testing the prophylactic 
efficacy of r ifaximin, producing an 84.6% attack rate among participant s receiving placebo [ 67]. In the initial dose -finding study, 3 
unexpected events of microbial recrudescence of the challenge strain occurred in two participant s (8.7%) [ 66]. All three events 
occurred after apparent clearance of the C. jejuni  strain and discharge from the clinical unit, after completing a course of azithromycin 
treatment. The recrudescent events were treated with additional courses of antibiotics, closely monitored, and evaluated by t he clinical 
team. Subsequent studies with this strain have closely monitored for recrudescent infection, to include extended antibiotic t reatment 
and duration of follow -up. In the most recent study, a higher rate (17.9%) of recrudescence 3 -4 weeks post -inoculation was observed 
[67]. One possible explanation for this higher recrudescence rate is a slight modification of the stool microbiological methods used 
for Campylobacter culture post -inoculation. Specifically, stool specimens were incubated in thioglyco late broth prior to plating on 
CVA (cefoperazone, vancomycin, and amphotericin B) solid media. This intermediate incubation in thioglycolate had not been ut ilized 
in previous trials but  will be utilized for the study described herein.  
2.0 OBJECTIVES  
2.1 Primary Objectives  
The primary objectives of this study are:  
1. To estimate protective efficacy of CampETEC HBC against campylobacteriosis  following challenge with C. jejuni  strain 
CG8421  
360_CampETEC _Campy_Protocol_V 1.1_12September 2023  20 The primary efficacy outcome is campylobacteriosis, defined as a clinical illness meeting at least one of the following patterns 
starting within 144 hours of challenge:  
• Moderate diarrhea (4 to 5 loose/liquid stools or 401 -800 grams) OR  
• Severe diarrhea ( ≥ 6 loose/liquid stools or > 800 grams) OR  
• Fever (present on at least 2 occasions, at least 20 minutes apart) without diarrhea, plus an associated symptom (nausea, 
vomiting, abdominal cramps, tenesmus, or gross blood in ≥ 2 stools); with consideration of potential alternative diagnosis 
per clinical  investigator based on illness time course and associated symptoms.  
 
2. To assess the safety and tolerability of CampETEC HBC  
 
2.2 Secondary Objectives  
The secondary objectives of this research are to assess a variety of clinical endpoints to further evaluate the efficacy of CampETEC. 
Secondary efficacy endpoints are chosen to support the primary endpoint in determining the PE of the CampETEC product. They 
further quantify and qualify the degree to which a participant experiences  Campylobacter -attributable  diarrhea.  
• Secondary endpoints will be to e valuate the efficacy of CampETEC in reducing various clinical and microbiological 
outcomes (e.g. disease severity, fever, dysentery, stool frequency, shedding).   
 
2.3 Exploratory Objectives  
Exploratory objectives are to measure mucosal and systemic immune responses to the challenge organism, and to obtain and archi ve 
samples for future immunologic, proteomic, microbiome, and/or systems biology efforts. Additionally, . Additionally, we  will assess 
the utility of a novel Campylobacter  disease scoring metric, and participant s may also be evaluated to assess the role of sleep on 
disease susceptibility as well as the effect of acute infection on cognition (as assessed by a psychomotor vigilance test ). 
3.0 STUDY DESIGN  
This is a randomized, double -blind, placebo -controlled study designed to investigate whether CampETEC HBC protects adult 
volunteers from clinical disease upon challenge with C. jejuni  strain CG8421 . Up to 30 participant s will be randomized to receive 
either the investigational product or a placebo followed by challenge with C. jejuni  strain CG8421 .  
Table 2 : Description of Study Groups  
Test Article  n Dose Amount (in grams IgG)  
CampETEC  HBC  15 1.0 g tid  
Placebo (ProMilk 85)  15 1.0 g tid  
 
The trial will consist of 1 -3 screening visits, approximately 1 3 inpatient days, 5-6 out-patient follow -up visits, and a follow -up phone 
call at 6 months post challenge. Participant s will be admitted 3 days prior to challenge (SD -3), receive HBC or placebo three times 
daily starting 2 days prior to challenge (SD -2). The  C. jejuni  strain CG8421 challenge  will be administered on Study Day 1. 
Participant s will continue HBC  dosing through the end up study day 6 ( until antibiotic treatment is initiated on study day 7), or sooner 
if criteria for early treatment are met.  
Each CampETEC  HBC  unit (1 g of product in a foil packet), will be reconstituted by the research pharmacist  in 150 mL water 
containing 2 g sodium bicarbonate for ingestion by a single individual. Each volunteer will receive either the HBC  or placebo 3 times 
a day , approximately 15 minutes post meals for a period of 8 days (from 2 days prior to challenge through study day 7) or until 
antibiotic treatment is initiated.  
Previous CHIM studies utilizing this formulation have been successful, with participant s exhibiting minimal complications other than 
flatulence [1]. A high protein milk product called ProMilk 85 will be commercially sourced and used as a placebo control in t he study. 
The placebo will be repackaged and labeled to mirror the HBC  product and should appear similar to the HBC product when 
reconstituted.  
Upon admission to the inpatient unit, clinical monitoring will consist of  
• daily medical assessments with adverse event (AE) determination,  
• vital signs at least three times daily,  
• weighing and grading of all stools,  
• stool culture for the challenge study strain (up to 3 samples  daily)  starting day after challenge , and  
• safety laboratory tests –- CBC, chemistry, renal, and hepatic panels.  
Antibiotic treatment will be initiated on study day 7 or according to criteria for early antibiotic treatment. Participant s will be 
discharged from the inpatient facility when they feel well enough (clinical symptoms are resolved or resolving), 2 consecutiv e stool 
samples culture negative for the challenge strain and at least two doses of antibiotic treatment have been taken.  Routine discharge is 
scheduled for day 10–- when most participant s are expected to meet the discharge criteria. Participant s may be discharged earlier than 
day 9 on if they meet criteria  per the PIs’ discretion . Participant s who do not meet the discharge criteria on day 10 will remain on the 
unit until all criteria have been met. The duration of the active study period is approximately twelve  months, encompassing up to 90 
360_CampETEC _Campy_Protocol_V 1.1_12September 2023  21 days of screening/enrollment, 12 weeks for the inpatient/outpatient phase when data and samples will be collected, 12 weeks for 
immunology assays, and 3 months for analysis and reporting. Additionally,  participant s will be contacted approximately 6 months 
after challenge to assess SAEs , AESIs, and any new chronic illnesses , and to complete the functional bowel disorder survey.  
4.0 STUDY POPULATION  
The study site will recruit participants from the greater Baltimore, Washington DC and the broader mid -Atlantic and the northeast 
regions using a wide range of IRB -approved print, digital, video and audio advertisements including (but not limited to) flyers, 
brochures and recruitment scripts. General advertisements  approved under the CIR adult screening protocol in addition to study 
specific ads approved under this protocol may be used to recruit for this study. Other recruitment methods may include (but a re not 
limited to) the use of third -party marketing and advertising services, social media platforms, websites dedicated to pairing research 
participants with research studies, electronic medical record recruitment messaging, and reaching out to previous CIR study 
participants who’ve agreed to be contacted about upcoming studies.  
Participants responding to advertisements may contact the CIR directly by phone, email, or website. If responding to a third -party 
marketing campaign, they may submit their contact information directly to the website(s) to be contacted by CIR study staff ( note: 
identifiable information obtained on 3rd party platforms is encrypted, stored according to applicable guidelines and regulations and 
accessible only to authorized CIR staff). Interested individuals will be pre -screened for eligibility using a standar d pre -screening 
questionnaire administered on -line or by CIR staff. Participants who successfully complete the online questionnaire will be contacted 
by CIR staff to schedule a screening visit. In both cases, some elements of the inclusion/exclusion criteria will be discussed with the 
participant to determine preliminary eligibility prior to scheduling a screening visit. Telephone and on -line pre -screening and in -
person screening visits are conducted under a separate IRB -approved general screening protocol (“Screening of Adult Subjects  for 
Eligibility to Participate in Clinical studies evaluating investigational vaccines, antimicrobial agents, other  disease preventi ve 
measures or the pathogenesis of infectious agents” CIR 200, JHSPH IRB 00010083).  Participants  who are eligible after completing 
the general CIR200 screening may be asked to complete a study -specific screening under this protocol . 
4.1 Participant  Inclusion Criteria  
Inclusion Criteria:  
1. Adult between 18 and 50 years of age, inclusive.  
2. General good health, without significant medical illness, abnormal physical examination findings, or clinical laboratory 
abnormalities, as determined by principal investigator (PI) or PI in consultation with the research monitor and sponsor.  
3. Demonstrate comprehension of the protocol procedures, requirements, and CHIM by passing a written examination (passing 
grade ≥ 70%).  
4. Willing to participate, as evidenced by signing the informed consent document.  
5. Available for all planned follow -up visits.  
6. Negative serum pregnancy test at screening and negative serum and/or urine pregnancy test on the day of admittance to the 
inpatient phase for participants of childbearing potential. Participants of childbearing potential must agree to use an effic acious 
hormonal or barrier method of bi rth control during the study. Abstinence from intercourse with a male partner is acceptable. 
Participants who no longer have childbearing potential must have this documented (e.g., tubal ligation or hysterectomy).  
4.2 Participant Exclusion Criteria  
 
1. Presence of a significant medical condition (e.g., psychiatric conditions, such as significant anxiety, depression, or 
somatization disorder; gastrointestinal disease, such as peptic ulcer, symptoms or evidence of active 
gastritis/dyspepsia, gastroesophage al reflux disease, inflammatory bowel disease, irritable bowel syndrome (as 
suggested by the functional bowel disorder survey or medical diagnosis); alcohol or illicit drug abuse/dependency; 
or laboratory abnormalities that in the opinion of the investigat or preclude participation in the study. Significant 
medical conditions include evidence of cardiac, pulmonary, endocrine, neurologic or renal disease that is 
uncontrolled or poorly controlled, any diabetes mellitus, and other such illnesses that can put a volunteer at 
increased risk. Exclusionary laboratory abnormalities include any abnormality that is grade 2 or above.  
2. Immunosuppressive illness or evidence of IgA deficiency (serum IgA < 7 mg/dL or below the limit of detection of assay), or 
any autoimmune disease.  
3. Positive serology results for HIV, hBsAg, or HCV antibodies, and confirmatory tests if appropriate.  
4. Positive urine toxicology screen for amphetamines, barbiturates, benzodiazepines, cocaine metabolite, methadone metabolite, 
opiates, oxycodone, or phencyclidine.  
5. Significant abnormalities in screening laboratory hematology or serum chemistry, as determined by PI or PI in consultation 
with the research monitor and sponsor.  
6. Evidence of abnormal ECG findings per PI (e.g., QT prolongation)  
7. Use of any medication known to affect immune function (e.g., regular systemic corticosteroids, monoclonal antibodies that 
target key aspects of the immune system (such as rituximab or TNF blockers); others [topical, intranasal and inhaled steroids  
will be permitted]) within 30 days preceding receipt of the investigational product or planned to be used during the active 
study period.  
8. Nursing or lactating on the day of admittance to the inpatient unit.  
9. Inability to tolerate 150 mL sodium bicarbonate buffer (based on requirement for frequent dosing).  
10. Recent vaccination  (including licensed vaccines) or receipt of an investigational product (within 30 days before challenge 
through 30 days following the last challenge dose).  
11. Prior history of C. difficile  infection  
12. History of diarrhea in the 2 weeks prior to planned inpatient phase.  
13. Fewer than 3 stools per week or more than 3 stools per day as the usual frequency, or loose or liquid stools other than on an  
360_CampETEC _Campy_Protocol_V 1.1_12September 2023  22 occasional basis.  
14. Regular use of laxatives or any agent that increases gastric pH (regular defined as at least weekly).  
15. Use of proton pump inhibitors, H2 blockers, or antacids within 48 hours of dosing.  
16. A fever (≥ 38.0°C)  in the 2 weeks prior to time of challenge.  
17. Use of antibiotics during the 7 days before bacterial dosing or receipt of more than 2 courses of antibiotics over the two 
months prior to dosing.  
18. Blood donation within 30 days prior to the planned receipt of this IP.  
19. Lactose intolerance or allergy to milk or milk products.  
20. Personal or documented family history of Guillain -Barré syndrome or neuromuscular disease; or an inflammatory arthritis 
such as reactive arthritis, ankylosing spondylitis, or rheumatoid arthritis.  
21. Evidence of inflammatory arthritis on exam.  
22. HLA -B27 positive.  
23. Allergy or prior intolerance to two or more of the following: fluoroquinolones, azithromycin, augmentin or cephalosporins   
24. Have household contacts who are < 2 years old or > 80 years old or infirm or immunocompromised.  
25. Employment as a healthcare worker with direct patient care, in a daycare center (for children or the elderly), or direct food  
handler; includes individuals who work directly with food in commercial establishments.  
26. History of microbiologically confirmed Campylobacter  infection in last 3 years.  
27. Serological immunological evidence of prior Campylobacter  exposure defined as Campylobacter  antigen -specific 
(GE)specific anti -glycine extract serum IgA endpoint titer > 1:4,000.  
28. Occupation involving handling of Campylobacter , currently  or in the past 3 years.  
29. Symptoms consistent with travelers’ diarrhea concurrent with travel to countries where Campylobacter , Cholera, Salmonella, 
Shigella , Typhoid  or ETEC infection  are endemic (most of the developing world) within 3 years prior to dosing, OR planned 
travel to endemic countries during the length of the study.  
 
30. Vaccination for or ingestion of Campylobacter , Cholera, Salmonella. Shigella, Typhoid or ETEC  within 5 years prior to 
dosing.  
31. Other dietary or environmental exposures that may place the participant at high risk for prior Campylobacter  exposure (to be 
determined on a case -by-case basis by the PI) . 
 
Vaccination  
5.0 STUDY PROCEDURES  
5.1 Study -Specific Screening and Consenting  
Screening, consenting and eligibility evaluations and procedures will be carried out over about 1 - 3 visits under the general screening 
protocol and/or this study protocol during the study specific screening and consenting visit. Medical history, laborato ry specimens 
and physical examination may be obtained/completed during general screening or deferred to study specific screening under thi s 
protocol. See Section 6.0, Study Schedule for detailed information about screening procedures and assessments.  
During study -specific screening, study staff will present study information , employing multiple IRB -approved formats to aid 
understanding across a wide range of volunteers from different backgrounds. Potential volunteers will be asked to read the in formed 
consent document and complete a multiple choice/short answer comprehension assessment.  
Prior to signing the informed consent document, all volunteers must be able to pass a written comprehension assessment with a 
minimum passing grade of 70%. Incorrect answers will be discussed with volunteers and corresponding parts of the consent revi ewed. 
Participant s who are not able to achieve a passing score on the first attempt may retake the comprehension assessment on the same 
day or may reschedule for another time. Participant s who are unable to demonstrate comprehension of essential study informati on by 
answering 70% of the questions correctly after two attempts are not be eligible for study enrollment. Informed consent is an ongoing 
process. Ensuring that consent is voluntary and competent throughout the duration of the trial is a component of ever y assessment and 
procedure.  
Consent forms will be signed and dated by participant s as well as by the PI or design ated study staff  prior to completing any study 
assessments or procedures. As part of the consent interview, participant s will also be asked to read and sign additional IRB -approved 
forms. Participant s will receive a signed copy of the Informed Consent document as well as other signed documents and encouraged 
to keep them with their other health records. Screening, consenting and eligibility evaluations/procedures will be ca rried out over 1 - 
3 visits under the general CIR200 screening protocol and/or this study protocol during the study specific screening and consenting 
visit. See Section 6.0, Study Schedule for detailed information about screening procedures and assessments.  
Based on current COVID -19 illness in the community and CDC and JHU guidelines, volunteers may be asked to come to the center 
or obtain a COVID -19 test 1 -5 days prior to admission or they may be contacted and asked about COVID -19 symptoms. All volunteers 
will be COVID -19 tested on admission to the unit. Any volunteer who tests positive for COVID -19 will not be eligible for that 
admission.  
360_CampETEC _Campy_Protocol_V 1.1_12September 2023  23 During screening, participants will be asked to complete a Functional Bowel Disorder Survey to screen for GI dysfunction and 
establish a baseline of general GI health for subsequent surveys (may be administered by study staff or self -administered ). 
More volunteers may be consented for study participation than can be enrolled , to allow for alternates to replace anyone who does not 
report for admission  or is deemed ineligible prior to receiving the investigational product. Up to two alternates may be admitted on 
Day -3, complete Day -3 continuing eligibility review and remain on the unit overnight until the first dose of IP is given. Volunteers 
designated as alternates will replace participant s who become ineligible during continuing eligibility review  or decide not to participate 
after admission  but prior to receipt of IP . Alternates  not replacing a participant  will be discharged on Day -2 prior to IP administration  
and no further follow up will be d one. Enrolled participant s who do not complete the study will not be replaced.  
5.2 Randomization  
Should more than the requisite number of participants remain eligible and interested in participating in the study, participa nts will be 
selected using a random number generator stratified by gender to ensure appropriate room allocation.  
Consenting, eligible participants will be randomized in a 1:1 ratio to receive either the test article or placebo. The random ization 
scheme will utilize block sizes as described in the MOP  to ensure comparable numbers of  HBC  and placebo recipients.  
The randomization procedure will be described in the MOP. A study statistician will write code and the seed(s) for the random  
number generator will be documented. When a participant is randomized, the statistician will conduct and document quality con trol 
(QC) of the randomization plan, treatment table and all other related documents using the statistical considerations. Once th e 
treatment table has been finalized, the person performing product formulation will be provided a list of the coded treatment numb ers 
with their corresponding unblinded treatment assignments, as well as the sealed back -up manual randomization list. In the event a 
randomized participant is no longer eligible prior to receiving the IP, one of the alternates will replace that participan t (as available).  
5.3 Study Identification Number  
Once study specific consent has been obtained  participant s will be assigned a study number. Participant s will receive the test 
article/placebo in containers bearing their assigned study  number. This number will be linked to the randomization code list securely 
maintained throughout the clinical phase of the study by the designated NMRC staff and the JHU research pharmacist. Study num bers 
will also identify all samples for laboratory analyses.  
5.4 Blinding  
Investigators and participants will remain blinded to group assignments until completion of the clinical phase of the trial a nd validation 
of the clinical and immunological data. Each sachet will be labeled with an open label. The research pharmacist will use the 
randomization list to prepare the IP product for dosing. All mixing and administration of the test article/placebo will be performed per 
formulation and product administration study specific procedures. Administration will occur in a separate room from where the doses 
are formulated. Participants will receive the test article/placebo in containers bearing their assigned study numbers which are linked 
to the randomization code list securely maintained by unblinded members of the research team throughout the clinical phase of  the 
study.  
In the event of emergency, the site Investigator may require that the blind be broken for the participant  experiencing the emergency , 
when knowledge of the participant 's treatment assignment may influence the participant 's clinical care. Emergency unblinding can 
occur by using the randomized list of participant investigational product assignment that will be kept in a sealed envelope under lock  
and key at the clinical site . Every effort will be made not to unblind the participant  unless it is considered nec essary for the welfare of 
the participant . Prior to unblinding, the site Investigator is encouraged (to the extent possible, without jeopardizing the participant 's 
health) to contact the Sponsor (or designee) to discuss the decision to break the blind. The PI will be expected to provide a  rationale 
for the necessity of unblinding based on the expectation that knowledge of the participant 's treatment assignment will have a 
meaningful impact on the participant 's medical care in the short term. If a participan t's treatment assignment is unblinded, the 
participant  will remain in the study and continue with protocol -defined study visits, but not receive additional investigational product. 
The decision to unblind will be communicated to any regulatory bodies (e.g., institutional review boards [IRBs]) as required.  
5.5 Clinical Evaluations  
5.5.1 Monitoring During Inpatient Phase  
The Center for Immunization Research’s (CIR) inpatient facility at the Johns Hopkins Bayview Medical Center is a self -contained 
unit, suited for conducting inpatient  studies. Participant s will remain at the inpatient facility under clinical observation  by study staff 
at all times . During each day of the inpatient period, volunteers will be evaluated by a study physician, nurse practitioner, or physicia n 
assistant. The study providers will conduct daily medical assessments with AE determination. Participant s will be monitored for 
solicited signs and symptoms listed in section  8.4.1.2  and/or an abnormal abdominal exam. Vital signs will be assessed at least three 
times daily – more often if participant  is ill. Volunteers will collect all the stool they produce from study day -22 until 2 consecutive 
stool samples test negative for the challenge strain. All s tools will be weighed, graded and evaluated for blood. Stool cultures or rectal 
swabs for the challenge study strain will be done at least once daily starting  on Study Day 2 (or study day 1 if volunteer develops 
grade 3 -5 stools and might be started on early antibiotic  treatment) . If a participant  is unable to provide a stool sample by 1300 hours, 
they will be asked to obtain a sample using a rectal swab. Safety laboratory tests are also planned. In cases of moderate to sever e 
diarrhea, postural blood pressure (BP) and pulse may be assessed as tolerated, to support clinical management decisions according to 
the judgment of the PI/study providers. Participant s will be examined for other signs and symptoms of dehydration, including thirst, 
dizziness on standing, decreased skin turgor, lightheadedness and dryness of mucous membranes.  
360_CampETEC _Campy_Protocol_V 1.1_12September 2023  24 5.5.1.1  Rehydration Procedures  
Participant s passing grade 3 -5 stools post -challenge will be offered ORS and electrolyte drinks to prevent dehydration, at the same 
volume as their stool output. ORS /electrolyte drinks  will not be considered a concomitant medication , while IV fluids will. Treatment 
for severe nausea or vomiting may be needed. Participant s who experience severe nausea or vomiting may be given ondansetron 
(Zofran) ODT or ondansetron IV.  
A participant  may be given IV fluids at the PI or d esignee’s discretion , for the following reasons:  
• Participant  experiences abrupt onset of diarrhea , defined as passage of an initial grade 3 -5 stool of > 300 grams or passage 
of > 400 grams of grade 3 -5 stools within  2 hours.  
• Participant  becomes hypovolemic as defined below.  
• It is determined necessary by a study clinician , i.e., the participant has diarrhea with nausea/vomiting and is unable to 
drink enough to replace their  output, or other reason.  
Hypovolemia is a significant decrease in blood volume, characterized by:  
• Hypotension, characterized by a confirmed systolic blood pressure (BP) < 90 mmHg and associated symptoms  
• Or orthostatic hypotension defined as  a confirmed postural change in BP or pulse. Postural vital signs will be measured lying  
supine  and again after 2 minutes  of standing, if tolerated by participant . The following will be conside red a significant change: 
decrease in systolic BP of > 20 mmHg, or diastolic BP of > 10 mmHg or increase in pulse of > 30 beats/min  
5.5.1.2  Routine Discharge  
Routine discharge is scheduled for study day 10. Two consecutive negative stool cultures for the challenge strain are required before 
discharge (can be collected on the same study day). If the participant  has not completed antibiotics, then the remaining doses of 
antibiotic will be given to the participant , along with education on  self-administration. Vital signs will be collected  and a focused 
physical exam will be done . 
5.5.1.3  Early Discharge  
Early discharge is permitted in cases where early antibiotic treatment has been initiated and the participant  has otherwise met discharge 
criteria , including : 
• 2 consecutive stool cultures negative for the challenge strain,  
• 2 doses of both antibiotic taken, and  
• resolved or resolving clinical symptoms.  
Participants who meet early discharge criteria will be given the option to leave the unit and return for Day 8 as an outpatient  or to 
remain on the unit as a boarder. Once a participant is eligible for discharge,  they will  only undergo the procedures required for Day 8 
and outpatient visits ,, rather than the usual daily procedures . Concomitant medications  will still be administered by study staff  to any 
boarders . Participant s who are discharged and leave the unit before Study Day 8 will be provided with any remaining doses of 
antibiotic and will return on day 8 and provide the requisite samples (stool, blood) and undergo required procedures as delineated in 
Table 1.  
5.5.2 Monitoring During Outpatient Phase  
The participant s will return to the CIR for outpatient visits on Study Days 15, 29, 42, 57, and 85. There is a phone call visit on Study 
Day 181. Some or all of the following procedures may be conducted, as outlined in Table 1: Time and Events Schedule.  
• Interim medical history  
• Review of any new or change in AEs through day 85  
• Physical assessment , (only if participant with GI symptoms, SAE or AESI, as indicated ) 
• Assessment AEs (through day 85) , AESIs, and/or SAEs (through day 181)  
• Vital signs (heart rate, blood pressure, and oral temperature)  
• Serum sample for immunological testing  (per schedule of events)  
• A stool sample for assessment of eradication of the challenge strain of C. jejuni, if the patient cannot produce a stool sample 
they should reschedule to a different day within the allocated window (e.g. ±2), as a last resort a rectal swab could be obta ined 
• A stool sample for exploratory endpoints when required  
• Serology for assessment of anti -C. jejuni specific serum immune responses  when required  
• Review of any new or change in  concomitant medications  (through day 57) 
• Functional Bowel Survey on day 181 
 
5.6 Concomitant Medications/Treatments  
Only concomitant medications approved by the study physician will be administered  during the study. Participant s needing to take 
unapproved or excluded medication s will not be eligible for enrollment . Participant s taking a permitted medication (i.e., birth control 
pills) prior to enrollment will be allowed to continue. Prescription medications brought onto the unit must be in in the original 
packaging, will be stored in a locked drawer in the nurse’s station and will be dispensed by a study clinician to the volunte er as 
prescribed. Any medication ordered during the trial (i.e., Acetaminophen, Ibuprofen, Azithromycin, or alternative, anti -emetics) as 
well as ongoing medications will be documented in the participant ’s study chart and on the appropriate page of the eCRFs.  
 
360_CampETEC _Campy_Protocol_V 1.1_12September 2023  25 5.6.1 Antibiotic Treatment  
Antibiotic treatment after challenge will be administered according to criteria for early antibiotic treatment, or on Study D ay 7 if early 
treatment criteria are not met. All participant s will be treated with azithromycin (500 mg by mouth once daily for 5 days)  concurrently 
with ciprofloxacin (500 mg by mouth BID for 5 days)  Alternate antibiotic treatment to which the strain is susceptible may also be 
considered, as clinically appropriate. If the study physician determines that IV antibiotics are required,  then these will be supplied 
through Bayview pharmacy.  
5.6.2 Criteria for Early Antibiotic Treatment  
Early antibiotic treatment after challenge may commence when any of the following criteria are identified and a study physici an 
considers it to be warranted , (once antibiotics are started the participant will no longer take the HBC/placebo IP) : 
• When participant  meets the primary endpoint (clinical definition of campylobacteriosis )  
• Confirmed oral temperature ≥ 39°C (after volunteer has not had anything to drink for about 20 minutes)  
• Any other reason warranting early treatment in the physician’s opinion  
 
Administration of IV antibiotic treatment may be performed if warranted by the investigators .  
 
5.6.3 Unscheduled Visit  
If an unscheduled visit occurs, a member of the clinical study team will in terview and evaluate the subject to determine the cause of 
the visit and provide care as needed and information documented in the source data. Adverse events and concomitant medication s 
may be reviewed as indicated . Clinical laboratory tests and physical examination may be done as indicated.  
5.7 Laboratory Evaluations  
5.7.1 Specimen Preparation, Handling, and Shipping  
Research microbiology, including the preparation of live inoculum and culturing of specimens, will be carried out in the labo ratory 
of the CIR in the JHSPH. Immunologic assays will be carried out at the Operationally Relevant Infections Department (ORI) at 
NMRC . Samples collected under this protocol will be used to conduct protocol -related safety , microbiologic,  and immunogenicity 
evaluations. Samples for immunogenicity will be collected at the CIR and maintained at the CIR or core lab until transport to  NMRC 
at a mutually agreed upon time . Storage at NMRC of these biological samples will be handled according to appropriate procedures. 
Any future research use of these biological samples will require IRB approval. Participant s will be asked to consent for the future use 
of their specimens as part of consenting to participate in this study.  
5.7.2 Laboratory Evaluations  
Standard clinical laboratory tests for the purpose of inclusion and exclusion of potential participant s and for safety monitoring will be 
carried out at JHH, JH Bayview Medical Center, or Quest Diagnostics in Baltimore City. Microbiology tests will be done in the  CIR 
bacteriology laboratory. It is possible  that isolates may be sent to the JHH microbiology lab for further testing. Study -related samples 
will be collected, processed, stored, shipped,  and labeled according to the relevant MOP /SSPs. The maximum volume of blood to be 
drawn over any 3 month period of the trial is less than 500 mL, which healthy adults should regenerate within this period and  which 
should not compromise the health of trial participants.  
5.8 Outcome Measures  
5.8.1 Clinical  
The primary safety and tolerability outcome is the presence of CampETEC HBC -associated adverse events during the study period.  
 
The primary efficacy outcome is campylobacteriosis, defined as a clinical illness meeting at least one of the following patte rns 
starting within 144 hours of challenge:  
• Moderate diarrhea (4 to 5 loose/liquid stools or 401 -800 grams in any 24 hour period) OR  
• Severe diarrhea ( ≥ 6 loose/liquid stools or > 800 grams in any 24 hour period) OR  
• Fever (present on at least 2 occasions, at least 20 minutes apart) without diarrhea, plus an associated symptom (nausea, 
vomiting, abdominal cramps, tenesmus, or dysentery (gross blood in ≥ 2 grade 3 – 5 stools with in any 24 hour period); 
with considerati on of potential alternative diagnosis per clinical investigator based on illness time course and associated 
symptoms.  
 
Stool will be graded based on a standard stool grading scale as follows:  
Grade 1 = Firm,  formed (normal)  
Grade 2 = Soft , but still formed  (normal)  
Grade 3 = Thick liquid (diarrheal)  
Grade 4 = Opaque , thin liquid  (diarrheal)  
Grade 5 = Clear or translucent, watery  (diarrheal)  
Secondary efficacy endpoints are chosen to support the primary endpoint of determining the protective efficacy of the CampETEC 
HBC product. They further quantify and qualify the degree to which a participant experiences diarrhea . 
Additional comparisons between the placebo and test article groups as per secondary objectives  Section 2.2.  
360_CampETEC _Campy_Protocol_V 1.1_12September 2023  26 5.8.2 Exploratory Immunological Analysis  
Blood and stools will be collected per the Time and Events Schedule (Table 1) to assess for Campylobacter challenge antigen -
specific serum IgA and IgG responses.  The blood  collected at the clinical unit  will be transferred to the NMRC laboratory and  
assayed for IgG and IgA antibody titers  against Campylobacter  antigen (GE) . Stools will be collected and transferred to the NMRC  
ORI laboratory for extraction to  determine total IgA content and GE-specific fecal IgA responses. The antibody titer ascribed to 
each sample will be reported as reciprocal endpoint titer.  Qualitative (responder rates) and quantitative assessments (log -
transformed values) may be made , in addition to evaluation of the kinetics of the immune response. Median increases (fold -rises) of 
anti-GE antibody titers  and seroconversion rates will be calculated. Exploratory immunological assays may include immunologic 
responses to other relevant Campylobacter  antigens, antibody in lymphocyte supernatant (ALS) responses, memory B cell 
evaluation, flow cytometric assays, fecal inflammatory marker assays, and systems biological assays (proteomics, 
phosphoproteomics) as outlined in the Time and  Events Schedule.  
5.8.3 Microbiological  
Study Day 1  post challenge  though Study Day 9, or  through day of discharge eligibility (if sooner) and  at Days 1 5 (±2), 29 (±2), 42 
(±2), 57 (±2) and 8 5 (±2), intestinal colonization by the challenge strain will be assessed by monitoring fecal shedding patterns by 
qualitative culture.  In the event of a recrudescence on day 8 5, participant s with no prior recrudescence  will be asked to return for a 
follow -up visit on day 11 3 (±2) to provide a stool sample for monitoring of fecal shedding by qualitative culture . Stool  and/or rectal 
swab  samples (at least 1 per participant  per day starting on  Study Day 2) will be screened for the presence of the  C. jejuni  strain 
CG8421  challenge strain. A sample from Day 1, after Challenge may be processed if the participant meets treatment criteria on 
Study Day 1 or 2. Samples will be collected, processed and shipped as per the MOP  and lab SSPs, for qualitative cultures. 
Quantitative cultures for the challenge strain may be performed on selected inpatient days. Additional culture -independent methods 
may be used to quantitate C. jejuni  strain CG8421  shedding.  
5.8.4 5.8.4 Exploratory  
5.8.4.1  Functional Bowel Symptom Development  
An IRB -approved functional bowel disorder survey  will be used to assess the prevalence of baseline bowel symptoms, as well as the 
development of such symptoms at about 6 months after challenge. Incidence of functional bowel symptoms will be compared among 
those who develop the primary endpoint after challenge relative to those who do not, and against the expected incidence in th e normal 
population.  
5.8.4.2  Microbiota  
An assessment of changes in microbiota may be performed employing 16s ribosomal RNA sequencing and/or shotgun metagenomics, 
which assess the entire microbial community present in the collected stool sample. Human gut microbiota is stable in a given host, 
but highly variable amongst individuals. For this reason, stool from each individual participant will be collected prior to in fection to 
establish their specific baseline gut microbiota composition.  
Gut microbiota changes of individual participants may be evaluated following Campylobacter  challenge and compared to their 
“normal” gut microbiota composition (prior to infection). This survey will identify  gut microbiota dysbiosis during the development 
of illness and following CampETEC  HBC  and antibiotic treatments.  
5.8.4.3  Proteomics (Serum & Fecal)  
Stool and serum may be used to evaluate a panel of exploratory biomarkers which may be acutely and persistently modified in 
individuals who are exposed and may or may not develop diarrhea. These specimens will be collected and archived for future us e with 
additional funding being sought. Biomarker domains to be evaluated include:  
Barrier Dysfunction & Dysbiosis: Fecal samples may be assayed for fecal α1 -antitrypsin, a marker of protein leakage into the intestinal 
tract. In addition, to measure changes in barrier function and response, serum may be collected to test for changes in i mmunodominant 
antigens of the microbiota that stimulate T cells and have been shown to be associated with inflammatory bowel diseases. 
Seroreactivity to these flagellins is found in multiple experimental models of colitis in mice. The protein -based microar ray includes 
45 select antigens. Blood samples may be taken for a Limulus amebocyte lysate (LAL) assay . 
Inflammatory dysregulation: Samples may be analyzed for biomarker antigens through the use of multiplex technology (e.g. MSD,  
Luminex). Selected biomarkers may be chosen based upon an assessment for Th1, Th2, anti -inflammatory, pro -inflammatory and 
Th17 re sponses. These cytokines will include but not be limited to , IL-1beta, IL -2, IL -4, IL -5, IL -6, IL -7, IL -8, IL -10, IL -12, IL -13, 
IL17, G -CSF, GM -CSF, IFNg, MCP -1, MIP1b, TNFa, IL -22, IL -23 and IL-33. 
Intestinal Inflammation & Repair: Serum samples may also be tested for changes in levels of leptin (and IL -8), and fecal samples will 
be obtained to evaluate REG1, calprotectin, neopterin, and myeloperoxidase.  
5.8.4.4  Cognitive Evaluation and Actigraphy  
Exploratory evaluations of the cognitive impact of acute diarrhea (assessed by psychomotor vigilance testing (PVT) may be per formed 
according to the Time and Events Schedule. The se outcomes are exploratory in nature and will not be utilized as part of the regulatory, 
safety, immunogenicity, or efficacy evaluations of the study product. If performed, p articipant s will complete PVT assessments while 
at the inpatient facility. The PVT is a measure of a participant ’s ability to respond to an external stimulus over a period of time. Three 
PVT tests per day would  be performed by each participant  up until discharge from the inpatient facility or as outlined in the  MOP . 
Comparisons would  be made between symptom presence/severity and adjusted for other confounding variables.  
360_CampETEC _Campy_Protocol_V 1.1_12September 2023  27 5.9 Outcome Adjudication Committee  
To ensure  an unbiased determination of the efficacy outcomes, an independent outcome adjudication committee, the members of 
which will be blinded as to the treatment regimens of the participant s, will evaluate challenge outcome data after completion of the 
inpatient phase of the study.  
The committee will be comprised of at least 3 individuals, independent of the study sponsor and investigative team, who are e xperts 
on diarrheal illness case identification and pathogen diagnosis. The committee will also include a statistician/data analyst  who will 
lead and coordinate the committee but will not have a voting role in deliberations.  
The committee voting members will review all potential efficacy -related cases and endpoint data. The committee’s responsibilities  
include ,  
(1) review ing and confirm ing all primary endpoint cases , 
(2) review ing all protocol -specified entry criteria, adherence, and compliance issues to ascertain classification in the per -protocol 
and other study populations; and  
(3) provid ing guidance regarding secondary and other endpoint classifications , to include agreement on objective criteria for 
classification of endpoints.  
Specific duties and responsibilities will be outlined by charter prior to the start of the study.  
6.0 STUDY SCHEDULE – PROCEDURES BY STUDY DAY  
See also Time and Events Schedule ( Table 1). 
6.1 Screening (Day –120 to Day –5) 
The following screening assessments and procedures may be completed under the general screening protocol , CIR200,  and/or under 
this CampETEC protocol over the course of 1 – 3 visits depending on screening visit outcomes.  
a. Oral and/or audio visual  presentation of clinical trial design, risks, and study schedule and requirements  
b. Read informed consent document (s) 
c. Complete written comprehension assessment (minimum of 70% accuracy required for eligibility ) 
d. One-on-one discussions with principal investigator or designee  
e. Informed consent document signed, dated  and timed by volunteer and the study team member obtaining consent  
f. Review and sign additional IRB -approved forms, which may include, but are not limited to the Alternate Agreement, Inpatient 
Unit Guidelines, Correct Hand  Washing Procedure, HIPAA Medical Record Release Form, HIV Test Counseling and/or 
COVID Vaccination Form  
g. Copies of signed documents given to volunteer  
h. Medical history, including height, weight, and any allergies.  
i. Vital signs (heart rate, blood pressure, and oral temperature)  
j. Pregnancy prevention counseling  
k. Physical examination including assessment of HEENT, heart, lungs, abdomen, skin,  neurological and musculoskeletal 
systems  
l. Ingestion of 150 mL of sodium bicarbonate buffer to assess volunteer’s ability to tolerate  consumption  
m. Functional Bowel Disorder Survey  
n. Begin a ssess ment of  inclusion and exclusion criteria  
o. PI or designee review and confirm pending eligibilit y 
p. Record demographics - gender, date of birth, race, ethnicity  
q. Screening laboratory analyses   
(a) Titer (May  be done up to 120  days prior to  enrollment ) 
(b) Complete blood count with differential  (day -30 – day -4) 
(c) Complete  Metabolic Panel (CMP)  must  include  but not limited to : Serum transaminase (ALT ), Na, K+ , BUN, 
creatinine , random glucose  (day -30 – day -4) 
(d) IgA level,  HLA B27  (Maybe done within 120 days of enrollment)  
(e) Pregnancy test (serum and/or urine ß -hCG) for people of childbearing potential (will be repeated on admission 
and prior to administration of challenge ) 
(f) Serum HIV antibody and confirmatory test (day -30 to day  -4) 
(g) Hepatitis B surface antigen (HBsAg) (day -30 to day  -4) 
(h) Hepatitis C virus ELISA and confirmatory test (day -30 to day -4) 
(i) Urine drug screen  must include (but is not limited to) testing for the presence of amphetamine, barbiturates, 
opiates, phencyclidine, cocaine, benzodiazepine, and methadone, at screening and at the discretion of the study 
clinician. In addition, the study clinician may ask  for a sample to test for the presence of antibiotics.  
(j) ABO blood typing  and Rh status  (may be done up to 120 days prior to enrollment)  
(k) ECG  (day -30 – day -4) 
If the initial screening visit is within 30 days of enrollment, all screening activities may be performed at the one visit.  
Participant s may be notified of their screening laboratory results either in person or over the telephone .. Participant s with clinically 
significant abnormalities (determined by the PI) may be asked to have additional blood drawn. If the abnormal result(s) persi sts, 
360_CampETEC _Campy_Protocol_V 1.1_12September 2023  28 participant s will be referred to their primary care physician. A copy of the screening laboratory results may be provided to the 
participant  at their request.  
6.2 Inpatient Phase (Day –3 to Day 9) 
6.2.1 Admission to the Inpatient Unit (Study Day –3) 
Up to 34 eligible and consenting adults will be asked to come to the CIR inpatient unit (IPU) for admission  on Study Day -3. A 
maximum of 32  participants will be admitted. More volunteers may be asked to come to the unit for admission than can be enrolled , 
which  allow s for some dropout of volunteers due to ineligibility or withdrawal of consent. Up to 30 participants will be randomized  
and receive the IP and challenge as per Time and Events Schedule. Volunteers who are admitted but not enrolled  , will be discharged 
and will not be followed.  
On arrival to the unit, the following procedures will be completed:  
a. Based on community COVID -19 rates and CDC and JHU guidelines, volunteer s may be COVID -19 tested (either at the C IR 
or independently) 1 -5 days prior to admission .  Volunteers will be tested upon arrival to the unit. A positive COVID -19 test 
will be exclusionary for admission to the unit.  
b. Personal items will be inventoried. Items not allowed on the unit will be placed into storage for the duration of the admissi on  
c. Medications brought by volunteers must be  properly  labelled . The PI or designee must approve all medications. All 
medications will be stored in the nurses’ station and dispensed by qualified study staff.  
d. Unit orientation and fire drill  
e. Continuing eligibility review  
o Inclusion and exclusion criteria reviewed by PI or designee  
o Medical history and concomitant medications since screening reviewed   
o Blood draw for hematology (complete blood count with differential), serum chemistries ( Na, K, creatin ine, BUN, 
glucose, ALT)  
o Complete physical exam  
o Serum and/or urine pregnancy tests (for participant s of childbearing potential )  
o Pregnancy risk assessment and pregnancy prevention counseling  
f. Vital signs (BP, HR and temperature) recorded  
g. Blood will be collected for research, including immunological assays and serology , and a fingerstick blood draw .  
h. Stool will be collected as per Time and Events Schedule and the MOP. An initial stool may be collected any time on the day 
of admission or on Day -2, prior to initiating the CampETEC product. A participant's inability to produce a stool on Day -3 
or -2 will not be exclusionary for IP or Challenge.  
i. PVT demonstration  (if applicable)  
6.2.2 Study Days –2 to 6 CampETEC/Placebo Dosing  
Participant s will be randomized as per Section 5.2 and MOP . Dosing will occur three times a day , approximately  15 minutes (range: 
10 – 25 minutes) after breakfast, lunch, and dinner for a period of 8 days (day -2 to day 6) as per MOP . The time meals are completed 
will be recorded  by study staff . Study Day 1  (Challenge Day) , is an exception to this order of events (see Section  6.2.3 ).  
If a participant decides not to participate prior to receiving any IP (enrollment), the participant will be discharged from the unit and 
no further follow up will be required. If a participant is enrolled (receives Camp/ETEC HBC or placebo ) and does not continue to be 
eligible or withdraws consent prior to challenge, they will be discharged from the unit and no further inpatient samples will  be 
collected. If possible, they will complete a study day 6 follow up visit for safety  this should include:  
• Interim medical history review will be completed  
• Assessment of any AEs , AESI, and SAEs related to the investigational product  
• A focused physical exam  
The following assessments and procedures will comprise the daily routine on study days -2 through 6: 
• Vital signs (BP, heart rate, and oral temperature) at least 3 times a day; once in the morning, afternoon, and evening.  
• Focused PE, with the assessment and grading of new or evolving solicited and unsolicited AEs.  
• All medications will be provided by clinical staff and recorded on an inpatient medication administration record.  
• All stools will be collected weighed, graded commencing on study day -2. Failure to produce stool will not be considered a 
protocol deviation.  
• Routine s tool bacteriology for C. jejuni  strain  CG8421  detection will begin on study day 2, or prior to initiation of early 
antibiotic  therapy, whichever is sooner . 
• Stool will be processed daily per the MOP  while inpatient. A minimum of one (maximum of 3) stool sample s or rectal swabs  
will be collected daily for culture. If a volunteer is unable to provide a stool sample, rectal swabs will be obtained ( per the 
MOP ). If the participant does not produce a stool or enough stool on any day to obtain all samples, it will not be considered a 
protocol deviation.  
• Stool output and hydration status will be monitored to support clinical decisions post -challenge . 
• Blood and stool for immunological assessments will be collected  per the Time and Events Schedule . 
▪ Collection of whole blood on filter paper from fingerpricks as per Time and Events Schedule.  
360_CampETEC _Campy_Protocol_V 1.1_12September 2023  29 • Urine samples may be obtained on any of the study days , at the discretion of the PI , to assess surreptitious antibiotic use or 
protocol -restricted drug intake.  
• PVT . 
 
6.2.3 Campylobacter Challenge (Day 1)  
On the day of Campylobacter  challenge, participant s will be monitored as detailed above for days -2 to 66. All participants will be 
challenged at the same time.   
Urine pregnancy will be collected prior to challenge for people of childbearing potential. Participants of childbearing poten tial must 
have a negative pregnancy test prior to challenge.  
Table 3: Order of Events on Day of Challenge  
Event  Volume (approximate)  
1st daily  dose of test article/placebo  150 ml  
Approximately 90 minute fast  - 
Bicarbonate buffer  120 ml  
1 minute interval (up to 2 minutes)  - 
Bicarbonate buffer + Challenge  30 ml  
15-minute  interval (range 10 – 25 minutes after 
challenge)  - 
2nd daily dose of test article/placebo  150 ml  
Approximately 90 minute  fast - 
Lunch  - 
Dinner  - 
15-minute interval (range 10 – 25 minutes)  - 
3rd daily dose of test article/placebo  150 ml  
 
Volunteers will be monitored for post -challenge adverse reactions for at least 30 minutes , then have their vital signs done.  No test 
article/placebo dose is scheduled after lunch, but routine dosing will commence again at dinner.  
6.3 Day 7- Antibiotic Treatment  
• Daily procedures will be conducted per the Time and Events Schedule (Table 1)  
• Initiate antibiotic treatment for all volunteers who have not started treatment earlier  - azithromycin 500 mg by mouth once 
daily for 5 days and ciprofloxacin 500 mg by mouth  twice daily  for 5 days . 
• Assess volunteers for discharge criteria. Participant s meeting discharge criteria prior to completing antibiotics may be released 
with the remaining antibiotic treatment to be taken at home.  
6.4 Study Days 8 – 10 Planned Discharge  
Volunteers will be eligible for discharge when symptoms are resolved or are resolving, and they have had at least two consecu tive 
stool cultures negative for the challenge strains (can be collected on the same study day) and have received at least 2 doses  of both 
antibiotics. At discharge, participant s will be reminded not to donate blood or blood products for one month following the 
completion of study participation and advised that the American Red Cross will not allow blood donations for 1 year following  
participation in an investigational research study.  
Volunteers will have:  
• Focused PE prior to discharge  
• Review of solicited and unsolicited AEs  
• Receive morning dose s of antibiotics (if course is not complete)  
• Receive remaining doses of antibiotics and directions for  complet ing the course of treatment at home  
• At least one set of vital signs prior to discharge  
•  Blood s ample /fingerstick  collection as per T ime and Events Schedule  
Volunteers who do not meet criteria for discharge will remain on the unit and continue:  
• Daily focused PE  
• Vital signs at least  three times a day  
• Receive antibiotics (if not complete)  
• Review of solicited and unsolicited AEs  
• All stools will be collected, weighed, graded and assessed for blood  
• Up to 3 stool samples and/or rectal swabs will be collected for culture  daily  
• 3 times daily PVT testing  (if applicable)  
• Stool will be collected for exploratory objectives  
360_CampETEC _Campy_Protocol_V 1.1_12September 2023  30 6.5 Outpatient Monitoring  
6.5.1 Study Day 1 5 Safety Follow -Up (±2 Days)  
• Interim medical history will be obtained  
• AEs, AESIs  and SAEs will be recorded, including assessment of relatedness to challenge , study procedures  and antibiotics 
and severity grade  
• Concomitant medications will be recorded  
• Vital signs (BP, HR, and oral temperature)  
• Focused PE only if participant has any continuing, or worsening  complaints/AEs or new GI symptoms  
• Blood for safety (CBC w/differential and comprehensive  metabolic panel)  
• Serology for assessment of anti-C. jejuni specific serum immune responses  
• A stool sample from within 8 hours of the visit , for assessment of eradication of the challenge strain of C. jejuni . If the 
participant  cannot produce a stool sample within a reasonable amount of time on the un it, a rectal swab may be obtained . 
• A stool sample for exploratory endpoints  
• A serum sample for immunological testing  
6.5.2 Study Day 2 9 (± 2 Days)  
• Interim medical history will be obtained  
• AEs, AESIs  and SAEs will be recorded, including assessment of relatedness to challenge , study procedures  and antibiotics 
and severity grade  
• Concomitant medications will be recorded  
• Vital signs (BP, HR, and oral temperature)  
• Focused PE only if participant has any continuing, or worsening complaints/AEs or new GI symptoms  
• A stool sample f rom within 8 hours of the visit , for assessment of eradication of the challenge strain of C. jejuni . If the patient 
cannot produce a stool sample they should reschedule to a different day within the allocated window (e.g. ±2), as a last reso rt 
a rectal swab could be obtained . 
• A stool sample for exploratory endpoints  
• Serum for exploratory objectives  
• PBMCs for exploratory objectives  
• Fingerstick for the c ollection of whole blood on filter paper  
• Urine pregnancy test for participants of childbearing potentia l 
6.5.3 Study Day 42 (± 2 Days)  
• Interim medical history will be obtained  
• AEs, AESIs  and SAEs will be recorded, including assessment of relatedness to challenge , study procedures  and antibiotics 
and severity grade  
• Concomitant medications will be recorded  
• Vital signs (BP, HR, and oral temperature)  
• Focused PE only if participant has any continuing, or worsening complaints/AEs or new GI symptoms  
• A stool sample from within 8 hours of the visit, for assessment of eradication of the challenge strain of C. jejuni . If the patient 
cannot produce a stool sample they should reschedule to a different day within the allocated window (e.g. ±2), as a last reso rt 
a rectal swab could be obtained  
• A stool sample for exploratory endpoints  
6.5.4 Study Day 57 (± 2 Days)  
• Interim medical history will be obtained  
• AEs, AESIs and SAEs will be recorded, including assessment of relatedness to challenge , study procedures  and antibiotics 
and severity grade  
• Concomitant medications will be recorded  
• Vital signs (BP, HR, and oral temperature)  
• Focused PE only if participant has any continuing, or worsening complaints/AEs or new GI symptoms  
• A stool sample from within 8 hours of the visit, for assessment of eradication of the challenge strain of C. jejuni . If the patient 
cannot produce a stool sample they should reschedule to a different day within the allocated window (e.g. ±2), as a last reso rt 
a rectal swab could be obtained  
• A stool sample for exploratory endpoints  
• Serum for exploratory objectives  
6.5.5 Study Day 85 (± 2 Days)  
• Interim medical history will be obtained  
• AEs, AESIs  and SAEs will be recorded, including assessment of relatedness to challenge , study procedures  and antibiotics 
and severity grade  
360_CampETEC _Campy_Protocol_V 1.1_12September 2023  31 • Vital signs (BP, HR, and oral temperature)  
• Focused PE only if participant has any continuing, or worsening complaints/AEs or new GI symptoms , AEI or SAEs  
• A stool sample from within 8 hours of the visit, for assessment of eradication of the challenge strain of C. jejuni . If the patient 
cannot produce a stool sample they should reschedule to a different day within the allocated window (e.g. ± 7), as a last resort 
a rectal swab could be obtained  
• A stool sample for fecal IgA and exploratory endpoints  
• Serum for exploratory objectives  
• PBMCs for exploratory objectives  
6.5.6 Study Day 11 3 (± 2 Days) -  
In the event of a recrudescence in any subject  on day 8 5, if there are no recrudescences on day 85 Day 113 will not occur.  
• AESIs and SAEs will be recorded, including assessment of relatedness to challenge or antibiotics and severity grade  
• Focused PE only if participant has any continuing, or worsening complaints/AEs or new GI symptoms /AESIs/SAE s  
• A stool sample from within 8 hours of the visit, for assessment of eradication of the challenge strain of C. jejuni . If the patient 
cannot produce a stool sample they should reschedule to a different day within the allocated window (e.g. ±2), as a last reso rt 
a rectal swab could be obtained  
• A stool sample for exploratory objectives . 
6.5.7 Study Day 1 81 Telephone Follow -up (± 1 Month )  
A phone check will be done  to track:  
• Assessment  of SAEs, AESIs and any new chronic illnesses  (specifically  GBS, ReA, IBD , or IBS  or hospitalizations.  
• Completion of Functional Bowel Survey  
• Participants  with new onset of bowel disorders will be asked to report to the JHU CIR for an in -person follow up visit and 
counseling with a provider.  
6.6 Management plan in the event of C. jejuni  recrudescence  
The participant will be followed for a total of 6 months from the date of documented infection recurrence. The date of produc tion of 
the stool demonstrating recrudescence will be designated as day R1 for follow -up purposes.  
Table 4. Time and Events Schedule for Recrudescence  
Study Event  R 3 (+7)  R 15  R29 R 42 R 57  R 85  R 181  
Interim History  X X X X X X  
Focused physical exam  X (X) (X) (X) (X) (X)  
Assess AEs  X X X X X X  
Assess AESIs and SAEs  X X X X X X X 
Assess con comitant medications  X X X X X   
Start another round of antibiotic 
treatment  X       
Vital Signs  X X X X X X  
HIV and/or 
hypogammaglobulinemia  (X)       
Serum chemistry         
Urine hCG X  X   X  
Functional bowel disorder survey        X 
C-diff testing antigen test  X       
Confirm strain micro and PCR  X       
Confirm antibiotic sensitivity  X       
Stool bacteriology ( C. jejuni  
detection)   X X X X X  
Stool for exploratory objectives   X X X X X  
Approximate Blood Volume  20      0 
 
The participant will be assessed as soon as possible and dual antibiotic treatment with ciprofloxacin and azithromycin for 10 days will 
be initiated, (same dose as initial regimen , longer duration ). R1 will be the day stool was produced . R 3 (+7) will be the day the 
participant returns and is started on antibiotic s. Blood may be drawn to assess for hypogamma globulinemia and repeat HIV test may 
be performed .  Any volunteer who recrudesces will continue blood draws per the normal schedule, however, the visit times will be 
adjusted to the recrudescent schedule  so that they don’t have to make extra visits.  
360_CampETEC _Campy_Protocol_V 1.1_12September 2023  32 6.7 Early Termination  
Participant s have the right to withdraw from the study at any time and for any reason without affecting the ir right to treatment by the 
investigator (for study -related conditions).  
An excessive number of withdrawals can affect the scientific validity of the study, therefore unnecessary withdrawal should b e 
avoided. Should withdrawals occur, efforts will be made to ensure participant  safety and continued monitoring as thoroughly as 
possible. To facilitate this, such participants  will be consider ed “off -treatment” once they complete antibiotics  and may be encouraged 
to continue with outpatient follow -up visits per the PI’s discretion.  In case of participant  withdrawal, for whatever reas on, a study 
status form  must be completed , stating the reasons. Withdrawals due to non -attendance must be followed -up to the extent possible to 
obtain the reason for non -attendance.  
A minimum of three attempts to contact the volunteer using the contact information provided by the volunteer will be document ed 
before the volunteer is determined to be lost to follow -up. 
Participant s who would like to leave the inpatient unit but d o not express the desire to withdrawn entirely, after receiving 
CampETEC/placebo will be considered “off -treatment” once they complete antibiotics  and asked to return to the inpatient unit  on 
study day 8 for a brief physical exam and medical history, and blood draw for safety laboratory testing. Participant s withdrawing after 
receiving the challenge , will receive antibiotics for outpatient treatment and will be educated on the importance of complying with 
treatment. Attempts will be made to follow the participant  for safety through study day s 29, 42, 57, 85  and for the 6 month telephone 
call. 
7.0 STUDY INTERVENTION/INVESTIGATIONAL PRODUCTS  
7.1 Study Products  
7.1.1 CampETEC  
The CampETEC HBC  product is a lactose - and fat -reduced, freeze -dried natural product, high in protein and contains no artificial 
additives or nutrients. The drug substance contains antibodies targeted against the fimbrial subunits of CFA/I expressed by s ome 
strains of ETE C and the CPS of C. jejuni  serotype HS23/36. The drug substance powder is harvested from the first milking of 
dairy cows that have been immunized with a conjugated vaccine to produce high levels of specific antibodies. The CampETEC 
drug product contains ov er 80% proteins , out of which approximately 15% - 35% are antibodies (immunoglobulins) in the dry 
powder. The main classes of immunoglobulins found in bovine colostrum will be IgG (mainly IgG1) with smaller amounts of 
IgM and IgA. The colostrum will be assessed for its ability to provide passive protecti on against C. jejuni . 
7.1.1.1  Packaging  
The dried powder CampETEC was packaged in single -dose sachets. Quality control (QC) tests were performed for the final 
product.  
360_CampETEC _Campy_Protocol_V 1.1_12September 2023  33 Figure 1: Label for CampETEC Product  
 
 
7.1.1.2  Storage  
CampETEC sachets will be stored at 2 -8°C in the Research Pharmacy . 
7.1.1.3  Product Shipping  
Prior to the commencement of the study, the IP will be transferred directly to the Research Pharmacy. Any use of the IP will be done 
under the supervision of the Research Pharmacy, and the Research Pharmacist will maintain the IP accountability log , which tracks 
the status of all IP received. Any sachets remaining at the end of the study will be returned to NMRC or destroyed per the MO P or 
pharmacy SOP. 
7.1.1.4  Dose Preparation  
Each CampETEC or placebo unit (1 g of product in foil packet), will be reconstituted in 150 mL water containing 2 g sodium 
bicarbonate for ingestion by a single individual. Each volunteer will receive either the CampETEC or placebo 3 times a day  on 
specified study days . Previous CHIM studies utilizing this formulation have been successful, with participant s exhibiting minimal 
complications other than flatulence [35].  
The CampETEC preparation and placebo will be administered orally. On Study Day -2,, participant s will begin taking the assigned 
treatment. Each participant  will ingest the assigned treatment three times a day, approximately 15 minutes after each meal, except for 
a variation of dosing schedule on the day of challenge. Participant s will continue the thrice daily dosing until for the initiation of  
antibiotic treatment.  
7.1.2 Placebo  
A commercially sourced high protein milk powder called ProMilk 85 will be used as a placebo control. The placebo was manufact ured 
by Tantura Milk Industries and repackaged in the same facility and in the same manner, packaging, and has the same  labeling as the 
investigational product. The milk protein concentrate is a food grade product which consists of 85% pure milk protein, 1.3% f at 
content, 5.3% moisture content, and has a pH of 7.0. The placebo contains no detectable antibiotics or bacteria l content. T he placebo 
is an off -white colored, food -grade powder product that should appear similar to the CampETEC product when reconstituted.  
7.1.2.1  Packaging  
The placebo high protein milk powder is packaged in single -dose sachets. The placebo product is labeled as shown below.  

360_CampETEC _Campy_Protocol_V 1.1_12September 2023  34 Figure 2: Placebo Label  
 
7.1.2.2  Storage  
The placebo will be stored at 2 -8°C. in the research pharmacy . 
7.2 C. jejuni  CG8421 Challenge Strain  
A human challenge model for studies investigating C. jejuni has already been established. It uses the strain C. jejuni  CG8421. The 
CG8421 strain mitigates the risk of GBS because it lacks ganglioside mimicry. It has a consistently high attack rate and elicits robust 
immune responses when even using a low concentration of inoculum (5x105 CFUs).  
When tested previously, clinical disease after CG8421 infection consisted of moderate to large volume diarrhea with symptoms of 
headache, myalgia, and abdominal cramping. Fever occurred in 9 (39%) participant s and was severe (>39 °C) in 2 persons (9%). There 
were no significant clinical differences between patients who received 1x106 and 1x105 CFUs of C. jejuni, although participant s who 
received the lower dose had a slightly longer incubation period and a lower total volume of loose stools. There were no se rious adverse 
events related to CG8421 and no hypotension/shock or post -infectious sequelae occurred. After initiation of antibiotics in participant s, 
symptoms resolved,  and stool cultures cleared rapidly  [66]. In a double blind, randomized study testing the prophylactic efficacy of 
rifaximin , CG8421 was given at a dose of  1.7 x 105 CFU, producing an 84.6% attack rate among participants receiving placebo . 
Recrudescence  was detected in 17.9% of those challenged  [67].  
The challenge dose that will be used for this study will use 5 x 105 CFU of C. jejuni CG8421.  
7.2.1 Challenge Inoculum  
The C. jejuni challenge  strain underwent cGMP production at Charles River Laboratories (358 Technology Drive, Malvern, PA 19355,  
610-640-4550)  in October 2006.  A Master Cell Bank (MCB) was prepared from the research seed upon release of the strain (refer to 
Investigator Brochure). The cGMP cell bank was released based on the criteria outlined in Table 5 below. 
Table 5 : Release Criteria for C. jejuni  cGMP MCB . 
Parameter  Methodology Specification 
Viability  Plating on Mueller-Hinton agar, incubation in a jar 
with Campylobacter-specific gas mix at 37ºC for 
48 h. ≥106 CFU/vial 
Purity  Plating on the appropriate selective agar to include 
sheep blood and Sabouraud-Dextrose agar. Incubation 
of plates under aerobic conditions, 37ºC 18-24 h. No contaminating 
organisms on agar 
plates 
Identity  16S RNA analysis and C. jejuni-specific PCR C. jejuni 
 
7.2.2 Packaging and Labeling  
The CG8421 challenge strain is stored as 1  mL aliquots in 2  mL cryostorage tubes (1  mL per tube) held at –80°C ± 10°C 
in the WRAIR PBF. The cryotubes are labeled as shown below:  

360_CampETEC _Campy_Protocol_V 1.1_12September 2023  35 Figure 3: Label for C. jejuni  stain challenge product  
 
7.2.3 Storage and transportation  
The vials will be transferred on dry ice from the WRAIR Pilot Bioproduction Facility to Johns Hopkins Bloomberg School of Public  
Health Research Laboratory , logged in, and stored at -80 ºC ± 10ºC in a locked and temperature monitored ultra-low temperature freezer. 
Any use of these vials will be done under the supervision of JHSPH Research Laboratory  personnel and tracked in a strain 
accountability log. Any  vials remaining at the end of the study will be returned to NMRC or disposed by autoclaving. 
7.2.4 Preparation, administration and dosage  
An appropriate number of master seed vials that have been stored at –80ºC + 10ºC in Mueller-Hinton broth with 15% glycerol will be 
thawed at room temperature. One hundred microliters of the master seed lot will be spread onto an appropriate number of Mueller-
Hinton agar plates for confluent growth and incubated overnight (22-24 hours) at 42°C under microaerobic conditions achieved 
using a BBL CampyPak Plus (BD). After overnight growth, C. jejuni identity will be confirmed by Gram stain, oxidase testing and 
confirmation of darting motility. After confirmation, bacterial biomass will be harvested by suspension in sterile PBS (0.01M 
sodium phosphate, 0.138M  sodium chloride, 0.0027M  potassium chloride, pH 7.4) and adjusted to the appropriate OD600 to 
achieve the target infectious dose. Challenge inoculum will be verified by enumeration of viable counts on Mueller Hinton agar in 
duplicate on the sample both the pre- and post-dosing. The mean of the pre- and post-dose CFU will be used for the estimated 
inoculum size. Purity will be determined by plating the challenge inoculum on sheep blood agar and incubating at 37ºC for 48 hours 
under aerobic conditions. 
C. jejuni CG8421 will be administered with bicarbonate buffer (2  g/dose in a total of 150  mL). Participant s will drink 120  mL of 
buffer, followed approximately 1 minute later by 30  mL of buffer containing CG8421. The CG8421 will be added to the bicarbonate 
immediately before dosing.  
7.3 Accountability Procedures for the Investigational Products  
The investigator must ensure that the IP supplies are stored as specified in the protocol and in a secured area, with access limited to 
authorized study personnel. The investigator has the following responsibility for the products: maintaining inventory; m aintaining 
accurate records of the receipt of IP, including date received, randomization code, manufacture or expiration date, amount re ceived 
and disposition; holding the amount of product needed; and adequate storage and dispensing of the IP (HBC/placebo ).). A record 
will be maintained that includes the dispensation date, amount of IP dispensed, initials and identification number. The IP mu st be 
administered only at the specified institution. Unused product will be shipped to NMRC or destroyed per the MOP.  
7.4 Assessment of Participant  Compliance with Investigational Products  
Member s of the study team will witness the ingestion of the test article/placebo  on the source document . 
8.0 ASSESSMENT OF SAFETY  
 Assessment of CampETEC product safety is limited to the two days prior to receipt of the challenge dose (day -2 and -1). Unless 
AEs are temporally related to receipt of CampETEC, AEs that begin  post-inoculation will be attributed to the inoculum . 
AEs will be summarized and compared between study groups for the periods prior to and after challenge. Summaries of the numbe r 
and proportion of participant s who report a given coded term will be reported. Safety data, including AEs, vital signs, and laboratory 
tests will be listed by study participant . 
 During the inpatient period, participant s will be monitored for the symptoms of Campylobacter  illness listed under 8.4.1.2 .  
Safety monitoring will be conducted throughout the study; therefore, safety concerns will be identified by continuous review of the 
data by the PI, clinic staff, clinical monitor, research monitor, and the sponsor.  
Study Safety Management : The research monitor and PI will review any safety concern s. A data safety monitoring board (DSMB) 
is not required for this study.  
Research Monitor : The research monitor will function as an independent safety advocate for participant s per AR 70 -25 and 
Department of Defense (DoD) Instruction 3216.02. An independent research monitor is required to review all unanticipated prob lems 
involving risk to participant s or others, SAEs, and all participant  deaths associated with the protocol and provide an unbiased written 
report of the event. At a minimum , the research monitor should comment on the outcomes of the event or problem and, in the case 
of a SAE or death, comment on the relationship to participation in the study. The research monitor should also indicate wheth er they 
concur with the details of the report provided by the study investigator. Reports for events determined by either the investi gator or 
research monitor to be probably or definitely related to participation and reports of events resulting in death should be promptly 
forwarded to the IRB s, ORP HRPO, and USAMRMC Division of Regulated Activities and Compliance.  
The research monitor, in accordance with JH BSPH guidelines, will have the following responsibilities:  

360_CampETEC _Campy_Protocol_V 1.1_12September 2023  36 • Evaluate ongoing safety data and make recommendations in order to ensure participant  safety as required  
• Be available for consultation by the clinical investigative team through the period of the clinical study in which there is a n 
interaction with human participant s 
• Be available to review all SAEs and other unanticipated problems involving risk to participant s  
• Be available to discuss SAEs and significant safety issues  
• Provide clinical advice, in accordance with the study protocol, on the clinical management of participant s. This advice may 
include, but is not limited to − Decisions on “borderline” laboratory values and eligibility for enrollment − Confirmation an d 
discussion of treatment decisions for difficult clinical situations  
• Must document all clinical decisions including date, time and signature  
• Must communicate all decisions to the study PI and other study investigators, which must be stored with participant  source 
documents  or study binder . 
 All safety reports (i.e., serious adverse events, deviations, unanticipated problems involving risk and participant  deaths) will be 
submitted to the JHSPH IRB and NMRC IRB.  
8.1 Vital Signs  
Vital signs ( oral temperature, blood pressure, heart rate) will be obtained throughout the inpatient period and at each study visit after 
discharge. Respiratory rates will be obtained on a case -by-case basis at the discretion of the study clinician. See Table 6 for applicable 
AE coding.  
Table 6: Reference Ranges and Adverse Event Coding for Vital Signs Parameters  
Vital Signs  Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe  
(Grade 3)  Potentially Life 
Threatening  
(Grade 4)  
 Tachycardia  
101–115 116-130 >130  ER visit or  
hospitalization for  
arrhythmia  
 Bradycardia  
50-54a 45–49 <45 ER visit or  
hospitalization for  
arrhythmia  
Fever (°C)  
 (°F)  38.0–38.4 
100.4 –101.1  38.5–38.9 
101.2 –102.0  39.0-40 
102.1 - 104 >40 
>104  
 Hypertension  
 (systolic, mm Hg)  141–150 151 - 155 >155  ER visit or  
hospitalization for  
malignant  
hypertension  
Hypertension  
(diastolic, mm 
Hg) 91–95 96 – 100 >100  ER visit or  
hospitalization for  
malignant  
hypertension  
Hypotension  
(systolic, mm 
Hg)b 85–89 80 – 84 <80 ER visit or  
hospitalization for  
hypotensive shock  
aGrade 1 bradycardia will not be considered an abnormality for this study unless judged to be clinically significant by the PI  or the PI in consultation with the Research Monitor 
and sponsor.  
b If a participant  has a baseline systolic BP in the 90’s then a decrease in BP < 10 without associated clinical symptoms will not be considered  an abnormality for this study unless 
judges to be clinically significant by the PI.  
8.2 Physical Examination  
A complete physical exam will be conducted during the screening visit and on Day -3 as part of the admission  process; a focused 
physical exam will be conducted prior to receipt of first IP, prior to challenge and daily during participant ’s inpatient stay. Focused 
physical exams may occur at outpatient visits  with specific attention to the identification of local, systemic or other adverse reactions 
for participants who have new or continuing gast rointestinal symptoms.  
8.3 Laboratory Assessments  
Venous blood samples will be collected for chemistry, hematology, and immunological parameters during the screening phase of this 
study and to provide a baseline sample – see Table 1, Time  and Events Schedule. Hematology and chemistry analyses will be 
performed by commercial laboratory (Quest, Incorporated in Baltimore City or by Johns Hopkins Medical Institutions). Addition al 
specimens may be collected to confirm and evaluate any abnormal values. Additional blood for chemistry and hematology are planned 
for collection following experimental infection per the time and events schedule. However, samples may be obtained as part of  the 
clinical care of an individual participant . The clinical toxicity grading scale that will be used as a guideline is based on the FDA’s 
Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Subjects enrolled in Preventive Vaccine Clinic al 
Trials and the DAIDS Table for Grad ing and Severity o f Adult and Pediatric Adverse Events.  
Final grading determination will be made by the PI based on normal lab values for the specific lab and clinical symptoms. Abn ormal 
laboratory values based on hematology, and clinical chemistry (SGPT/ALT, glucose, creatinine,  BUN  and electrolytes) after test 
article dosing will be considered an AE . The investigator w ill determine  severity based on clinical symptoms and using the attached 
grading scale as a guideline. In the event of a clinically significant abnormal  laboratory value, the test will be repeated. If the abnormal 
value persists, follow -up evaluations will be determined by the PI in consultation with the medical monitor. Additional clinical 
laboratory evaluations may be performed at other times as require d to follow -up a serious or severe adverse event or as deemed 
360_CampETEC _Campy_Protocol_V 1.1_12September 2023  37 necessary by the investigator. Slightly abnormal laboratory values that remain consistent from the time of screening througho ut the 
study will not be recorded as AEs  but will be included in the medical history . 
Serologic evidence of chronic HIV -1, HCV, and HBV infections will be obtained during the screening process. Evidence of current 
infection will make a participant  ineligible. Targeted drug screenings are planned for this study at screening and at the discretion of 
the study clinician.  
A serum sample for pregnancy testing will be collected at the screening visit and on Day -3 from participants of childbearing potential . 
A urine pregnancy test maybe done on day -2 if the serum pregnancy test  from Day -3 results are not available. A urine pregnancy 
test will be collected on Day 1 prior to challenge and day 85 from participants of childbearing potential . A participant will not be 
enrolled if that have a  positive pregnancy test prior to HBC/placebo IP administration. Any participant s who become pregnant during 
the study will be considered “off treatment – safety  only” and followed until pregnancy resolution. Procedures to be followed in the 
event a study participant becomes pregnant during the study period are outlined below.  
Procedures to be followed in the event of a pregnancy  
• When possible, a safety visit will be completed, this will include:  
• Interim history  
• Focused PE  
• Vital signs   
• Safety Labs - CBC with differentials, CMP, serum pregnancy test if not already completed at day 15 or at PI discretion  
• No further research labs will be collected  
• Follow up  calls will be completed to obtain updates in pregnancy and a final call will be made at the time of resolution. 
Required IRB and study information will be collected.  
Table 7: Reference Ranges and Adverse Event Coding for Clinical Hematology Parameters  
Test Normal Mild 
(Grade 1) Moderate 
(Grade 2) Severe 
(Grade 3) Potentially Life 
Threatening  
(Grade 4)  
Hemoglobin (g/dL) 
(for screening purposes only) M: LLN = 11.0 
F: LLN = 10.5      
Hemoglobin, low  M: 10.0 to 10.9  
F:9.5 to 10.4  M: 9.0 to 
<10.0  
F: 8.5 to <9.5  M: 7.0 to <9.0  
F: 6.5 to <8.5  M: <7.0  
F:<6.5  
Eosinophils (cells/mm3) 15-500 551-1,500 1,501 -5,000 > 5,000 ER Visit  
Leukocytes (white blood 
cells) (cells/mm3) 2,500 to 10,800      
Leukopenia  2,000 to 2,499  1,500 to 1,999  1,000  to 1,499  < 1,000  
Leukocytosis  10,801-15,000 15,001- 
20,000 20,001- 25,000  >25,000  
Lymphocytes, low  
(cells/mm3) >650  600 to <650  500 to <600  350 to <500 <350  
Neutrophils, low  
(cells/mm3) >1,000  800 to 1,000  600 to 799  400 to 599 <400  
Platelets  decreased 
(cells/mm3) ≥125,000  100,000 to 
<124,999  50,000 to 
<100,000  25,000  to 
<50,000  <25,000  
 
Table 8: Reference Ranges and Adverse Event Coding for Blood Chemistry Parameters  
Test Normal Mild 
(Grade 1) Moderate 
(Grade 2) Severe 
(Grade 3) Potentially Life 
Threatening  
(Grade 4)  
BUN (elevation)  7-25 26-28 29-31 > 31 Requires dialysis  
Creatinine (elevation)  M: 0.7-1.4 
F: 0.5-1.1 1.1 to 1.3 x ULN  
 > 1.3 to 1.8 x 
ULN OR 
Increase of > 
0.3 mg/dL 
above baseline  > 1.8 to <3.5 x 
ULN OR 
Increase of 1.5 
< 2.0 x above 
baseline  ≥ 3.5 x ULN 
OR Increase of 
≥ 2.0 x 
participant’s 
baseline  
Glucose, Random (mg/dL)  
 65 to115      
360_CampETEC _Campy_Protocol_V 1.1_12September 2023  38 Hypoglycemia   55 to 64  40 to <55  30 to <40  <30 
Hyperglycemia   116 to 160  >160 to 250  >250 to 500  > 500 
Potassium (mEq/L; mmol/L ) 3.4 to 5.6      
Hypokalemia   3.0 to < 3.4  2.5 to <3.0  2.0 to <2.5 <2.0 
Hyperkalemia   5.6 to <6.0  6.0 to <6.5  6.5 to <7.0  ≥7.0 
SGPT/ALT (elevation)  M:9 to 46  
F: 6 to 29  1.25 to <2.5 x 
ULN  2.5 to <5.0 x 
ULN  5.0 to <10 x 
ULN  ≥ 10x ULN  
Sodium (mEq/L; mmol/L ) 136 to145      
Hyponatremia   130 to <135  125 to <130  121 to <125 ≤120  
Hypernatremia   146 to <150  150 to <154  154 to <160  ≥ 160  
 
8.4 IND Safety Reporting  
The following terms, as defined by 21 CFR 312.32, apply to IND safety reporting.  
8.4.1 Adverse Event or Suspected Adverse Reaction  
Adverse event means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered dr ug 
related. This includes an exacerbation or worsening of pre -existing conditions or events, intercurrent illnesses, injuries, or v accine or 
drug interaction, or worsening of abnormal clinical laboratory values. Anticipated day -to-day fluctuations of pre -existing conditions 
that do not represent a clinically significant exacerbation do not need to be considered AEs. Discrete episodes or worsening of chronic 
conditions occurring during a study period will be reported as AEs to assess changes in frequency or severity. Stable, pre -existing 
conditions and/or elective procedures are not AEs.  
AEs will be documented in terms of signs and symptoms observed by the investigator or designee or reported by the participant s at 
each study encounter. Pre -existing conditions or signs and/or symptoms (including any which are not recognized at study entry but 
are recognized during the study period) present in a participant  prior to the start of the study will be recorded in the Medical History 
form within the participant ’s source and in the eCRF. AEs occurring after informed consent is obtained, but prior t o HBC  receipt, will 
be documented in the Medical History form within the participant 's source and in the  eCRF.  
Hospitalization for elective surgery related to a pre -existing condition which did not increase in severity or frequency following 
initiation of the study, or for routine clinical procedures (including hospitalization for "social" reasons) that are not the  result of an 
AE is not itself considered an AE, but must be recorded in the AE page of the eCRF. If hospitalization aris es from a pre -existing 
condition, or was planned prior to the first test article dose, it will be recorded in the Medical History form of the eCRF. If planned 
after the first dose, it will only be recorded in the AE page of the eCRF. In both cases, it will  be recorded as `Hospitalization (Not an 
AE)', and the relationship to test article receipts will be checked "No". Because hospitalization under these circumstances n eed not be 
considered an AE, it is therefore also not considered a SAE.  
A “suspected” adverse reaction means any adverse event for which there is a reasonable possibility that the drug caused the a dverse 
event. For the purposes of IND safety reporting, “reasonable possibility” means there is evidence to suggest a causal relati onship 
between the drug and the adverse event. Suspected adverse reaction implies a lesser degree of certainty about causality than adverse 
reaction, which means any adverse event caused by a drug. The investigator is responsible for documentation of AEs a ccording to the 
detailed guidelines set out below. Participant s will be instructed to contact the investigator immediately should s/he manifest any signs 
or symptoms perceived as serious during the study period. Approximately six months after study completion, participant s will be 
contacted by phone to document any intervening medically significant new chronic illnesses or serious health events. These da ta will 
be documented in a telephone log and summarized in an annex to the final clinical study report.  
All AEs and their grad e and relationship to  investigational product,  challenge, study procedures and  antibiotics will be recorded in the 
participants source document and in the appropriate eCRF . AEs will be tabulated separately for pre -and post -challenge data. The 
assessment of the safety of the CampETEC IP and control products will be primarily limited  to the 2 days prior to receipt of challenge. 
Following receipt of the challenge inoculum, gastrointestinal and systemic symptoms will likely be attributable to the C. jejuni  
CG8421  challenge strain unless temporally related to receipt of the CampETEC/placebo or antibiotics. AEs occurring after receipt of 
the challenge inoculum (day 1) will also be  assessed as to their relationship with the challenge strain and the antibiotic (if treatment 
has started).  
8.4.1.1  Solicited and Anticipated Adverse Events  
A solicited AE is a predetermined event, which may reflect safety concerns related to the IP. Previous clinical studies using  much 
higher quantities of bovine colostrum products than planned for this study , have been orally administered and well tolerated (e.g., 10 
g/day anti -ETEC bovine milk IgG [47]; 30 g/day anti -C. parvum  bovine milk IgG [58]; 30 g/day anti -S. flexneri  bovine milk IgG [33]. 
In comparison, each CampETEC unit (1 g of product in foil packet), will be reconstituted in 150 mL water containing 2 g sodiu m 
bicarbonate for ingestion by a single individual. CHIM studies utilizing this formulation have been succes sful, with participant s 
exhibiting minimal complications other than flatulence [35].  
This study is evaluating a human challenge with live Campylobacter bacteria, and therefore all the symptoms of Campylobacter 
infection are solicited AEs with severity grades ranging from 1 -4. The most common effects of Campylobacter infection are moderate 
360_CampETEC _Campy_Protocol_V 1.1_12September 2023  39 to severe diarrhea (which may lead to dehydration, electrolyte abnormalities and the need for oral or intravenous rehydration ), 
abdominal cramping, and fever. Nausea with or without vomiting, chills, gross blood in stools, loss of appetite, headache, mu scle 
aches and bloating may also occur. Recrudescent events have been documented in up to 17% of previous participant s receiving this 
dose [67]. 
8.4.1.2  Surveillance Period for Adverse Event Occurrence  
Inpatient surveillance  
Solicited  symptoms of campylobacteriosis will be assessed  daily during the inpatient periods. These symptoms/signs include:  
1. Abdominal cramping  
2. Abdominal pain  
3. Anorexia (poor appetite)  
4. Arthralgias  
5. Bloating  
6. Chills  
7. Constipation  
8. Excessive flatulence  
9. Generalized myalgia  
10. Headache  
11. Lightheadedness  
12. Malaise  
13. Nausea  
14. Urgency  
Symptoms that will be assessed objectively include:  
• Diarrhea  (via stool logs)  
• Vomiting  
• Fever  (oral temperature  > 100.4° F)  
• Hypovolemia  
• Dysentery (confirmed by hemoccult testing)  
 
These symptoms of Campylobacter illness are only considered solicited during the inpatient period. If a participant reports any of 
these symptoms during the outpatient period, they will be considered unsolicited, per the Data Management Handbook.  
Open -ended questions will also be used to capture any unsolicited  symptoms during the study period. All AEs should be recorded on 
the appropriate AE form of the participant ’s source documents  per the Data Management Handbook.  
Outpatient surveillance  
Participant s will be educated to contact the study staff  if they experience any symptoms of diarrhea (3 loose stools/24 hours) or fever 
≥ 38°C (100.4°F) with any severe associated symptoms (nausea, abdominal cramps, vomiting, myalgia, headache, arthralgia, or gross 
blood in their stool).  
8.4.1.3  Serious Adverse Event or Serious Suspected Adverse Reaction  
An adverse event or suspected adverse reaction is considered “serious” if, in the view of either the investigator or sponsor,  it results 
in any of the following outcomes:  
• Death  
• Life-threatening adverse event  
• Inpatient hospitalization or prolongation of existing hospitalization  
• Persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions  
• Congenital anomaly/birth defect (abortion, stillbirth and any malformation/disease must be reported as an SAE).  
Although not considered SAEs, cancers will be reported in the same way as SAEs. Pertinent definitions include:  
• Life threatening - An AE is life threatening if the participant  was at risk of death at the time of the event; it does not refer 
to an event that hypothetically might have caused death if it were more severe.  
• Disabling/incapacitating - An AE is incapacitating or disabling if it results in a substantial disruption of the participant ’s 
ability to carry out normal life functions. This definition is not intended to include experiences of relatively minor medica l 
significance such as headache,  nausea, vomiting, diarrhea, influenza or accidental trauma (e.g. sprained ankle).  
• Hospitalization:  Hospitalization signifies that the participant  spent 24 hours or longer in a hospital  for treatment that 
would not be appropriate in a primary care office or on an outpatient ba sis. Hospitalization for either elective surgery 
related to a pre -existing condition (which did not increase in severity or frequency following initiation of the study ), or 
for routine clinical procedures (including hospitalization for "social" reasons) , need not be considered AEs and are 
therefore not SAEs.  
• Routine Clinical Procedure: A procedure which takes place during the study and does not interfere with the test article 
administration or any of the ongoing protocol specific procedures.  
360_CampETEC _Campy_Protocol_V 1.1_12September 2023  40 Note: If anything  untoward is reported during an elective procedure, that occurrence must be reported as an adverse event, 
either `serious' or non -serious according to the usual criteria. When in doubt as to whether ‘hospitalization’ occurred or was 
necessary, the AE will b e considered serious. Important medical events that may not result in death, be life -threatening, or 
require hospitalization may be considered serious when, based upon appropriate medical judgment, they may jeopardize the 
participant  or may requir e medical or surgical intervention to prevent one of the outcomes listed in this definition. Examples 
of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room, blood dyscrasias 
or convulsions that do not resul t in inpatient hospitalization, or the development of drug dependency or drug abuse.  
8.5 Serious Adverse Events  
8.5.1 Unexpected Adverse Event or Unexpected Suspected Adverse Reaction  
An adverse event or suspected adverse reaction is considered “unexpected” if  
• it is not listed in the investigator brochure  
• it is not listed at the specificity or severity that has been observed; or,  
• an investigator brochure is not required or available, is not consistent with the risk information described in the general 
investigational plan or elsewhere in the current application, as amended.  
For example, under this definition, hepatic necrosis would be unexpected (by virtue of greater severity) if the investigator brochure 
referred only to elevated hepatic enzymes or hepatitis. Similarly, cerebral thromboembolism and cerebral vasculitis would be 
unexpected (by virtue of greater specificity) if the investigator brochure listed only cerebral vascular accidents. “Unexpect ed,” as used 
in this definition, also refers to adverse events or suspected adverse reactions that are mentioned in the investig ator brochure as 
occurring with a class of drugs or as anticipated from the pharmacological properties of the drug, but are not specifically m entioned 
as occurring with the particular drug under investigation.  
8.5.2 Other Adverse Events  
Other adverse events will be identified by the PI during the evaluation of safety data. Significant adverse events of particu lar clinical 
importance, other than SAEs and those AEs leading to discontinuation of the participant  from the study, will be classified as other 
adverse events. For each, a narrative may be written and included in the clinical study report.  
8.6 Relationship to Investigational Product (Assessment of Causality)  
The investigator or designee must assign a relationship of each AE to the receipt of the IP. The investigator or designee wil l use 
clinical judgment in conjunction with the assessment of a plausible biologic mechanism, a temporal relationship between the o nset of 
the event in relation to receipt of the IP, and identification of possible alternate etiologies including underlying disease,  concurrent 
illness or concomitant medications. Every effort will be made to explain AEs and assess causal relationships, i f any, to administration 
of the CampETEC test article, challenge, study procedures or antibiotic treatment. AEs occurring on study days -1 to 1 will be assessed 
as to their relationship with the CampETEC test article  or study procedures (i .e. being on unit) . AEs occurring after receipt of the 
C. jejuni challenge ( Study D ay 1) will be assessed as to their relationship with the CampETEC test article, C. jejuni  CG8421 challenge 
strain, study procedures or the antibiotic, if applicable. The degree of certainty with which an AE can be attributed to these products 
(or alternative causes, e.g., natural history of the underlying diseases, concomitant therapy, etc.) will be determined by how well the 
event can be understood in terms of one or more of the following:  
• Reaction of similar nature having previously been observed with other similar  bovine colostrum  products, C. jejuni  challenge 
strains, or antibiotic administration  
• Published literature accounts supporting causality  
• Temporal relationship with administration  
The following guidelines should be used by investigators to assess the relationship of an AE to study product administration.  Only a 
physician , physician’s assistant  or nurse practitioner can make this determination. The investigator will assess causality of all AEs as 
below . Non-serious and serious adverse events will be evaluated as two distinct types of events given their different medical nature. 
If an event meets the criteria to be determined ‘serious’ it will be examined by the investigator to the extent possible to d etermine 
ALL contributing factors applicable to the event. Other possible contributors include:  
• Underlying disease  
• Other medication  
• Protocol required procedure  
• Other cause (specify)  
8.6.1 Causality  
Causality of all AEs will be assessed by the investigator using the following criteria:  
In the investigator’s opinion, is there a reasonable possibility that the AE may have been caused by the product or procedure  under 
consideration?  
Definitely r elated : AE can only be explained by receipt of the product  
Probable (l ikely related ): AE occurs within a reasonable time after the administration of the product and cannot be reasonably 
explained by other factors (i.e., clinical condition, environmental / toxic factors or other treatments)  
360_CampETEC _Campy_Protocol_V 1.1_12September 2023  41 Unlikely  related : AE does not have a reasonable temporal relationship or good evidence for a more likely alternative  
Unrelated : AE is not suspected to be related to the product, there are other more likely causes, and administration of the product is 
not suspected to have contributed to the AE . 
8.7 Recording of Adverse Events  
8.7.1 Methods for Assessing, Recording, and Analyzing Safety Endpoints  
All AEs either observed by the investigator or one of his/her clinical collaborators or reported by participant s spontaneously or in 
response to a direct question , will be evaluated by a study investigator. The nature of each event, date of onset, outcome, severity, and 
relationship to test article, challenge, study procedures and/or antibiotic will be established. Details of any symptomatic/corrective 
treatment will be recorded in the source and on the appropriate page of the eCRF. Participants will be ask ed specifically if they have 
experienced solicited symptoms (listed above) Participant s will be asked non -leading questions initially when assessing other AEs, 
followed by more direct questions as necessary. AEs already documented in the eCRF, i.e., at a previous assessment, and desig nated 
as ‘ongoing’ will be reviewed at subsequent follow -up assessments. If resolved, documentation in the eCRF will be comple ted. If an 
AE changes in frequency or intensity during a study period, a new record of the event will  be started  as per the Data Management 
Handbook (DMH) .  
AEs, solicited AEs, AESIs  and SAEs will be reviewed  at all scheduled points of contact, documented in the source records, and 
recorded on the eCRFs using accepted medical terms and/or the diagnoses that accurately characterize the event. Solicited AEs  will 
be recorded as individual events. Unsolicited AE m ay be recorded as a diagnosis. When a diagnosis is known, the AE term recorded 
on the eCRF will be the diagnosis rather than a constellation of symptoms. The investigator will assess all AEs for seriousne ss, 
relationship to IP,  challenge, study procedures, a nd/or antibiotic, severity , and other possible etiologies. When an event has not 
resolved by the proscribed reporting period, it will be left open/without an end date on the AE eCRF and will be updated with end 
date or “ongoing at visit.”  
8.7.2 Recording Period for Adverse Events  
• . AEs will be assessed  through D85 and AESI and SAEs will be collected through the day 181 . 
8.7.3 Duration of Follow -Up of Participant s after Adverse Events  
Investigators are required to follow SAEs to resolution, even if this extends beyond the prescribed reporting period. Resolut ion is the 
return to baseline status or stabilization of the condition with the probability that it will become chronic. The SAE ou tcomes will be 
reported to the sponsor.  
 Investigators are not obligated to actively seek SAEs in former participant s; however, if a SAE, considered to be related to either the 
HBC or challenge strain is brought to the attention of the investigator at any time until closure of the study, the event will be reported.  
Investigators should follow -up adverse events at least until the final study visit. This may include repeat safety laboratory analysis. 
Outcome should be assessed as:  
• Resolved  
• Resolved  with sequelae  
• Severity change - the highest severity captured  in a day will be recorded  in the eCRF . E.g. if the severity on day 1 is mod erate , 
then mild and then moderate  again , it will be entered as moderate for that date in the eCRF . If on day 2 , the severity  is mild, 
the moderate AE will end and a new AE will be entered  with a mild severity )  
• Ongoing at day 85 /181 
• Died  
• Lost to follow -up 
All SAEs must be documented and followed until the event either resolves, subsides, stabilizes, disappears,  or is otherwise explained 
or the participant  is lost to follow -up, but not longer than 6 months after the last receipt of the CampETEC HBC . All follow -up 
activities have to be reported, if necessary, on one or more consecutive SAE report forms, in a timely manner. All fields wit h additional 
or changed information must be completed and the report form will be forwarded to the study contact fo r reporting SAEs as soon as 
possible, but not more than 7 calendar days after receipt of the new information. Clinically significant laboratory abnormali ties will  
be followed up until they have returned to normal or until stable. Reports relative to the subsequent course of an AE noted f or any 
participant  must be submitted to the Sponsor. The outcome of SAEs will be assessed in the same manner as all AEs.  
8.7.4 Safety Assessment  
All AEs will be assessed for severity by an investigator. Inherent in this assessment , is the medical and clinical consideration of all 
information surrounding the event , including any medical intervention required. Each event will be assigned one of the following 
categories: mild, moderate, severe  or potentially life -threatening . The criteria below may be used for any symptom not included in the 
grading scale s. Any life -threatening AE must be reported as an SAE.  
The eCRF for unsolicited AEs will reflect only the highest severity reported for continuous days an event occurred , per the Data 
Management Handbook .  
Mild  Grade 1  Does not interfere with routine activities; minimal level of 
discomfort  
Moderate  Grade 2  Interferes with routine activities; moderate level of 
discomfort  
360_CampETEC _Campy_Protocol_V 1.1_12September 2023  42 Severe  Grade 3  Unable to perform routine activities; significant level of 
discomfort  
Potentially Life Threatening  Grade 4  ER visit or potentially life -threatening event  
FDA guidelines for toxicity will be followed; however, if a participant  is evaluated in an emergency room for non -life threatening 
illness or symptoms (i.e., visits emergency department on weekend for mild problems because the physician’s office is closed) , the 
information from that visit will be reviewed and severity of the adverse event will be assessed according to  the participant ’s clinical 
signs and symptoms.  
As defined by the International Conference on Harmonization (ICH) guideline for Good Clinical Practice (GCP), the term “sever e” 
is often used to describe intensity (severity) of a specific event (as in mild, moderate, or severe myocardial infarction); t he event itself 
however, may be of relatively minor medical significance (such as severe headache). This is not the same as “serious”, which is based 
on participant /event outcome or action criteria usually associated with events that pose a threat to  a partic ipant ’s life or functioning. 
Seriousness (not severity) serves as a guide for defining regulatory reporting obligations.  
During the challenge phase of the study, Campylobacter  disease -specific adverse events will be graded in accordance with the table 
below.  
Table 9: Challenge Phase Campylobacter  Infection Anticipated Adverse Event / Endpoint Assessments  
Adverse Event  Severitya Parameter  
Diarrhea, based on highest output of 
loose/liquid stools in any 24 -hour 
window . (A diarrhea episode ends 
when there is a 24-hour window with 
no grade 3 -5 stools.)  1 Mild: 2 -3 grade 3 -5 stools totaling ≤400 grams  
2 Moderate: 4 to 5 grade 3 -5 stools or 401 -800 grams of loose/liquid 
stool  
3 Severe: 6 or more grade 3 -5 stools totaling >800 grams  
4 ER visit or potentially life -threatening event  
Body temperature (t)  1 ≥100.4 °F and ≤101.1 °F (38.0 -38.4°C) 
2 >101.1 °F and ≤102.0 °F (38.5 -38.9°C) 
3 >102.0 °F (39.0 °C) and ≤ 104°F (40.0 °C) 
4 >104 °F (40.0 °C) 
Vomiting  1 One episode within a 24 -hour period  
2 Two episodes within a 24 -hour period  
3 More than two episodes with a 24 -hour period  
4 ER visit or potentially life-threatening event  
Other solicited and non -solicited 
adverse events  1 Discomfort noted, but no disruption of normal daily activities; 
slightly bothersome; relieved with or without symptom treatment.  
2 Discomfort sufficient to reduce or affect normal daily activity to some 
degree; bothersome; interferes with activities, only partially relieved 
with symptom treatment.  
3 Discomfort sufficient to reduce or affect normal daily activity 
considerably; prevents regular activities; not relieved with symptom 
treatment.  
4 ER visit or potentially life -threatening event  
a 1=mild; 2=moderate; 3=severe ; 4= ER visit or potentially life -threatening.  
8.8 Reporting Adverse Events  
The PI will report all AEs to the sponsor and the local IRB in the appropriate safety, annual, and/or final reports. The NMRC staff in 
conjunction with the clinical site will draft annual and final clinical study reports and provide files to the sponsor for re view and 
submission to the FDA.  
8.8.1 Reporting Serious and Unexpected Adverse Events  
All SAEs must be reported immediately by the investigator without filtration, whether or not regarded as possibly attributabl e to the 
test articles, placebo, study procedures or antibiotic. SAE reports will be provided to the Sponsor, medical monitor, JHSPH IRB, and 
NMRC IRB. The investigator must report SAEs within one calendar day of becoming aware of the event via the E DC per the Data 
Management Handbook.  This initial notification will include minimal, but sufficient information to permit identification of the 
reporter, the participant , the test articles, AEs, and date of onset. The investigator will not wait for additional information to fully 
document the event before notifying. The first notification will be confirmed by an acknowledgement letter. The report is the n to be 
followed by  submission of a completed SAE Report Form  as soon as possible , but not more than 3 calendar days past the initial report, 
detailing relevant aspects of the SAE in question. All investigator actions and event outcomes must a lso be reported in  a timely 
manner . SAE Report Forms are to be used for documentation of these various aspects regarding the event. Hospital records and 
autopsy reports will be obtained if applicable.  
The research monitor is required to review all unanticipated problems involving risk to participant s or others, SAEs, and all participant  
deaths associated with the protocol and provide an unbiased written report of the event. At a minimum, the medical monitor wi ll 
comment on the event outcomes, and in the case of a SAE or death, comment on the relationship to participation in the study. The 
medical monitor will indicate concurrence or nonconcurrence with the details of the report provided by the investigat or. Reports for 
events determined by either the investigator or medical monitor to be probably or definitely related  to participation and reports of 
events resulting in death will be promptly forwarded to the JHSPH IRB  and NMRC IRB.  
360_CampETEC _Campy_Protocol_V 1.1_12September 2023  43 8.8.1.1  Reporting to the Sponsor  
All SAEs and unexpected  or unexpected suspected AEs  must be reported promptly (within 72 hours) to the sponsor as per 21 CFR 
312.64, whether or not the event is considered related to study product. Further, the investigator should comply with relevan t study 
site SOPs on reporting SAEs.  
The minimum information that the investigator will provide to the sponsor is specified in  Table 10. 
Table 10 : Study Contacts for Reporting Serious Adverse Events  
Sponsor  David Sack, M.D.  
Department of International Health  
Johns Hopkins Bloomberg School of Public Health  
dsack1@jhu.edu  
615 N. Wolfe Street  
E5537  
Baltimore, Maryland 21205  
Telephone: 443 -287-8795  
Institutional Review Board  JHSPH IRB Office  
615 N. Wolfe Street  
Suite E1100  
Baltimore, Maryland 21205  
Phone: 410 -955-3193  
Toll-Free: 1 -888-262-3242  
Fax: 410 -502-0584  
Email: JHSPH.irboffice@jhu.edu  
Collaborating Institutional Review Board  Naval Medical Research Command (NMRC) IRB  
Research Services Directorate  
Office of Research Administration  
Code 025, Building 500, Rm 004  
Silver Spring, MD  
Telephone: 301 -319-7276  
Fax: 301 -319-7277  
Research Monitor  Nekhonti Adams, MD  
 
Table 11: SAE Information to Be Reported to the Sponsor  
Notification Method  Information to be provided  
Email or Telephone (within 72 hours)  IND number, sponsor study number, name of the IP, and 
investigator name and contact number  
 Participant  identification number  
 SAE, onset date, date of IP administration, severity, 
relationship, and participant ’s current status  
AND   
Email or Fax  Cover sheet or letter  
 Adverse event case report form  
 Serious adverse event report form  
 Concomitant medication case report form or a list of 
concomitant medications  
 Medical record progress notes including pertinent 
laboratory/diagnostic test results  
NOTE: When submitting SAE reports via email, the participant  line of each email notification will read as 
follows:  
SAFETY REPORT – IND # _____, Study #_____, Participant # _____, Event term: _____  
 
In order to comply with regulations mandating sponsor notification of specified SAEs to the FDA within 7 calendar days, inves tigators 
must submit additional information as soon as it is available. The sponsor will report unexpected SAEs associated with the  use of the 
challenge strain to the FDA as specified at 21 CFR 312.32 (c).  
Investigators must follow all relevant regulatory requirements as well as specific policy at each institution regarding the t imely 
reporting of SAEs to the local IRB and research monitor.  
Reporting to the sponsor does not fulfill the investigator’s duty to report all unanticipated problems involving risk to huma n 
participant s or others to the IRB. The PI will notify the local IRB and the research monitor.  
8.8.1.2  Reporting to the IRB  
Unanticipated problems involving risk to participant s or others, serious adverse events related to participation in the study and all 
participant  deaths should be promptly reported by phone, email, or fax to the JHSPH IRB. A written report will follow the initial 
notification.  
360_CampETEC _Campy_Protocol_V 1.1_12September 2023  44 Investigators are required to forward safety information provided by the sponsor’s representative to the IRB. All SAEs will b e reported 
to the JHSPH IRB according to IRB guidelines.  
JHSPH IRB Guidelines: IRB Phone 410 -955-3193; Fax 410 -502-0584. Investigators are required to promptly report adverse events 
that fit the following criteria using the Problem/Event Report Form:  
Event (including adverse event reports, injuries, side effects, breaches of confidentiality, or other problems) that occurs a ny time 
during or after the research study, which in the opinion of the principal investigator:  
1. Involved harm to one or more participants or others, or placed one or more participants or others at increased risk of harm;  
2. Is unexpected (an event is “unexpected” when it is not described with specificity in the protocol and informed consent 
document; or if described with specificity, it occurs beyond the expected frequency and/or severity identified); and  
3. Is related to the research procedures (an event is “related to the research procedures” if in the opinion of the principal 
investigator, it was more likely than not to be caused by the research procedures.)  
8.8.2 Immediately Reportable Events  
8.8.2.1  Pregnancy  
For s ubjects  who receive challenge  strain , each pregnancy must be reported within 72 hours of identification  by email , eCRF,  or fax 
to the sponsor and the IRB. The investigator must report all pregnanc ies to the Research Monitor within 14 calendar days of learning 
of this occurrence.  
Participant s who become pregnant after Day 1 through visit 85 after receiving the investigational product will be followed to final 
outcome , and the following information will be gathered for outcome: date of delivery and health status of the participant  and child , 
including the child’s gender, height, and weight. Complications and/or abnormalities should be reported including any prematu re 
terminations. A pregnancy is reported as an SAE only when there is suspicion that the IP may have interfered with the effecti veness 
of contraception or there was a serious complication in the pregnancy including a spontaneous abortion or an elective termina tion for 
medical rationale.  
A pregnancy outcome other than abortion  or stillbirth, and any malformation/ congenital disease , as well as follow -up of the neonate 
must be reported by the Investigator within 14 days of learning of its occurrence using local site procedures.  
8.8.2.2  AE-Related Withdrawal of Consent  
Any AE -related withdrawal of consent during the study must be reported within 24 hours of identification  by email or fax to the 
sponsor and the IRB.  
8.8.2.3  Pending Inspections/Issuance of Reports  
The knowledge of any pending compliance inspection/visit by the following bodies, including the FDA, Office for Human Research 
Protections (Department of Health and Human Services), or other government agency , concerning clinical investigation or research, 
the issuance of Inspection Reports, FDA Form 483, warning letters, or actions taken by any Regulatory Agencies including lega l or 
medical actions and any instances of serious or continuing noncompliance with the regulations or requirements will be reported 
immediately to IRB and the sponsor.  
8.8.3 IND Reporting  
8.8.3.1  Annual Reports  
The NMRC lead investigator will be responsible for the preparation of a detailed annual synopsis of clinical activity, includ ing adverse 
events, for submission to the sponsor. Each annual report will summarize IND activity for 1 year beginning approximately 3 mo nths 
before the IND FDA anniversary date. The sponsor will notify the NMRC lead investigator of the due date with sufficien t time for 
the NMRC lead investigator to assemble the required information.  
8.8.3.2  Final Clinical Study Report  
A final study report will be prepared in accordance with “Guidance for Industry: Submission of Abbreviated Reports and Synops es 
in Support of Marketing Applications” and ICH E3 Guideline “Structure and Content of Clinical Study Reports” and provided to the 
sponsor for review and approval. The sponsor representative will use this report to prepare the final clinical study report f or submission 
to the FDA. The investigative team will report all AEs to the sponsor and the local IRB in the appropriate safety, a nnual, and/or final 
reports.  
8.9 Safety Criteria for Stopping Doses  
The PI, along with the research monitor, may determine if certain events warrant discontinuation of challenges and/or HBC 
administration for all participant s in a cohort. If any of the additional following events occur, administration of the HBC  will be 
discontinued for all participant s in that cohort, and the PI and the research monitor will undertake a thorough review of the events:  
• The occurrence of one or more Grade 3 adverse  event or serious adverse events (SAEs) determined to be related to the HBC .  
• The occurrence of o ne serious or unexpected AE , which in the opinion of  the PI, research monitor and sponsor is determined 
to be an unacceptable risk to the health and safety of the participant s. 
• The occurrence in two or more participants  of a s ystemic allergic reaction, including , but not limited to , generalized urticaria, 
generalized petechiae, or erythema multiforme.  
360_CampETEC _Campy_Protocol_V 1.1_12September 2023  45 • The occurrence in any participant of b ronchospasm or anaphylaxis.  
Based on prior experience with C. jejuni  challenge studies, it is expected that some participant s will have severe AEs (such as severe 
diarrhea)  after the challenge. This will not be stopping criteria . 
Once pausing/stopping criteria are met, the study will be paused (no IP or challenge will be given) to allow for review and c ausality 
assessment by the research monitor prior to resumption of the study. The sponsor, IRB and FDA will be informed.  
 
AEs which will prompt stopping the CampETEC HBC  administrations for an individual participant  include:  
• Grade 4 AE or SAEs unrelated to the test articles (event will be discussed with the medical monitor to determine if the event 
precludes further participation and administration of the HBC  or challenge ) 
• The investigator deems that stopping test article administration is in the best interest of the participant  
Additional reasons for participant  withdrawal include:  
• The participant  does not wish to continue with the study  
• The participant  is lost to follow -up 
Further challenge, in accordance with the protocol, may be resumed with the concurrence of the research monitor, sponsor, PI, 
and the FDA.  
8.10 Treatment of Adverse Events  
Treatment of an AE is the responsibility of the investigator according to the best treatment currently available. The applied  measures 
will be recorded in the eCRF of the participant . 
8.11 Study Termination Criteria  
The PI, research monitor, NMRC IRB, JHSPH IRB, Sponsor, or FDA may stop or suspend the use of the CampETEC HBC  at any 
time.  
8.12 Six Month Follow -Up Safety Surveillance  
Data will begin to be entered into the study database beginning on or after the inpatient period . It will subsequently  be verified and 
locked. Approximately 6 months after challenge , participant s will be contacted by phone to track the occurrence of any medically 
significant new chronic illnesses or serious health events and verbally  complete a functional bowel disorder survey. If a participant  
cannot be contacted after three attempts, a registered letter will be mailed asking them to contact study staff.  These attempts  will be 
documented in a contact  log and summarized in an annex to the final clinical study report.  
9.0 CLINICAL TRIAL MONITORING  
Monitoring will be conducted according to an approved monitoring plan. Local monitoring may commence prior to beginning, at 
initiation, during the study, and at closeout.  
The study monitor shall be available for consultation with the investigator. The study monitor or other authorized representa tives of 
the Sponsor may inspect all documents and records maintained by the investigator, including, but not limited to, medical r ecords 
(office, clinic or hospital) and pharmacy records for the participant  in this study. The clinical study site will permit access to such 
records. The investigator will obtain, as part of informed consent, permission for authorized representatives of the Sponsor, or 
regulatory authorities, to review, in confidence, any records identifying individuals in this clinical study.  
The investigator will notify the Sponsor within 24 hours following contact by a regulatory agency. The investigator and study  
coordinator will be available to respond to reasonable requests and audit queries made by authorized representatives of regul atory  
agencies. The investigator will provide the Sponsor with copies of all correspondence that may affect the review of the curre nt study 
or his/her qualification as an investigator in clinical studies conducted by the Sponsor. The Sponsor will provide any ne eded assistance 
in responding to regulatory audits or correspondence. The investigator will permit independent auditors (employees of the Spo nsor or 
an external company designated by the Sponsor) to verify source data validation of the regularly monitored clinical trial. The auditors 
will compare the entries in the eCRFs with the source data and evaluate the study site for its adherence to the clinical stud y protocol 
and GCP guidelines and applicable regulatory requirements.  
The study team and data management group will arrange visits prior to beginning, at initiation, during the study, and at clos eout by 
the study monitor or designee.  
10.0 STATISTICAL CONSIDERATIONS  
10.1 Introduction  
Safety, efficacy, clinical outcomes, and immunogenicity data will be entered into the eCRFs using standard software for data 
management. Data will be edited with standard strategies for range and consistency checks. All participant s who receive CampETEC 
HBC or placebo, irrespective of the number of doses of CampETEC HBC  or receipt of the challenge and all AEs, will be included in 
the safety analyses. The null hypothesis for this study is that the diarrhea rates will be the same in groups receiving the p lacebo and 
CampETEC HBC product.  
360_CampETEC _Campy_Protocol_V 1.1_12September 2023  46 10.2 Sample Size Considerations  
Using a Fisher’s Exact Test with a two-sided alpha =0.05 and a conservative campylobacteriosis rate of 70% in placebo recipients, a 
sample size of 15 participant s per study arm (CampETEC HBC or placebo) yields an approximate 80% power to detect a significant 
difference in the moderate -severe diarrhea rate in placebo and CampETEC HBC participant s when the efficacy of the HBC product 
is >70%. Of note, a one -sided alpha  is utilized based on the extensive existing data supporting a 1 -way effect of bovine colostr um 
products on disease rates in CHIM studies.  
 
10.3 Analysis  
10.3.1  Safety  
Assessment of the CampETEC product safety is limited to the two days prior to receipt of the C. jejuni  challenge dose (day –2 and –
1). Unless AEs are temporally related to receipt of the IP, most will likely be attributed to the Campylobacter inoculum. Duri ng each 
day of the inpatient period, participant s will be monitored for loose stools (not meeting the diarrhea definition), diarrhea, nausea, 
vomiting, abdominal cramps, fever, headache, abdominal tenderness, abdominal distention,  and an abnormal abdomina l exam. 
Additionally, participant s will have vital signs taken at least 3 times per day . As clinically indicated, postural blood pressure and heart 
rate may be taken to facilitate clinical decision -making  per the judgement of the study providers.   
The sample size is designed to indicate trends but not to show statistically significant differences between groups. Adverse events will 
be summarized and compared between study groups for the periods prior to and after challenge. Safety data, including ad verse events, 
vital signs, and laboratory tests will be listed by study participant . Side effects to the challenge  will be coded as defined in the protocol, 
and will be listed (group, time of onset, duration, and severity). Summaries of the number and prop ortion of participant s who report a 
given coded term will be reported. Safety data, including AEs, vital signs, and laboratory tests will be listed by study participant . 
10.3.2  Protective Efficacy Determination  
The primary endpoint for determination of efficacy is Campylobacter -induced moderate -severe diarrhea occurring during the post -
challenge period; however, participant s will be monitored for additional GI and non -GI complaints daily. Data will be analyzed to 
determine the incidence of illness among participant s in the placebo vs. the CampETEC HBC group.  
Equation 1. Protective Efficacy  
PE (%) = 𝑖𝑛𝑐𝑖𝑑𝑒𝑛𝑐𝑒  (𝑝𝑙𝑎𝑐𝑒𝑏𝑜 )−𝑖𝑛𝑐𝑖𝑑𝑒𝑛𝑐𝑒  (𝐵𝑜𝑣𝑖𝑛𝑒  𝐼𝑔𝐺 )
𝑖𝑛𝑐𝑖𝑑𝑒𝑛𝑐𝑒  (𝑝𝑙𝑎𝑐𝑒𝑏𝑜 ) x 100%  
Additional comparisons between the placebo and the CampETEC groups include:  
• Maximum 24 -hour loose stool (Grades 3 -5) output  
• Total loose stool (Grades 3 -5) output  
• Percent of participant s with severe diarrhea  
• Percent of participant s with diarrhea of any severity  
• Percent of participant s with fever, nausea, vomiting, anorexia, or abdominal pain/cramps rated as moderate to severe  
• Time to diarrhea onset and diarrhea resolution  
• Number of colony -forming units of the challenge strain per gram of stool at 48 hours post challenge  
• Percent of participant s requiring early antibiotic treatment  
• Percent of participant s requiring IV fluids  
• Comparison of groups using a Campylobacteriosis severity score  in development  
Initial efficacy analyses will be based on an intent -to-treat and will include all participant s who receive the test article/placebo and the 
challenge. A secondary, per protocol analysis , may limit the number of participant s evaluated. Participant s who miss more than one 
dose of test article (or placebo) in the 24 hours prior to receipt of the challenge inoculum will be excluded from this secon dary analysis. 
Participant s who miss more than one dose of test article in the 72 hours following receipt of the ch allenge inoculum and who do not 
meet the primary outcome before missing their second dose will also be excluded. A similar analysis will be performed for the  
secondary outcomes outlined above. Analysis of participant s who miss doses and are not included in this time period will only be 
descriptive in nature.  
10.3.3  Immunogenicity  
Immunological outcomes, including serology  and fecal IgA  will  be summarized in a tabular format and graphed to demonstrate 
kinetics of response. Qualitative (responder rates) and quantitative assessments (log transformed values) will be analyzed. Between -
groups comparisons will be examined with nonparametric tests (Kruskal -Wallis for continuous data and Fisher’s Exact test for 
categorical data) unless assumptions are fulfilled for Student’s t or chi -squared test . Paired t -tests will be used to compare individual 
post-vaccination to baseline response within each treatment group. Only participant s receiving the experimental infection will be 
included in these analyses. All statistical tests will be performed using GraphPad Prism version 9.4.1 or  SAS version  9.2 and will be 
interpreted utilizing a two -sided alpha=0.05 and 95% confidence intervals for proportions will be estimated utilizing exact binomial 
distributions.  
11.0 DATA MANAGEMENT  
The investigator will maintain complete and accurate documentation for the study in accordance with applicable regulatory obl igations 
and Good Clinical Data Management Practices (GCDMP) guidance. All study records will be kept confidential to the extent pr ovided 
by national and local laws. (State laws require that positive HIV, hepatitis B and hepatitis C tests be reported to state health agencies). 
360_CampETEC _Campy_Protocol_V 1.1_12September 2023  47 When collecting clinical data, participant s will be identified by a unique participant  identification number and on source documents 
by initials and the participant study number . No personal identifier will be used in any publication or communication used to support 
this research study. The participant  study  number will be used if it becomes necessary to identify data specific to a single participant . 
All laboratory specimens, reports, study data collection, and administrative forms will be identified by coded number only to  maintain 
participant confidentiality. Samples are identified by coded participant  number only.  
Complete source documentation (study visits, laboratory reports, etc.) is kept for each participant  in his/her individual study chart. 
Study charts and documents will be retained at the study site in locked cabinets in locked rooms with limited access. Forms, lists, 
logbooks, appointment books, and any other listings that link participant ID numbers to other identifying information will be stored 
in a separate, locked file cabinet  in an area with limited access.  
An electronic data capture (EDC) database will be used to collect study data in an electronic format by the staff at the clin ical study 
site. The EDC database system will be designed based on the protocol requirements, the approved eCRF layouts and specifi cations, 
and in accordance with 21 Code of Federal Regulations Part 11. The eCRF layouts and specifications define and identify the ap plicable 
source data that will be collected and captured into the EDC database system. The applicable source data will be electronically 
transcribed by the site designee onto the eCRF (data entry screens) in the EDC database system. Information in the electronic  database 
is password -protected and access is available only to authorized research team members. Additionally, each  authorized research team 
member is assigned a level of security clearance (also password -protected) with mandatory password changes every 90 days) for the 
purpose of limiting access to certain areas or functions of the database. Any information printed fr om this database is stored in locked 
files until its use is complete and then shredded. Access to the database system is defined by the role and responsibility of  the project 
staff.  
11.1 Ethics and Legal Compliance  
Ethical Data Issues - Prior to the involvement of any human subjects, an appropriate Human Subjects Research Determination will be 
made. Research that is determined to be considered Human Subjects Research will obtain the appropriate Institutional Review B oard 
(IRB) and Department of Navy Human Research Protection Program (DoN -HRPP) review and approvals. Any data collected from 
participant s will be protected in accordance with Federal and Navy regulations. PII will not be released as part of data sets. Any d ata 
shared will be stripped of all identifiers to protect participant  identity. All sensitive data will be securely stored; electronic data will 
be encrypted and password protected with only IRB approved researchers permitted access. All paper data will be considered as 
PII/PHI  and stored in locked cabinets within locked rooms.  
Copyright regulations will follow Title 17 U.S.C. 101  
Intellectual Property Rights will be determined by review of all data created by the NMRC Office of Partnerships and Business  
Development and The Office of Legal Counsel. Patents applications will be filed as applicable. Patented work may be licensed to 
third parties under the guidance of the Office of Partnerships and Business Development.  
Data generated by NMRC  are considered to be property of the United States Government and its contracted support, as outlined in 
specific support contract agreements.  
Prior to public release, all data are reviewed for IP concerns. Should potential IP be identified, release of data will be delayed until 
such time that IP rights can be secured.  
11.2 Storage of Data and Samples  
All records pertaining to this protocol will be stored in a locked filing cabinet at JHU or at an offsite, locked storage fac ility per 
regulations for a minimum of 5 years. Access to these records will be limited to researchers in the Enteric Disease Depar tment at 
NMRC and the JHU CIR as well as those responsible for regulatory monitoring of data to include representatives of the DoD and  
JHU. A copy of study records will be made available to the Sponsor. The investigator will obtain permission from the spon sor in 
writing before destroying any study records and the sponsor will notify the investigator in writing when records can be destr oyed. 
Relevant IRBs will be notified in writing prior to destruction of any research records. Specimens will be stored indef initely in the JHU 
or the  Campylobacter  laboratory at NMRC.  
12.0 OBLIGATIONS AND ROLES OF THE SPONSOR, INVESTIGATOR, AND STUDY PERSONNEL  
This study will be conducted using GCP and in accordance with all federal regulations regarding the protection of human subject s in 
research including The Nuremberg Code, The Belmont Report, US 21 CFR Part 50 – Protection of Human Subjects, 32 CFR 219 
(The Common Rule) and all regulations pertinent to the Department of Defense.  
The investigators agree to conduct the research in strict accordance with this protocol, the ICH Guideline for GCP 
(CPMP/ICH/135/95), as well as in conformity with any federal, provincial or local regulations regarding the conduct of clinic al 
studies. The sponsor and investigator must comply with all applicable regulations. In addition, the investigator must follow local and 
institutional requirements including, but not limited to, IP, clinical research, informed consent,  and IRB regulations. The Sponsor wi ll 
provide notification to the investigator of protocol and amendment approvals by regulatory authorities when applicable. Excep t where 
the investigator's signature is specifically required, it is understood that the term "investigator" as used in this pro tocol and on source 
documents refers to the investigator or appropriate study personnel that the investigator designates to perform a certain dut y. The 
investigator is ultimately responsible for the conduct of all aspects of the study. Sub -investigators or  other appropriate study personnel 
are eligible to sign for the investigator on designated source documents.  
13.0 QUALITY CONTROL AND ASSURANCE  
13.1 QA/QC Monitoring  
Data monitoring and management will be performed in the EDC database system by the study monitor and the designated Data 
Management group. A detailed data management, monitoring and quality assurance plan will be written and approved by the study  
team and the principal investigator.  
360_CampETEC _Campy_Protocol_V 1.1_12September 2023  48 During the study, the principal investigator (PI) is responsible for procuring data, and for the quality of data recorded in the eCRFs. 
The study monitor will ensure accuracy of the eCRFs. At the end of the clinical trial, the data will be transferred to N MRC as part of 
a data transfer package. The data and the documentation to be transferred will be checked for quality control. Review will in clude:  
Comparison of the data transfer with the terms of the transfer with respect to contents, identification, documentation, and t imeline.  
• Specific safeguards that all applicable guidelines for protecting patient confidentiality have been made, including complete 
absence of any personal identifiers.  
• Proofreading the documentation relative to the data set(s), for completeness and accuracy.  
13.2 Protocol Deviation Management  
All amendments to the protocol, consent form and/or questionnaires, including a change of PI, will be submitted to the JHSPH IRB 
and NMRC IRB for review and approval prior to implementation. Other -than-minimal -risk changes and all unanticipated major 
problems involving human subjects or others will be reported promptly to the IRBs, and no such changes will be made to the re search 
without IRB approval unless necessary to eliminate apparent immediate hazards to human subjects. Minor minimal  risk deviations 
necessitated during the course of the trial will be made on site as needed and documented for subsequent review within a reas onable 
time period. Deviations from the protocol that potentially impact participant  safety will be promptly reported to the Research Monitor, 
IRBs, and the Sponsor. Other deviations will be reported at the time of continuing review.  
14.0 HUMAN PARTICIPANT S PROTECTIONS CONSIDERATIONS  
14.1 Risks/Benefits  
14.1.1  Risks  
14.1.1.1  Risks Related to the Investigational Product  
The HBC products are expected to be safe with possible mild to moderate discomfort , likely related to consumption of the sodium 
bicarbonate buffer, such as bad taste, bloating, nausea, gas, etc. As with any investigational drug or biologic, there is a p ossibility of 
severe allergic reaction.  
14.1.1.2  Risks Related to the Challenge Inoculum  
Naturally acquired illness caused by Campylobacter organisms ranges from mild -to-severe watery diarrhea that may contain mucus 
and/or blood. Nausea, vomiting, abdominal cramping, headache, abdominal gurgling or gas, anorexia, fever, muscle and/or joint ach es, 
and malaise, may occur. For most adults the illness is not life -threatening but often leads to mild to moderate dehydration and 
significant inconvenience associated with loss of sleep and activity. There is also a risk of recrudescence of Campylobacter infection. 
Study facilities will have personnel and resources capable to manage diarrheal illness and potential complications. Side effe cts from  
the antibiotic (azithromycin and ciprofloxacin) used to treat the Campylobacter infection are possible.  
A less common, but potentially life -threatening, complication of C. jejuni infection  is Guillain -Barré syndrome (GBS), a post -
infectious polyneuropathy that is a leading cause of paralysis and the related syndrome , Miller Fisher Syndrome (MFS)  [69-75]. 
Although many infectious agents are associated with GBS, C. jejuni is the most frequent pathogen associated with the syndrome and 
it has been estimated that between 1 :1000 to 1 :3000 cases of C. jejuni enteritis progress to  some form of GBS  [76-79]. A more recent 
direct estimate of GBS incidence in a cohort of patients presenting with Campylobacter enteritis in England was found to be 1.17/1000 
person -years  [79]. The  association between GBS and Campylobacter infection is supported by both serologic, culture, and 
experimental data. Published data from a large case -control study of Campylobacter -associated GBS by Rees and colleagues  showed 
evidence of C. jejuni infection in 26% of the 103 GBS and Miller  Fisher syndrome patients, compared to 2% of household controls, 
and 1% of hospital controls. The pathogenesis of Campylobacter -associated GBS is hypothesized to involve “molecular mimicry,” 
where peripheral nerves share epitopes with some C. jejuni antigens. Thus, an immune response, which is initially mounted against 
the infection, may be misdirected to peripheral nerve in some convalescing patients.  
Research supports the hypothesis that the association between C. jejuni and GBS is due to molecular mimicry between the outer 
lipooligosaccharide cores (LOS) and human gangliosides  [80-82]. Thus, the outer LOS cores of some strains of C. jejuni have a similar 
structure to multiple human gangliosides, including GM1. It is hypothesized that the Campylobacter epitopes stimulate the human 
immune system to attack gangliosides that are components of neural coverings throughout the human nervous system, thereby le ading 
to the development of GBS. This mimicry results from the ability of most strains of C. jejuni to synthesize N -acetyl neuraminic acid 
(Neu5Ac) endogenously for incorporation into the outer LOS core. Cross -reactive antibodies between C. jejuni LOS and gangliosides 
have been identified in GBS and Miller Fisher patients  [83,84].  Thus, during infection antibodies directed against these Neu5Ac -
containing ganglioside mimics results in an autoimmune disease affecting the ganglioside -rich peripheral nerves.  This association 
with GBS has impacted vaccine strategies and the design of potential human vaccine challenge studies. Based on this knowledge , an 
extensive search followed by detailed characterization of strain CG8421 documented the lack of ganglioside mimi cry and therefore 
decreases the  risk of GBS.  
Like Salmonella , Shigella , and Yersinia , Campylobacter enteritis has been associated with development of a reactive 
arthritis/arthropathy (RA)  [85-92]. Studies of outbreaks [ 87-92] have found an incidence of reactive arthritis ranging from about 0.7 
to 1.8% in participant s with evidence of C. jejuni infection. A more recent report documented a 2.6% rate in a waterborne outbreak in 
Finland among 350 exposed persons  [93]. A population -based survey also in Finland found a higher rate of 8% with most cases being 
very mild  [94]. Based on the survey results, the authors estimated an incidence of reactive arthritis following Campylobacter infection 
in Finland at 4.3 per 100,000. Also observ ed was a higher likelihood of reactive musculoskeletal complications among Campylobacter 
cases with a longer median duration of illness, 10 vs. 7 days of diarrhea. Most  cases were mild with only 20% visiting a physician and 
one hospitalization. A genetic predisposition to acquiring a seronegative spondyloarthropathy after a bacterial enteric infec tion 
(approximate risk gradient: Yersinia spp. > Shigella spp. ( S. flexneri ) > non -typhoid Salmonella > C. jejuni ) has been observed in 
individuals with the human leukocyte antigen (HLA) -B27 [95]. An overall estimated 18 -fold increased risk of reactive arthritis exists 
for HLA -B27 positive as compared to negative individuals following one of these infections  [95]. The presence of HLA -B27 antigen 
in Campylobacter -associated reactive arthritis has been variable, ranging from 14% to as high as 53%  [94]. Restricting the assessment 
360_CampETEC _Campy_Protocol_V 1.1_12September 2023  49 to the more severe cases increases the proportion of individuals who are HLA -B27 positive in the range of 70%, suggesting a greater 
risk for these individuals to have more severe or prolonged disease. No bacterial factor has been identified in the pathogen esis of 
reactive arthritis; however, the increased risk observed in HLA -B27 positive individuals permits screening of prospective participant s 
as a risk mitigation strategy. All participant s will be screened for HLA -B27, and a positive result will be an ex clusion criterion from 
the study.  
14.1.1.3  Risks Related to Antibiotic Treatment  
Therapeutic antibiotics for use in this study are licensed approved medications that have been used extensively and shown to be very 
safe with only rare side effects. The most reported  side effects for ciprofloxacin are gastrointestinal symptoms (nausea, vomiting, and 
diarrhea) in as many as 5 persons in 100. Other reported symptoms , in less than 1 person in a 100 , include rash, dizziness, and 
headache. Rarely, allergic reactions to these medications have been observed. Azithromycin has been associated with  gastrointestinal 
symptoms (nausea, vomiting, diarrhea and abdominal pain), hepatotoxicity (abnormal liver function tests, cholestatic jaundice ) and 
QT prolongation. There is no evidence related to adverse effects to support an increase in risk due to combination of azithromycin 
and ciprofloxacin , although hypothetically, both can increase the cardiac QT interval . Ciprofloxacin is not recommended for use in 
pregnancy due to concerns of joint damage to the unborn child (based on studies in young  animals). Pregnancy is exclusionary for 
study participation and is documented through testing prior to study interventions and provided discussion on methods to prev ent 
pregnancy during study. Fluoroquinolones, including ciprofloxacin, are associated with  an increased risk of tend onitis and tend on 
rupture in all ages. The risk of developing fluoroquinolone -associated tendinitis and tendon rupture is further increased in older 
patients usually over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney heart or lung transplants, all 
of whom are excluded from this study. Second line antibiotics to be used in this study like Augmentin and oral 3rd generation 
cephalosporin are associated with anaphylaxis reaction and rarely, Steven Johnson syndrome  . Clostridium difficil e associated diarrhea 
(CDAD/pseudomembranous colitis) has been reported with use of nearly all antibacterial agents.  
14.1.1.4  Risks Related to Study Procedures  
There is a minor, transient pain associated with blood draw  and intravenous (IV) fluid administration . Hematomas or bleeding can 
occur at the puncture site. Rarely, there is lightheadedness, syncope or infection. Intravenous catheters may additionally infiltrate and 
cause swelling and/or discomfort.  
Volunteers may experience minor discomfort, annoyance, or embarrassment related to stool collection and rectal swabs. Rarely, rectal 
swabs may cause bleeding or irritation.  
Isolation from friends, family, work, school and sharing space with strangers can cause discomfort.  
There may be physical, psychological and social risks if participant s test positive for hepatitis B, hepatitis C and/or HIV. Participant s 
testing positive will be counseled and referred for treatment.  
14.1.1.5  Risk to Privacy and Confidentiality  
All data and medical information obtained about participants will be considered privileged and held in confidence. A breach o f 
confidentiality in which private health information is made public is possible. Participants will not be identified by name i n any 
published report/presentation of the results. The Sponsor, their delegates, and the FDA may inspect the records of this resea rch as part 
of their responsibility to oversee research and ensure protection of participants. Study results and data may be publ ished in 
scientific/medical journals; the identity of individual participants will not be disclosed.  
 
Complete confidentiality cannot be promised to participant s who are military personnel, because appropriate medical command 
authorities may require reporting information bearing on the health of their personnel. Representatives of the Sponsor, NMRC IRB, 
JHSPH IRB, or FDA may inspect the records of this research a s part of their responsibility to oversee research and ensure protection 
of participant s. 
The study monitors and other authorized representatives of the Sponsor may inspect all documents and records required to be 
maintained by the Investigator, including but not limited to, medical records. The investigator will inform the participant s that the 
above -named representatives will review their study  related records.  
Participant s’ study information will not be released without the written permission of the participant , except as required, these groups 
may include:  
1. Audit and Compliance Officers and Legal Counsel  
2. Office for Human Re search  Protections ( OHRP ) 
3. The U.S. Food and Drug Administration (FDA) and other similar regulatory agencies  
4. The study sponsor or designee  
5. Study monitors, Medical Monitors  
6. Department of Health and Human Services (DHHS) agencies  
7. Governmental health agencies to which HIV and hepatitis testing must be reported  
8. The Johns Hopkins University Bloomberg School of Public Health  
14.1.1.6  Risk of SARS -CoV -2 Exposure and Risk Mitigation  
SARS -CoV -2, the virus that causes COVID -19 infections and disease, is the cause of the  global pandemic that started in 2020. 
COVID -19 can cause respiratory symptoms and pulmonary disease. Symptoms include fever, increased cough, shortness of breath, 
trouble breathing, fatigue, chills, body aches, headache, sore throat, congestion/runny nose,  loss of taste or smell, nausea, and diarrhea. 
The virus can lead to more severe illness including pneumonia, respiratory failure, heart problems, liver problems, blood clots, septic 
shock, and death.  
360_CampETEC _Campy_Protocol_V 1.1_12September 2023  50 The CIR will follow recommendations from the CDC when implementing clinical trials. The CIR will also follow institutional 
guidelines and policies. Current recommendations include vaccination with one of the FDA -approved bivalent vaccines. To mitigate 
risk and provide a safe environment for participants while they are inpatient on the unit during the study , the CIR staff will educate 
and encourage all potential study volunteers to be fully vaccinated prior to enrolling in this study. Volunteers will not be required to 
be vaccinated against COVID -19; however, vaccinated volunteers will be prioritized for enrollment.   
All volunteers will sign a disclaimer regarding vaccination status and possible exposure to the virus . All volunteers will  be tested for 
COVID -19 upon admission to the inpatient unit  and any person found to be positive will be discharged . 
14.1.2  Risk Mitigation Strategies  
14.1.2.1  During Acute Diarrhea Episode  
Participant s will be questioned and examined daily for evidence of Campylobacter illness . Vital signs will be recorded at least three 
times per day. Based on prior studies, infected participant s tend to develop illness with incubation periods of approximately 1 -3 
days. The range varied from as short as 10 -12 hours in a minority of participant s up to 5.5 days. Therapeutic benefit seems to be 
optimal if treatment is given within the first three days of symptom onset. The risk of diarrhea complications will be minimi zed by a 
conservative approach to timing of antibiotic administration well within  an interval that has been shown to be efficacious as well as 
daily clinical monitoring. Stool output will be closely monitored. The plan will be to treat all participant s no later than day 6 post -
dosing. The participant s will be monitored for evidence of relapsed Campylobacter infection by clinical symptoms and repeat stool 
cultures on study days 1 5, 29, 42, 57, and 8 5. 
Aggressive fluid management will be undertaken to ensure the most common complication, dehydration, does not occur. The 
procedures to institute early oral and/or intravenous rehydration therapy are detailed above. In addition to rehydration ther apy, 
prospe ctively defined criteria and procedures to institute early antibiotic therapy are also fully described above. To ensure clinical 
resolution and limit the potential for secondary spread upon discharge, predefined discharge criteria have been established. 
Participant s will be discharged from the inpatient phase of the study when clinical symptoms are resolved or resolving , at least two 
doses of antibiotics have been taken  AND two consecutive stool cultures are negative for C. jejuni . 
Systemic or severe gastrointestinal complications rarely occur with Campylobacter infection. The following clinical findings 
necessitate immediate consideration and management of complicated enteritis:  
• Physical examination compatible with an acute abdomen  
• Severe GI bleeding (any evidence of GI blood loss other than hemoccult positivity only, with evidence of hemodynamic 
instability, decrease in hemoglobin, hypovolemia)  
• Sepsis (high fever: temp. >102ºF (39ºC), rigors, hemodynamic instability)  
Any of these findings require prompt clinical management and discussion with the independent Research Monitor.  
The C. jejuni strain has the potential for risk to both the environment and to the research personnel. Campylobacter spp. are common 
commensals of many birds and mammals with the usual route of transmission to humans through consumption of contaminated meat,  
poultry, milk and occasionally large waterborne outbreaks. Therefore,  the of potential transmission outside of the JHU CIR facility is 
low. There is a minimal risk of acquiring C. jejuni infection associated with participant  inoculum administration, pat ient care activities 
on the ward, or processing C. jejuni -infected stool. The risk to the environment will be reduced by ensuring that all human waste 
products from inpatients are disinfected with bleach prior to disposal  per the MOP , ensuring all participant s comply with discharge 
criteria ( including two consecutive negative stool cultures for C. jejuni ), emphasizing importance of hand washing for participant s 
and staff, ensuring proper disposal/cleaning of linen, and cohorting participant s in the JHU CIR while they are shedding C. jejuni . 
Additionally, participant s will not be discharged until they are no longer shedding the challenge strain per the procedures outlined in 
the protocol.  
If a recrudescent infection is detected, the follow -up clock will be reset according to expert panel’s recommendation. The risk of 
recrudescent infection will be minimized by the participation of only immunocompetent individuals, the use of an extended dur ation 
of concurrent antibiotics (five days), monitor ing of clinical symptoms, and evaluation of stool cultures. Follow up stool cultures at in-
person outpatient visits  will be performed to demonstrate continued eradication of infection.  
If a participant  is found to have recrudescence of infection, as defined in the definition section, the follow  procedures will be completed 
per Section 6.6. 
If there is an allergic reaction or adverse event, or if resistance emerges to both antibiotics, the planned course of treatm ent will be 
Augmentin (875  mg PO BID for 10 days) or the oral third generation cephalosporin, cefpodoxime (400  mg PO BID for 10 day s). 
Decisions regarding antibiotic use and combination of these second -line agents will be made by Principal Investigators on a case -by-
case basis in consultation with the Research Monitor.  
Post-Infectious Sequelae  
Post-infectious sequelae include neurologic, rheumatologic, and gastrointestinal syndromes. The risk mitigation strategies for pos t-
infectious sequelae differ between GBS and reactive arthritis. GBS risk reduction is based on selection of a strain with no evidence of 
inducing potential ganglioside mimicry coupled with participant  screening for personal or immediate family history of autoimmune 
or neurologic disease that may predispose the participant  to greater risk. Similar participant  eligibility screenin g for personal or 
immediate family member medical history of autoimmune or inflammatory arthritis will be used to reduce risk of reactive arthr itis. 
Also, participant s will be excluded if they are positive for HLA -B27 since  that is associated with higher risk as well as poorer 
prognosis. Predefined criteria to assure early treatment as appropriate also may further reduce risk of post -infectious sequelae as has 
been observed with reactive arthritis [9 4]. Recent studies also suggest an increased risk of post -infectious irritable bowel syndrome 
(IBS) following bacterial enteritis  [96]. Participant  eligibility will be restricted to individuals without IBS history. As observed with 
reactive arthritis, the duration of illness is a strong predictor of post -infectious IBS ris k [97]. Individuals with > 21 days of diarrhea 
360_CampETEC _Campy_Protocol_V 1.1_12September 2023  51 had an IBS relative risk of 11.4 compared to illness lasting < 7 days. All participant s will receive treatment no later than 6 days from 
time of inoculation , which should reduce this potential risk.  
The participant s will be monitored for evidence of post -infectious sequelae ( including reactive arthritis and GBS) on clinic visits at 
study days 1 5, 29, 42, 57, and 8 5 and a phone call at Day 18 1. IBS symptoms will be screened for by completing the Functional Bowel 
Disorder Survey on Study Day 181.  
The following describes the clinical evaluation required in the event of suspect post -infectious sequelae (GBS or reactive arthritis).  
Suspect reactive arthritis  
Participant s reporting new complaints consistent with the clinical definition of “arthralgia,” “arthritis” or “reactive arthritis” will be 
evaluated as soon as possible by one of the on -site clinical investigators. The participant  will be promptly evaluated by history, directed 
examination, ± indicated laboratory analysis , which may include, but is not limited to  a complete blood cell count (CBC), erythrocyte 
sedimentation rate (ESR) and /or a C-reactive protein (CRP). The participant ’s symptoms/exam finding s will be discussed with the 
independent Research Monitor and a rheumatologist. If the participant  meets the clinical definition of “arthritis” or “reactive arthritis,” 
then the participant  will be evaluated as soon as possible. If the participant  meets the definition of “arthralgia” only, then ESR and 
CRP will be obtained. If ESR/CRP is abnormal, then the participant  will be referred for evaluation. If ESR/CRP is normal, then the 
participant  will have a repeat examination at one week (sooner if new problems arise). The case will be discussed with a staff 
rheumatologist. The mechanism to provide a timely evaluation and prompt referral to a rheumatologist will be arranged prior t o study 
initiat ion.  
Suspect Guillain -Barré syndrome  
Participant s reporting new complaints concerning  for GBS (i.e., new onset extremity weakness, numbness/paresthesia especially if 
symmetric and/or progressive) require immediate evaluation . The independent Research Monitor will be notified prompt ly, and the 
participant  will likely receive a n urgent Neurology referral.  The presence or absence of an abnormal exam will be very important early 
on to determine the necessary management. Regardless of the findings, all suspected cases of GBS or equivocal symptoms that raise 
some concerns regarding GBS will require discussion with a staff neurologist. The mechanism to provide a timely evaluation an d 
prompt referral to a neurologist will be arranged prior to study initiation.  
Irritable Bowel Syndrome  
Recent studies also suggest an increased risk of post -infectious irritable bowel syndrome (PI -IBS) following bacterial enteritis with 
limited studies associating Campylobacter  infection specifically with this sequela  [98, 99]. PI-IBS, a functional bowel disorder 
characterized by unexplained abdominal discomfort or pain associated with changes in normal bowel patterns, has been describe d in 
a recent systematic review to occur 6 -7 times more frequently after an acute enteric inf ection compared to similar matc hed controls 
without such a history  [99]. Participant s with prior history of abnormal bowel patterns who might be at higher risk of this post -
infectious sequelae are excluded and predefined criteria to assure early treatment as appropriate also may further reduce ris k of post -
infectious sequelae as has been observed with reactive arthritis and  is likely to reduce the risk associated with PI -IBS given the positive 
association between diarrheal illness duration and PI -IBS risk  [100,101]. 
Medical records associated with this protocol are subject  to provisions of the Privacy Act of 1974, 5 U.S.C., Section 552A, and AR 
340-21. All data and medical information obtained about participant s will be considered privileged and held in confidence. See Privacy 
and Confidentiality  
14.1.3  Benefits  
There is no benefit to participant s for participating in this research study. However, there is potential societal benefit of the 
development of a product to prevent Campylobacter.  
14.2 Participant  Compensation  
Compensation for participation will occur as detailed below. Compensation will be provided only for completed study procedure s 
designated for compensatory payment. If a participant  is eligible to participate in the study after screening, is enrolled in the study, 
and completes all study visits, procedures and follows all the rules they will receive full compensation as described below:  
• $150 total for screening (only if enrolled in the study or presents as an alternate)  
• $4200 ($350 per night)  for the inpatient period (as long as all study requirements are met)  
• $750 ($150 per visit) for outpatient study visits: Days 1 5, 29, 42, 57, 85  
• $60 for the follow -up telephone contact: Day 18 1 
• $250 bonus upon completion of inpatient phase and outpatient visits  
 Maximum compensation for the planned schedule  of the study is $ 5410 ,  
If there is a day 11 3 visit, participant will be compensated an additional $150.  
If a participant  is not eligible for discharge on day 10, they  will receive $ 300 per additional inpatient day. Participant s will not be paid 
for missed outpatient visits and may forfeit some or all their bonus because of  missed visits or noncompliance.  
If a participant recrudesces  some of the visits may still be included in the compensation as above. It is likely that there will be additional 
visits required , participants will be compensated $ 150 for each additional visit not covered above.  
14.3 Research -Related Injury  
All study -related medical care will be provided to participant s without cost. Should a participant  be injured as a direct result of 
participating in this research project, they will be provided medical care by the staff at the Walter Reed National Military Medical 
Center (or other military -affiliated medical center), at no cost to the participant s, for that injury. The participant s will not receive any 
360_CampETEC _Campy_Protocol_V 1.1_12September 2023  52 injury compensation, only medical care. The participant s will not be compensated for care if they choose to seek care from their own 
medical care provider . 
If a participant  is injured because of participation in this research and is a DoD healthcare beneficiary (e.g., active duty in the military, 
military spouse or dependent), the participant  is entitled to medical care for that injury within the DoD healthcare system, as long as 
the participant  remains a DoD healthcare beneficiary. This care includes, but is not limited to, free medical care at Army hospitals or 
clinics.  
If a participant  is injured because of participation in this research and is not a DoD healthcare beneficiary, the participant  is entitled 
to free medical care for that injury at a DoD hospital or clinic. It cannot be determined in advance which DoD hospital or cl inic will 
provide care. If the participant  receives care for research -related injuries outside of a DoD hospital or clinic, the participant  or the 
participant ’s insurance will be responsible for medical expenses.  
During the challenge phase, participant s who require medical treatment beyond what can be provided safely at the CIR will be 
transferred to a tertiary medical facility, ideally  Johns Hopkins Bayview Medical Center. If a participant  is injured during the study, 
the investigators will help the participant s find medical care. Medical care at Johns Hopkins is open to all participant s, as it is to all 
sick or injured people. Neither Johns Hopkins Bloomberg School of Public Health nor the John Hopkins Hospitals h ave any plan to 
provide compensation to the participant s if they experience injury or other bad effects which are not the fault of the study doctors. 
Participant s will only be treated for injuries that are directly caused by the research study.  Follow -up as necessary may be provided at 
the Walter Reed National Military Medical Center.  
Transportation to and from military hospitals or clinics will not be provided. No reimbursement is available if the participant  incurs 
medical expenses to treat research -related injuries from outside or private providers. No compensation is available for research -related 
injuries. The participant  is not waiving any legal rights. The participant  should contact the PI if the participant  believes he or she has 
sustained a research related  injury  or has any questions .  
Requests for other benefits, such as compensation for lost time from work, are processed independently of this protocol. The right of 
other parties to seek redress against the United States Government is limited to that set forth by existing agency regulat ions and the 
Federal Tort Claims Act. The participant  should understand that this does not constitute a waiver or release of legal rights. This issue 
is addressed in the informed consent and will be discussed with the participant  by the investigator or des ignee before the participant  
signs the informed consent to participate in the study.  
14.4 Compensation for Investigators  
There is no financial compensation for investigators in this study. All investigators will be required to complete a form for  the 
disclosure of significant financial interest.  
14.5 Fair and Equitable Selection of Participant s 
Participant s will not be discriminated against based on  race, sex, or religion. Due to the early stage of development of this IP, we have 
excluded individuals under 18 and people  who are pregnant or nursing and we have excluded individuals who are over the age of 50 
due to the frequency of exclusionary medical conditions. Any individual who is unable to consent due to any reason will not b e 
included in this study.  
14.6 Informed Consent  
The informed consent process and document(s) will be reviewed and approved by the NMRC IRB and the JHSPH IRB prior to 
initiation of the study. The consent document(s) will contain a full explanation of the possible risks, advantages, and alter nate treatmen t 
options, and availability of treatment in the case of injury, in accordance with 21 CFR 50. Study information will be present ed in 
audio and visual formats in lay terms to facilitate understanding. The participant ’s signature on the informed consent docu ment will 
indicate the participant ’s permission to access relevant medical records by the sponsor’s representative and by representatives of the 
FDA. The sponsor’s representative will submit a copy of the initial IRB - and sponsor’s representative -approved consent form to the 
FDA and will m aintain copies of revised consent documents that have been reviewed and approved by the IRB/ethics committee. See 
Study Specific Screening and Consenting.  
The participant  should understand that the study product is investigational and is not licensed by the FDA for commercial use but is 
permitted to be used in this clinical research. Informed consent includes the principle that it is critical the participant  be informed 
about the principal potential risks and benefits. This information will allow the participant  to make a personal risk versus benefit 
decision and understand the following:  
• Participation is entirely voluntary.  
• Participant s may withdraw from participation at any time.  
• There is no penalty for declining to participate in the study.  
• The individual is free to ask any questions that will allow him/her greater understanding of the study.  
• A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as required by US law . 
All non -exempt research involving human participant s shall, at a minimum, meet the requirement of 32 CFR 219.116(a)(6) in the 
Code of Federal Regulations.  
14.7 Recruitment  
All study -related advertisements will be reviewed and approved by the JHSPH IRB, NMRC IRB and HRPO -ORP, if applicable. 
Active -duty military members will not specifically be recruited for this study. See Sections 4.0 and 5.0. 
15.0 PRIVACY AND CONFIDENTIALITY  
15.1 Provisions Protecting Privacy and Confidentiality  
Individual participant  medical information obtained because of  this study is considered confidential and disclosure to third parties, 
other than those cited below, is prohibited. Participant  confidentiality will be further ensured by utilizing participant  identification 
360_CampETEC _Campy_Protocol_V 1.1_12September 2023  53 code numbers and participant  initials. Neither NMRC nor the JHSPH are HIPAA -covered entities. See also Data Management and 
Safety.  
Confidentiality agreements may be developed with other clinical trials groups ( e.g., at the University of Maryland Vaccine Research 
Center or WRAIR Clinical Trials Center), and the investigative team may check verbally with these sites to see if participant s have 
participated in studies that would preclude their participation in this study. No written list will be exchanged with these s ites. 
All assessments will be conducted in private exam or procedure rooms.  
15.2 Safeguards for Vulnerable Participant s 
This study will not include individuals less than 18, incarcerated or unable to meet the requirements to sign the informed co nsent 
form. Military personnel will not be specifically recruited for this study. All active duty military participant s will need to have written 
permission from their superior to participate in this study.  
16.0 PROTOCOL REVIEW PROCESS  
The protocol will undergo scientific and ethical review at the two primary collaborating institutions: CIR and NMRC. In addit ion to 
these reviews, the JHU Biosafety Committee and Pharmacy and Therapeutics Committee will review the protocol. The protocol wi ll 
also require FDA review as part of the IND application. The IND sponsor will be Dr. David Sack. Continuing review will be 
undertaken in accordance with existing regulations.  
The investigator may deviate from the protocol without prior approval when the change is necessary to eliminate an apparent 
immediate hazard to the participant . In that event, the investigator will notify the sponsor promptly by phone, will notify the CIR 
(JHSPH IRB) and NMRC IRB, and will confirm notification to the sponsor in writing within 5 working days after the change is 
implemented. All protocol deviation s, including minor deviations not impacting participant  safety, will be noted in the continuing 
review reports, the annual report to the Sponsor, and in the final study report. Any modification to the protocol, consent for m and/or 
questionnaires, including changing the PI, must be submitted to both IRBs for review and approval prior to implementation of the 
modification. Any deviation to the protocol that may have an effect on the safety or rights of the participant  or the integrity of the 
study , must be reported to the NMRC ORA, JHSPH IRB and USAMRMC HRPO -ORP, if applicable, as soon as the deviation i s 
identified.  
17.0 PUBLICATION POLICY  
All data collected during this study will be used to support this IND. All publications and presentations are governed by the standards 
and norms detailed in NAVMEDRSCHCENINST 5721.1. All authors will submit the proposed publication/presentation at least 30 
days prior to the submission date. Prior to  submission, the directorate will conduct a substantive scientific and professional review. 
The document is routed to the Office of Research Administration (ORA) for review and routing for Command review and approval,  
ultimately by the NMRC Public Affairs Officer. Once it is cleared at NMRC, it will be forwarded to BUMED through NMSC, if 
appropriate. Prior to publication, an author must have a completed Publication Clearance Request Submission Form with signatu res 
from all approving and reviewing authoritie s. 
 
360_CampETEC _Campy_Protocol_V 1.1_12September 2023  54  
18.0 REFERENCE  
1. Scallan, E., et al., Foodborne illness acquired in the United States --major pathogens. Emerg Infect Dis, 2011. 17(1): 
p. 7-15.  
2. Olson, S., et al., Travelers' diarrhea: update on the incidence, etiology and risk in military and similar populations - 
1990 -2005 versus 2005 -2015, does a decade make a difference? Trop Dis Travel Med Vaccines, 2019. 5: p. 1.  
3. Collaborators, G.B.D.D.D., Estimates of the global, regional, and national morbidity, mortality, and aetiologies of 
diarrhoea in 195 countries: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect Dis, 
2018. 18(11): p. 1211 -1228 .  
4. Steffen, R., Epidemiology of travellers' diarrhea. J Travel Med, 2017. 24(suppl_1): p. S2 -S5.  
5. Connor, P., et al., Diarrhoea during military deployment: current concepts and future directions. Curr Opin Infect Dis, 
2012. 25(5): p. 546 -54.  
6. Riddle, M.S., et al., Incidence, etiology, and impact of diarrhea among long -term travelers (US military and similar 
populations): a systematic review. Am J Trop Med Hyg, 2006. 74(5): p. 891 -900.  
7. Connor, P. and M.J. Farthing, Travellers' diarrhoea: a military problem? J R Army Med Corps, 1999. 145(2): p. 95 -
101.  
8. Connor, B.A. and M.S. Riddle, Post -infectious sequelae of travelers' diarrhea. J Travel Med, 2013. 20(5): p. 303 -12.  
9. Curry, J.A., et al., The epidemiology of infectious gastroenteritis related reactive arthritis in U.S. military personnel: 
a case -control study. BMC Infect Dis, 2010. 10: p. 266. 10.  
10. Porter, C.K., et al., Travelers' Diarrhea: An Update on the Incidence, Etiology, and Risk in Military Deployments and 
Similar Travel Populations. Mil Med, 2017. 182(S2): p. 4 -10.  
11. Riddle, M.S., S.J. Savarino, and J.W. Sanders, Gastrointestinal Infections in Deployed Forces in the Middle East 
Theater: An Historical 60 Year Perspective. Am J Trop Med Hyg, 2015. 93(5): p. 912 -917.  
12. DuPont, H.L., Travelers' diarrhea: antimicrobial therapy and chemoprevention. Nat Clin Pract Gastroenterol Hepatol, 
2005. 2(4): p. 191 -8; quiz 1 p following 198.  
13. DuPont, H.L., Therapy for and prevention of traveler's diarrhea. Clin Infect Dis, 2007. 45 Suppl 1: p. S78 -84.  
14. Bartsch, S.M. and B.Y. Lee, Economics and financing of vaccines for diarrheal diseases. Hum Vaccin Immunother, 
2014. 10(6): p. 1568 -81.  
15. Bloom, D.E. and D. Canning, Policy forum: public health. The health and wealth of nations. Science, 2000. 
287(5456): p. 1207, 1209.  
16. Levine, M.M., et al., Immunity to enterotoxigenic Escherichia coli. Infect Immun, 1979. 23(3): p. 729 -36.  
17. Clemens, J.D., et al., Cross -protection by B subunit -whole cell cholera vaccine against diarrhea associated with heat -
labile toxin -producing enterotoxigenic Escherichia coli: results of a large -scale field trial. J Infect Dis, 1988. 158(2): 
p. 372 -7.  
18. Qadri, F., et al., Prevalence of toxin types and colonization factors in enterotoxigenic Escherichia coli isolated during 
a 2-year period from diarrheal patients in Bangladesh. J Clin Microbiol, 2000. 38(1): p. 27 -31.  
19. Cravioto, A., et al., Prospective study of diarrhoeal disease in a cohort of rural Mexican children: incidence and 
isolated pathogens during the first two years of life. Epidemiol Infect, 1988. 101(1): p. 123 -34. 
20. Lopez -Vidal, Y., et al., Enterotoxins and adhesins of enterotoxigenic Escherichia coli: are they risk factors for acute 
diarrhea in the community? J Infect Dis, 1990. 162(2): p. 442 -7.  
21. Snodgrass, D.R., Nagy, L.K., Sherwood, D. & Campbell, I., Passive immunity in calf diarrhea: vaccination with K99 
antigen of enterotoxigenic Escherichia coli and rotavirus. Infect. Immun., 1982. 37: p. 586 -91.  
22. Moon, H.W. and T.O. Bunn, Vaccines for preventing enterotoxigenic Escherichia coli infections in farm animals. 
Vaccine, 1993. 11(2): p. 213 -200.  
23. Murray, C.J., et al., Disability -adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990 -2010: a 
systematic analysis for the Global Burden of Disease Study 2010. Lancet, 2012. 380(9859): p. 2197 -223.  
24. Platts -Mills, J.A., et al., Pathogen -specific burdens of community diarrhoea in developing countries: a multisite birth 
cohort study (MAL -ED). Lancet Glob Health, 2015. 3(9): p. e564 - 75.  
25. Patrick, M.E., et al., Features of illnesses caused by five species of Campylobacter, Foodborne Diseases Active 
Surveillance Network (FoodNet) - 2010 -2015. Epidemiol Infect, 2018. 146(1): p. 1 -10.  
26. Schwartz, K.L. and S.K. Morris, Travel and the Spread of Drug -Resistant Bacteria. Curr Infect Dis Rep, 2018. 20(9): 
p. 29.  
27. Novik, V., D. Hofreuter, and J.E. Galan, Characterization of a Campylobacter jejuni VirK protein homolog as a novel 
virulence determinant. Infect Immun, 2009. 77(12): p. 5428 -36.  
28. Parkhill, J., et al., The genome sequence of the food -borne pathogen Campylobacter jejuni reveals hypervariable 
sequences. Nature, 2000. 403(6770): p. 665 -8.  
29. Karlyshev, A.V., et al., Analysis of Campylobacter jejuni capsular loci reveals multiple mechanisms for the generation 
of structural diversity and the ability to form complex heptoses. Mol Microbiol, 2005. 55(1): p. 90 -103.  
30. Maue, A.C., F. Poly, and P. Guerry, A capsule conjugate vaccine approach to prevent diarrheal disease caused by 
Campylobacter jejuni. Hum Vaccin Immunother, 2014. 10(6): p. 1499 -504.  
360_CampETEC _Campy_Protocol_V 1.1_12September 2023  55 31. Pike, B.L., P. Guerry, and F. Poly, Global Distribution of Campylobacter jejuni Penner Serotypes: A Systematic 
Review. PLoS One, 2013. 8(6): p. e67375.  
32. Tacket, C.O., et al., Protection by milk immunoglobulin concentrate against oral challenge with enterotoxigenic 
Escherichia coli. N Engl J Med, 1988. 318(19): p. 1240 -3.  
33. Tacket, C.O., et al., Efficacy of bovine milk immunoglobulin concentrate in preventing illness after Shigella flexneri 
challenge. Am J Trop Med Hyg, 1992. 47(3): p. 276 -83.  
34. Davidson, G.P., et al., Passive immunisation of children with bovine colostrum containing antibodies to human 
rotavirus. Lancet, 1989. 2(8665): p. 709 -12.  
35. Savarino, S.J., et al., Prophylactic Efficacy of Hyperimmune Bovine Colostral Antiadhesin Antibodies Against 
Enterotoxigenic Escherichia coli Diarrhea: A Randomized, DoubleBlind, Placebo -Controlled, Phase 1 Trial. J Infect 
Dis, 2017. 216(1): p. 7 -13.  
36. Savarino, S.J., et al., Hyperimmune Bovine Colostral Anti -CS17 Antibodies Protect Against Enterotoxigenic 
Escherichia coli Diarrhea in a Randomized, Doubled -Blind, PlaceboControlled Human Infection Model. J Infect Dis, 
2019. 220(3): p. 505 -513.  
37. Freedman, D.J., et al., Milk immunoglobulin with specific activity against purified colonization factor antigens can 
protect against oral challenge with enterotoxigenic Escherichia coli. J Infect Dis, 1998. 177(3): p. 662 -7. 
38. Korhonen, H., P. Marnila, and H.S. Gill, Bovine milk antibodies for health. Br J Nutr, 2000. 84 Suppl 1: p. S135 -46.  
39. Singh, B., et al., Antibodies Damage the Resilience of Fimbriae, Causing Them To Be Stiff and Tangled. J Bacteriol, 
2017. 199(1).  
40. Poole, S.T., et al., Donor strand complementation governs intersubunit interaction of fimbriae of the alternate 
chaperone pathway. Mol Microbiol, 2007. 63(5): p. 1372 -84.  
41. Maciel, M., Jr., et al., Intradermal or sublingual delivery and heat -labile enterotoxin (LT) proteins shape immunologic 
outcomes to CFA/I fimbriae -derived subunit antigen vaccine against enterotoxigenic E. coli. Infect Immun, 2019.  
42. Maciel, M., Jr., et al., Evaluation of the reactogenicity, adjuvanticity and antigenicity of LT(R192G) and 
LT(R192G/L211A) by intradermal immunization in mice. PLoS One, 2019. 14(11): p. e0224073.  
43. Bacon, D.J., et al., A phase -variable capsule is involved in virulence of Campylobacter jejuni 81 -176. Mol Microbiol, 
2001. 40(3): p. 769 -77.  
44. Keo, T., et al., Campylobacter capsule and lipooligosaccharide confer resistance to serum and cationic antimicrobials. 
Virulence, 2011. 2(1): p. 30 -40.  
45. Monteiro, M.A., et al., Capsule polysaccharide conjugate vaccine against diarrheal disease caused by Campylobacter 
jejuni. Infect Immun, 2009. 77(3): p. 1128 -36.  
46. Laird, R.M., et al., Evaluation of a conjugate vaccine platform against enterotoxigenic Escherichia coli (ETEC), 
Campylobacter jejuni and Shigella. Vaccine, 2018. 36(45): p. 6695 -6702.  
47. Casswall, T.H., et al., Treatment of enterotoxigenic and enteropathogenic Escherichia coliinduced diarrhoea in 
children with bovine immunoglobulin milk concentrate from hyperimmunized cows: a double -blind, placebo -
controlled, clinical trial. Scand J Gastro enterol, 2000. 35(7): p. 711 -8.  
48. Mietens, C., et al., Treatment of infantile E. coli gastroenteritis with specific bovine anti -E. coli milk 
immunoglobulins. Eur J Pediatr, 1979. 132(4): p. 239 -52.  
49. Otto, W., et al., Randomized control trials using a tablet formulation of hyperimmune bovine colostrum to prevent 
diarrhea caused by enterotoxigenic Escherichia coli in volunteers. Scand J Gastroenterol, 2011. 46(7 -8): p. 862 -8.  
50. Tacket, C.O., et al., Lack of prophylactic efficacy of an enteric -coated bovine hyperimmune milk product against 
enterotoxigenic Escherichia coli challenge administered during a standard meal. J Infect Dis, 1999. 180(6): p. 2056 -
9.  
51. Tawfeek, H.I., N.H. Najim, and S. Al -Mashikhi, Efficacy of an infant formula containing anti -Escherichia coli 
colostral antibodies from hyperimmunized cows in preventing diarrhea in infants and children: a field trial. Int J Infect 
Dis, 2003. 7(2): p. 120 -8.  
52. Talaat, K.R., et al., Oral delivery of Hyperimmune bovine serum antibodies against CS6 - expressing enterotoxigenic 
Escherichia coli as a prophylactic against diarrhea. Gut Microbes, 2020: p. 1 -11.  
53. Sarker, S.A., et al., Successful treatment of rotavirus diarrhea in children with immunoglobulin from immunized 
bovine colostrum. Pediatr Infect Dis J, 1998. 17(12): p. 1149 -54.  
54. Brunser, O., et al., Field trial of an infant formula containing anti -rotavirus and antiEscherichia coli milk antibodies 
from hyperimmunized cows. J Pediatr Gastroenterol Nutr, 1992. 15(1): p. 63 -72. 
55. Hilpert, H., et al., Use of bovine milk concentrate containing antibody to rotavirus to treat rotavirus gastroenteritis in 
infants. J Infect Dis, 1987. 156(1): p. 158 -66.  
56. McClead, R.E., Jr., T. Butler, and G.H. Rabbani, Orally administered bovine colostral anticholera toxin antibodies: 
results of two clinical trials. Am J Med, 1988. 85(6): p. 811 -6.  
57. Okhuysen, P.C., et al., Prophylactic effect of bovine anti -Cryptosporidium hyperimmune colostrum immunoglobulin 
in healthy volunteers challenged with Cryptosporidium parvum. Clin Infect Dis, 1998. 26(6): p. 1324 -9.  
58. Greenberg, P.D. and J.P. Cello, Treatment of severe diarrhea caused by Cryptosporidium parvum with oral bovine 
immunoglobulin concentrate in patients with AIDS. J Acquir Immune Defic Syndr Hum Retrovirol, 1996. 13(4): p. 
348-54.  
360_CampETEC _Campy_Protocol_V 1.1_12September 2023  56 59. Ungar, B.L., et al., Cessation of Cryptosporidium -associated diarrhea in an acquired immunodeficiency syndrome 
patient after treatment with hyperimmune bovine colostrum. Gastroenterology, 1990. 98(2): p. 486 -9.  
60. Nord, J., et al., Treatment with bovine hyperimmune colostrum of cryptosporidial diarrhea in AIDS patients. AIDS, 
1990. 4(6): p. 581 -4.  
61. Warny, M., et al., Bovine immunoglobulin concentrate -clostridium difficile retains C difficile toxin neutralising 
activity after passage through the human stomach and small intestine. Gut, 1999. 44(2): p. 212 -7.  
62. Kelly, C.P., et al., Survival of anti -Clostridium difficile bovine immunoglobulin concentrate in the human 
gastrointestinal tract. Antimicrob Agents Chemother, 1997. 41(2): p. 236 -41.  
63. Casswall, T.H., et al., Treatment of Helicobacter pylori infection in infants in rural Bangladesh with oral 
immunoglobulins from hyperimmune bovine colostrum. Aliment Pharmacol Ther, 1998. 12(6): p. 563 -8. 
64. Monteiro, M.A., et al., Capsule polysaccharide conjugate vaccine against diarrheal disease caused by Campylobacter 
jejuni. Infect Immun, 2009. 77(3): p. 1128 -36. 
65. Poly, F., et al., Characterization of two Campylobacter jejuni strains for use in volunteer experimental -infection 
studies. Infect Immun, 2008. 76(12): p. 5655 -67 
66. Tribble, D.R., et al., Campylobacter jejuni strain CG8421: a refined model for the study of Campylobacteriosis and 
evaluation of Campylobacter vaccines in human subjects. Clin Infect Dis, 2009. 49(10): p. 1512 -9.  
67. Rimmer, J.E., et al., Rifaximin Fails to Prevent Campylobacteriosis in the Human Challenge Model: A Randomized, 
Double -Blind, Placebo -Controlled Trial. Clin Infect Dis, 2018. 66(9): p. 1435 -1441.  
68. Kirkpatrick, B.D., et al., Lack of homologous protection against Campylobacter jejuni CG8421 in a human challenge 
model. Clin Infect Dis, 2013. 57(8): p. 1106 -13. 
69. Kuroki, S., et al., Campylobacter jejuni strains from patients with Guillain -Barre syndrome belong mostly to 
Penner serogroup 19 and contain beta -N-acetylglucosamine residues.  Ann Neurol, 1993. 33(3): p. 243 -7. 
70. Mishu, B. and M.J. Blaser, Role of infection due to Campylobacter jejuni in the initiation of Guillain -Barre 
syndrome.  Clin Infect Dis, 1993. 17(1): p. 104 -8. 
71. Rees, J.H., et al., Campylobacter jejuni and Guillain -Barre syndrome.  Q J Med, 1993. 86(10): p. 623 -34. 
72. Allos, B.M., Association between Campylobacter infection and Guillain -Barre syndrome.  J Infect Dis, 1997. 176 
Suppl 2 : p. S125 -8. 
73. Nachamkin, I., et al., Campylobacter jejuni from patients with Guillain -Barre syndrome preferentially expresses a 
GD(1a) -like epitope.  Infect Immun, 2002. 70(9): p. 5299 -303. 
74. Nachamkin, I., B.M. Allos, and T. Ho, Campylobacter species and Guillain -Barre syndrome.  Clin Microbiol Rev, 
1998. 11(3): p. 555 -67. 
75. Nachamkin, I., Campylobacter Enteritis and the Guillain -Barre Syndrome.  Curr Infect Dis Rep, 2001. 3(2): p. 116 -
122. 
76. Allos, B.M. and M.J. Blaser, Campylobacter jejuni and the expanding spectrum of related infections.  Clin Infect 
Dis, 1995. 20(5): p. 1092 -9; quiz 1100 -1. 
77. Koga, M., et al., Comprehensive analysis of bacterial risk factors for the development of Guillain -Barre syndrome 
after Campylobacter jejuni enteritis.  J Infect Dis, 2006. 193(4): p. 547 -55. 
78. McCarthy, N. and J. Giesecke, Incidence of Guillain -Barre syndrome following infection with Campylobacter 
jejuni.  Am J Epidemiol, 2001. 153(6): p. 610 -4. 
79. Tam, C.C., et al., Incidence of Guillain -Barre syndrome among patients with Campylobacter infection: a general 
practice research database study.  J Infect Dis, 2006. 194(1): p. 95 -7. 
80. Yuki, N., et al., Penner's serotype 4 of Campylobacter jejuni has a lipopolysaccharide that bears a GM1 
ganglioside epitope as well as one that bears a GD1 a epitope.  Infect Immun, 1994. 62(5): p. 2101 -3. 
81. Salloway, S., et al., Miller -Fisher syndrome associated with Campylobacter jejuni bearing lipopolysaccharide 
molecules that mimic human ganglioside GD3.  Infect Immun, 1996. 64(8): p. 2945 -9. 
82. Aspinall, G.O., et al., Lipopolysaccharides of Campylobacter jejuni serotype O:19: structures of core 
oligosaccharide regions from the serostrain and two bacterial isolates  from patients with the Guillain -Barre 
syndrome.  Biochemistry, 1994. 33(1): p. 241 -9. 
83. Jacobs, B.C., et al., Cross -reactive antibodies against gangliosides and Campylobacter jejuni lipopolysaccharides 
in patients with Guillain -Barre or Miller Fisher syndrome.  J Infect Dis, 1997. 175(3): p. 729 -33. 
84. Neisser, A., et al., Serum antibodies against gangliosides and Campylobacter jejuni lipopolysaccharides in Miller 
Fisher syndrome.  Infect Immun, 1997. 65(10): p. 4038 -42. 
85. Bengtsson, A., F.D. Lindstrom, and B.E. Normann, Reactive arthritis after campylobacter jejuni enteritis. A case 
report.  Scand J Rheumatol, 1983. 12(2): p. 181 -2. 
86. Ebright, J.R. and L.M. Ryan, Acute erosive reactive arthritis associated with Campylobacter jejuni -induced colitis.  
Am J Med, 1984. 76(2): p. 321 -3. 
87. Eastmond, C.J., J.A. Rennie, and T.M. Reid, An outbreak of Campylobacter enteritis --a rheumatological 
followup survey.  J Rheumatol, 1983. 10(1): p. 107 -8. 
88. Johnsen, K., et al., HLA -B27-negative arthritis related to Campylobacter jejuni enteritis in three children 
and two adults.  Acta Med Scand, 1983. 214(2): p. 165 -8. 
89. Berden, J.H., H.L. Muytjens, and L.B. van de Putte, Reactive arthritis associated with Campylobacter 
jejuni enteritis.  Br Med J, 1979. 1(6160): p. 380 -1. 
90. van de Putte, L.B., et al., Reactive arthritis after Campylobacter jejuni enteritis.  J Rheumatol, 1980. 7(4): 
p. 531 -5. 
91. Bremell, T., A. Bjelle, and A. Svedhem, Rheumatic symptoms following an outbreak of campylobacter 
enteritis: a five year follow up.  Ann Rheum Dis, 1991. 50(12): p. 934 -8. 
360_CampETEC _Campy_Protocol_V 1.1_12September 2023  57 92. Leung, F.Y., G.O. Littlejohn, and C. Bombardier, Reiter's syndrome after Campylobacter jejuni enteritis.  
Arthritis Rheum, 1980. 23(8): p. 948 -50 
93. Hannu, T., et al., Reactive arthritis following an outbreak of Campylobacter jejuni infection.  J Rheumatol, 
2004. 31(3): p. 528 -30. 
94.  Hannu, T., et al., Campylobacter -triggered reactive arthritis: a population -based study.  Rheumatology 
(Oxford), 2002. 41(3): p. 312 -8. 
95.  Lindsay, J.A., Chronic sequelae of foodborne disease.  Emerg Infect Dis, 1997. 3(4): p. 443 -52. 
96. Connor, B.A., Sequelae of traveler's diarrhea: focus on postinfectious irritable bowel syndrome.  Clin 
Infect Dis, 2005. 41 Suppl 8 : p. S577 -86.  
97. Neal, K.R., J. Hebden, and R. Spiller, Prevalence of gastrointestinal symptoms six months after bacterial 
gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients.  
BMJ, 1997. 314(7083): p. 779 -82. 
98. Marshall, J.K., Post-infectious irritable bowel syndrome following water contamination.  Kidney Int 
Suppl, 2009(112): p. S42 -3. 
99. Thabane, M., D.T. Kottachchi, and J.K. Marshall, Systematic review and meta -analysis: The incidence 
and prognosis of post -infectious irritable bowel syndrome.  Aliment Pharmacol Ther, 2007. 26(4): p. 535 -
44 
100. Smith, J.L. and D. Bayles, Postinfectious irritable bowel syndrome: a long -term consequence of 
bacterial gastroenteritis.  J Food Prot, 2007. 70(7): p. 1762 -9. 
101. Spiller, R.C., Role of infection in irritable bowel syndrome.  J Gastroenterol, 2007. 42 Suppl 17 : p. 
41-7. 
 
 
 